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Introduction Dehydro Amino Acids Investigated 
 A systematic evaluation of 
the incorporation for the 
regio and geometric 
unsaturated isosteres of the 
aliphatic amino acids 
isoleucine, leucine and 
valine has been conducted.  
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•  3,4-dehydrovaline, 3,4-dehydroleucine, 4,5-dehydroleucine and 4,5-dehydroisoleucine 
are efficiently incorporated into PpiB during cell-free protein synthesis 
 
•  Replacement with 3,4-dehydrovaline results in insoluble protein  
 
•  In most instances there is no observable change in catalytic activity 
•  The competition efficiencies of these dehydro amino acids have been determined by ESI 
mass spectrometry 
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Nature has selected only twenty amino acids in the construction of peptides and proteins 
as presumably these are enough to suffice the requirements for life. Despite an array of 
functionalities represented, no alkenes exist amongst these twenty. Incorporation of 
unsaturated analogues in place of their canonical amino acid counterparts has been 
demonstrated with wild-type biosynthetic machinery but only to a very limited extent.1  
 
 
 
 
 
In order for an unnatural amino acid to be incorporated it must bypass the selectivity of 
the amino acyl tRNA synthetase. The analogue also competes with the natural substrate 
for incorporation into a growing polypeptide chain. This competition can be biased by 
utilisation of a cell-free protein production system.2  
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The extent of which dehydro amino acids compete with 
proteinogenic amino acids for incorporation was 
investigated using ESI mass spectrometry  
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Abstract 
In nature proteins are synthesised using twenty standard proteinogenic amino acids. The 
unique linear sequences of these monomeric building blocks dictate the structure and 
functionality of the translated protein. Misincorporation of unnatural amino acids into this 
biosynthetic process is rare due to the high fidelity of aminoacyl-tRNA synthetases. This 
thesis is concerned with the in vitro residue-specific incorporation of unnatural amino acids 
to produce proteins and peptides with increased functional diversity and potential 
applications in biotechnology. 
 
The cellular lysate from E.coli is a common source of translational machinery for in vitro 
protein synthesis and has been shown to remove many commonly encountered protecting 
groups from α- amino acids. A chemically intractable unnatural amino acid has been 
supplied to this cellular extract and its facile deprotection then coupled to protein 
biosynthesis to produce highly modified protein. This method is not limited to only residue-
specific incorporation but is also compatible with site-specific systems.   
 
Post-translational oxidation of proteins has been implicated in the progression of various 
degenerative diseases. It is postulated that oxidation could also occur pre-translationally as a 
result of the misincorporation of oxidised amino acids during protein synthesis. To validate 
this concept the misincorporation of seven dehydro analogues for the aliphatic amino acids 
valine, leucine and isoleucine, have been evaluated during cell-free protein synthesis using 
native translational machinery. The dehydro analogues of valine and leucine as well as one 
of the isoleucine analogues were effective replacements with incorporation levels of at least 
75%. Typically misincorporation rates for proteinogenic amino acids (i.e., leucine in place of 
isoleucine) are estimated to be 0.01%. Here the relative misincorporation observed for the 
dehydro amino acids was significantly greater than typical misincorporation, with rates as 
high at 0.6%.  
 
The introduced alkene functionality of 4,5-dehydroisoleucine and 4,5-dehydroleucine amino 
acids has been utilised in a convenient method for site-specific protein backbone cleavage. 
! x!
Upon treatment with iodine these amino acids undergo iodo-lactonisation to give five-
membered ring lactones that undergo rapid hydrolysis of the proximal carboxyl amide 
bond. This has been exploited for the rapid production of peptide hormones from a parent 
fusion protein expressed using cell-free protein synthesis. 
 
By incorporating unnatural amino acids into protein, functionality not represented by the 
twenty proteinogenic amino acids can be introduced and utilised for a variety of 
applications. A trifluoromethylalkene and three vinyl halides were found to be translational 
substitutes of leucine. The degree of substitution for two of the analogues was found to be 
greater than 75%. The elaboration of the modified protein by cross-coupling chemistry has 
been investigated. 
 
Overall the work presented in this thesis sheds insight on the theory of pre-translational 
oxidation of proteins and their possible implications in degenerative diseases. The use of 
cell-free protein synthesis and subsequent site-specific cleavage of dehydro amino acids 
presents a rapid approach for the production of peptides and also has potential applications 
in broader areas of biotechnology. It describes the incorporation of functional vinyl halide 
amino acid derivatives at sites previously occupied by an aliphatic amino acid. 
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1 
 
Introduction 
 
 
1.1 Protein Biosynthesis 
The ribosomal biosynthesis of proteins commonly employs only twenty amino acids (Figure 
1.1). These building blocks consist exclusively of α-amino acids; that is the amino and 
carboxylic acid groups along with a variable side chain are attached to one central carbon 
atom. The side chain is particularly important as it confers the physical, chemical and 
biological properties to the amino acid. The side chains of proteinogenic amino acids are 
notably restricted in chemical functionality but this is compensated for by nature with 
numerous post-translational modifications of these protein bound residues. These include 
phosphorylation, sulfation, lipidation, glycosylation, acetylation, biotinylation, methylation 
and farnesylation.[1] 
 
Protein biosynthesis is part of the ‘central dogma of molecular biology’ which is 
described as the path of genetic information transfer within a biological system.[2] It consists 
of two key transfers of information: (i) transcription, followed by (ii) translation. 
Transcription is the transferal of information stored in the chemically resistant polymer, 
deoxyribonucleic acid (DNA) into messenger ribonucleic acid (mRNA) and is performed by 
ribonucleic acid (RNA) polymerase with assistance from various transcription factors. 
! 2 
 
 
Figure 1.1 The twenty common proteinogenic amino acids divided into classes based on the 
properties of their respective side chains. 
 
Translation is the decoding of mRNA and its rendition into an amino acid sequence. 
Transfer RNAs (tRNAs) are the interface between the two codes in this process and are 
loaded with their cognate amino acids by aminoacyl-tRNA synthetases (aaRS). These 
aminoacyl-tRNA conjugates are then transferred by EF-Tu (elongation factor thermo 
unstable) (in bacteria) to the ribosome. This molecular machine comprising RNA and 
protein ensures the correct amino acid is delivered to the nascent polypeptide as dictated by 
the mRNA nucleotide sequence. This process is repeated until a termination codon in the 
mRNA is read by the ribosome, stopping protein synthesis and allowing release of the 
polypeptide. 
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1.2 Fidelity in Protein Biosynthesis 
Maintaining translational fidelity of proteins is critical for cell viability since deviation from 
the defined primary sequence can cause major structural or functional changes.[3-5] Protein 
biosynthesis has evolved to be a highly discriminatory system where misincorporation 
between the proteinogenic amino acids is estimated to occur only once every 103 or 104 
amino acids.[6] Two processes are responsible for translational fidelity, (i) the esterification of 
an amino acid with its cognate tRNA and (ii) recognition of the mRNA codons by the 
complementary anticodons of the aaRSs. This thesis is concerned with errors involved in the 
former process. 
 
AaRSs are fundamental in upholding the fidelity in the first process and catalyse the 
esterification reaction via two-steps, consisting of activation of the amino acid with 
adenosine triphosphate (ATP) to form an aminoacyl-adenosine monophosphate, followed 
by transfer of the activated amino acid to the terminal 2’- or 3’–hydroxyl group of the 
cognate tRNA. In eukaryotes separate aaRSs exist for each of the twenty proteinogenic 
amino acids. However most bacteria lack aspartyl-tRNA synthetase and/or glutaminyl-
tRNA synthetase.[7,8] Instead the biosynthesis of these aminoacyl-tRNA conjugates occurs via 
an indirect approach. 
 
AaRSs can be thought of as a gatekeeper, able to reject or accept amino acids for 
protein biosynthesis. Selective activation of the correct amino acid based on the size and 
polarity of the binding pocket is not sufficient to discern between the proteinogenic amino 
acids. This has necessitated evolution of additional proof-editing mechanisms to safeguard 
the correct pairing of an amino acid to its cognate tRNA. The aaRSs must select not only the 
correct amino acid but also the appropriate tRNA. This step is typically without 
complication since the much larger tRNA molecules possess a greater number of identifying 
features. 
 
Proof-editing of the amino acids by the aaRSs can occur both before and after an 
activated amino acid is transferred to the tRNA (Figure 1.2). Pre-transfer editing targets 
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misactivated aminoacyl–adenylates for hydrolysis via a variety of approaches including 
enzymatic[9] or non-enzymatic[10] and tRNA dependent[11,12] or independent.[13,14] 
Additionally, roughly half of the aaRSs have an independent distal post-transfer editing site. 
This provides an additional layer of protection against misincorporation by catalysing the 
hydrolysis of misactivated aminoacyl-tRNA conjugates. There are two different mechanisms 
by which this editing occurs; the acceptor stem of the misactivated tRNA is translocated into 
the editing site where hydrolysis occurs,[15-18] or the misactivated tRNA is released from the 
activation site and captured by the distal editing site where it is hydrolytically cleaved.[19] All 
the aliphatic aaRSs possess this double sieve mechanism,[20-24] which accounts for the high 
fidelity observed for these enzymes. Based on the calculated differences in the binding 
energies between (2S,3S)-isoleucine and (S)-valine, the error rate of isoleucyl-tRNA 
synthetase activating (S)-valine should be approximately 1 in 20,[25] but experimentally this 
error rate is observed to be less than 1 in 38,000.[26] 
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1.3 Twenty-First and Twenty-Second Proteinogenic Amino Acids 
Apart from the base set of twenty amino acids, (R)-selenocysteine and (S)-pyrrolysine are 
genetically encoded (albeit rarely) in nature (Figure 1.3). Both amino acids are assigned to a 
stop codon with their incorporation depending upon the presence of their respective 
insertion sequences in the mRNA adjacent to the stop codon. (S)-Pyrrolysine is activated for 
protein synthesis directly and is bound to a tRNA designated specifically for (S)-pyrrolysine 
by its own pyrrolysyl-tRNA synthetase.[27] In contrast, (R)-selenocysteine is indirectly 
activated; serine is aminoacylated onto the specialised tRNA selenocysteinyl-tRNA by seryl-
tRNA synthetase.[28] This tRNA bound serine is then converted into (R)-selenocysteine by 
selenocysteine synthase utilising selenium monophosphate.[29] This indirect mechanism 
avoids the reactive (R)-selenocysteine existing freely in solution, this being strategic in the 
prevention of cellular damage.  
 
Figure 1.3 The twenty-first and twenty-second amino acids, (R)-selenocysteine and (S)-pyrrolysine. 
 
 
1.4 Incorporation of Non-Proteinogenic Amino Acids in Nature 
Amino acids are ubiquitous throughout biological systems with approximately 500-700 
occurring naturally.[30,31] Several of these non-proteinogenic amino acids are structurally 
similar to the proteinogenic amino acids. As such they are able to infiltrate the ribosomal 
translational machinery and become incorporated into polypeptides. The error rate 
associated with the misincorporation of these non-proteinogenic amino acids is typically 
much higher than that associated with the misincorporation of the proteinogenic ones. A 
prime example is the naturally occurring amino acid (S)-canavanine (Figure 1.4). (S)-
Canavanine is a potent insecticidal allelochemical, produced profusely by the Papilionoideae 
subfamily of Leguminosae (legumes).[32,33] It is an oxa-substituted structural analogue of the 
H3N
O
O
SeH
(R)-selenocysteine
H3N
O
O
(S)-pyrrolysine
HN
O
N
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proteinogenic amino acid (S)-arginine and it is this subtle structural mimicry that enables it 
to elude distinction from (S)-arginine. 
 
Figure 1.4 The non-proteinogenic amino acid (S)-canavanine. 
 
(S)-Canavanine is an effective substrate for arginyl-tRNA synthetase,[34] enabling its 
replacement of (S)-arginine in proteins.[35] Despite the structural similarity, the pKa of the 
guanidinooxy group (7.0)[36] is significantly lower than that of the guanidino group (12.5)[37] 
of (S)-arginine. This difference results in the formation of malfunctional canavanyl proteins. 
The weevil, Sternechus tuberculatus has adapted to consuming (S)-canavanine rich seeds of 
Canavalia brasiliensis as its arginyl-tRNA synthetase has evolved to discriminate between the 
two structural analogues.[38] The frequency with which (S)-canavanine is observed to replace 
(S)-arginine is approximately 1 in 500-1000 in this insect.[38]     
 
Expanding upon the existing protein constituents in a bottom up approach would 
enable access to new chemical diversity, imparting proteins with novel functionalities not 
possible using only the normal proteinogenic amino acids. In fact, a wide range of methods 
exist for the incorporation non-proteinogenic amino acids into proteins. 
 
 
1.5 Laboratory Methods for the Incorporation of Non-Proteinogenic 
Amino Acids 
There are two approaches for incorporation of non-proteinogenic amino acids into proteins: 
residue-specific and site-specific. For both approaches the methods can be biological, 
chemical or a composite of both. Residue-specific methods produce proteins with global 
replacement of non-proteinogenic amino acids in place of a proteinogenic counterpart.[39,40] 
In contrast, site-specific methods use a targeted approach to introduce very limited numbers 
H3N
O
O
(S)-canavanine
O
H
N NH2
NH2
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of non-proteinogenic amino acids into the protein.[41-43] These approaches are however 
complementary and can be used in parallel.[44] 
 
1.5.1 Synthetic Methods for Site-Specific Incorporation  
Synthetic methods commonly involve either solution or solid-phase peptide synthesis, the 
latter of which is championed for the preparation of short peptides. These methods enable 
the synthesis of peptides that contain non-proteinogenic amino acids including (R)-amino 
acids, as well the direct production of peptide sequences which are problematic to express in 
bacteria. However, these methods are not generally feasible for the synthesis of proteins 
since almost all proteins are larger than the practical limit of solution-phase synthesis at ca. 
20 residues and solid-phase at ca. 50 (~ 6 kDa). Instead peptides produced chemically can be 
stitched into proteins by either enzymatic[45,46] or chemoselective ligation.[47] The enzymatic 
approach utilises proteases under conditions where amide bond formation is favourable to 
fuse synthetic peptides.[46,48] In contrast chemoselective ligation stitches peptides together by 
chemical means. This can be done with synthetic peptides (total chemical synthesis of 
proteins)[49] or a combination of synthetic and biologically produced peptides (protein semi-
synthesis).[50]  
 
Techniques utilising synthetic peptides are not an all-encompassing solution for the 
incorporation of non-proteinogenic amino acids. Solution and solid-phase peptide synthesis 
is plagued by poor atom economy and is subject to the arithmetic demon, culminating in 
poor yield. That is, if every step gave a 99% yield of the desired product then after just 40 
steps the yield would be only 67%. Although these chemical methods can be performed on 
preparative and commercial scales,[51,52] automated solid-phase peptide synthesisers are 
expensive and generally have high overheads. Manual approaches are typically less efficient 
and more time consuming resulting in even higher expense. Prior to purification products of 
both methods are contaminated with a distribution of peptides with varying chain lengths 
and sequences. This is in contrast to biosynthetic systems that produce amino acid polymers 
with strict controls over length and sequence. Even after the desired peptide has been 
synthesised, both enzymatic and chemoselective ligation are not without further limitations. 
!9 
Peptide solubility, sequence requirements, protein size constraints and steric impediments 
are just some of the complications.[46,49,50] Biological systems are largely unaffected by these 
limitations as described below in further detail. To put simply, techniques harnessing 
biosynthetic machinery are unmatched by current synthetic methodology in scale, efficiency 
and fidelity. 
 
1.5.2 Biological Methods for Site-Specific Incorporation 
Site-specific incorporation allows for single and even multiple-site insertions with virtually 
any amino acid. However, if the non-proteinogenic amino acid to be incorporated is too 
structurally similar to a proteinogenic amino acid then competing residue-specific 
incorporation may also occur.[53] This method depends on genetic manipulation and has 
been utilised with a range of cells including those of bacteria,[54] yeast,[55] mammals[56] and the 
multicellular organism Caenorhabditis elegans.[57] 
 
 Site-specific methods allow control over the placement of non-proteinogenic amino 
acids in proteins. They are based upon utilisation of a stop codon with nonsense 
suppression, akin to that for (R)-selenocysteine and (S)-pyrrolysine incorporation (Section 
1.4). For this approach to be efficient at incorporating non-proteinogenic amino acids into 
proteins, the system must be completely orthogonal to the existing cell pathways for 
proteinogenic amino acid incorporation.  
 
These methods typically have the following: (i) a stop codon introduced into the 
mRNA at a targeted location, (ii) a suppressor tRNA that prevents termination of protein 
synthesis and recognises the introduced stop codon (variations of these methods now exist 
where specifically designed codons of four[58] or five[59] bases are utilised, instead of the 
typical three base codons, to prevent premature termination) and (iii) an aaRS that can 
aminoacylate the non-proteinogenic amino acid to the suppressor tRNA. Alternatively 
aminoacylation of the suppressor tRNA can be performed in vitro by chemical 
aminoacylation[60] or enzymatically with T4 RNA ligase.[61] Enzymatic aminoacylation is 
preferable to the chemical approach since in the latter the aminoacyl-tRNAs are single use 
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only and are not recycled which limits protein yield. These suppressor tRNAs 
aminoacylated in vitro have been directly injected into Xenopus oocytes[62] and introduced 
into cell-free extracts to produce protein.[63]  
 
1.5.3 Residue-Specific Incorporation 
Residue-specific methods employ ribosomal translational machinery to achieve the global 
replacement of a proteinogenic amino acid with a non-proteinogenic amino acid by 
exploiting the promiscuity of the biosynthetic machinery. The first studies into the 
incorporation of non-proteinogenic amino acids into proteins utilised this residue-specific 
approach.[64,65] 
 
Replacement of a proteinogenic amino acid with a non-proteinogenic counterpart is 
typically not observed with direct competition in unmodified organisms.[66] Most organisms 
have a plentiful supply of the twenty proteinogenic amino acids, whether this be through 
biosynthesis or cellular uptake, and as a result they greatly outcompete non-proteinogenic 
counterparts for incorporation into proteins. Protein biosynthesis is highly tuned toward the 
proteinogenic amino acids and as such non-proteinogenic amino acids are rarely activated 
by aaRSs,[67,68] although there are of course exceptions where misincorporation of amino 
acids can occur and this can have detrimental and even lethal effects. In addition to the 
incorporation of (S)-canavanine, another example is the misincorporation of (S)-N-β-
methylaminoalanine in place of (S)-serine or (S)-alanine.[69] This can occur in humans and 
has been associated with the progression of several neurodegenerative disorders.[69,70] In 
order to unequivocally determine whether an amino acid may become misincorporated 
(rather than chasing potentially minuscule levels of background misincorporation) it is 
necessary to bias the competition between proteinogenic and non-proteinogenic amino acid 
counterparts in favour of the latter. This can be achieved by reducing the available 
concentration of the proteinogenic amino acid during protein synthesis. 
 
Auxotrophic cells are frequently employed to bias this competition as they lack the 
ability to biosynthesise one of the proteinogenic amino acids enabling better incorporation 
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of non-proteinogenic amino acids into proteins. Most non-proteinogenic amino acids are 
toxic and are therefore unable to maintain cell viability and support growth.[71,72] Media shift 
or the use of selective-pressure are two methods commonly employed to overcome this 
toxicity restraint and enable the production of highly substituted proteins. 
 
Media shift involves growing the cells in a media with all twenty proteinogenic 
amino acids to mid-log phase. The cells are then pelleted, washed and resuspended in a 
media containing nineteen proteinogenic amino acids and the non-proteinogenic amino acid 
of interest. Protein synthesis is induced at this point. It is important that protein synthesis is 
repressed prior to addition of the non-proteinogenic amino acid in order to minimise the 
expression of native protein. The selective-pressure method differs slightly as the cells are 
grown in the presence of the non-proteinogenic amino acid with limited amounts of the 
corresponding proteinogenic amino acid. The concentration of the proteinogenic amino acid 
is depleted once the cells reach mid-log phase and protein synthesis is induced at this point 
leading to production of highly substituted protein.  
 
The use of auxotrophs with this approach offers several advantages: large amounts 
of protein can be easily prepared from bacterial,[68] yeast[73,74] or mammalian cells;[75,76] 
multiple non-proteinogenic amino acids can be incorporated simply and with ease; [77,78] and 
finally this method lacks the need for numerous and complicated genetic manipulations that 
are an essential aspect of site-specific incorporation. 
 
 
1.6 Cell-Free Protein Synthesis 
Cell-free protein synthesis (CFPS) can be employed not only for site-specific 
incorporation[79,80] but also for the residue-specific incorporation of non-proteinogenic amino 
acids. In this approach the non-proteinogenic amino acids are activated for protein 
biosynthesis either chemically,[81] by the endogenous aaRS,[82,83] or ribosomally.[84,85] CFPS 
relies upon cellular extracts as the source of the transcription/translational machinery, 
which is employed for the synthesis of protein. This system can utilise a variety of nucleic 
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acid templates for protein synthesis including linear polymerase chain reaction (PCR) 
products, linearized plasmid, circular plasmid and mRNA.[86] Whilst PCR products are 
easily prepared these and other linear nucleotide sequences have an increased susceptibility 
to degradation but are suitable for use in high throughput applications.[87,88] DNA plasmids 
in contrast are more stable but their preparation is time-consuming requiring a number of 
DNA cloning steps, which are then followed by plasmid purification. 
 
Cell extracts derived from both prokaryotic and eukaryotic cells have been utilised 
with the most common sources being Escherichia coli, wheat germ and rabbit reticulocytes. In 
vitro systems sourced from E. coli are the easiest to prepare in large quantities from 
inexpensive materials and typically provide excellent protein yields. A general protocol for 
the preparation of cell lysate from these cells involves mild cell lysis followed by 
centrifugation and collection of the appropriate fraction. For E. coli the supernatant after 
centrifugation at 30,000 x g is commonly utilised and is referred to as the s30 fraction. 
Although less common, the s12 fraction has also been employed.[89] Such cellular extracts are 
considerably less time-consuming to prepare than a recent alternative whereby the essential 
individual components are purified from the cellular extract for in vitro protein synthesis 
(protein synthesis using recombinant elements - PURE system).[90] This system is ideally 
suited for the production of proteins with no undesired modifications or bound co-factors 
and is devoid of nucleases so that PCR products can be utilised. PURE systems are more 
costly than lysate based systems and the protein yield is generally poor,[91] but this can be 
improved in part by using a continuous-exchange system.[92]  
 
CFPS can be conducted using either a batch or continuous flow approach. In the 
batch approach all the components are added into a single reaction vessel, while for the 
continuous-flow approach protein biosynthesis occurs within an enclosed dialysis 
membrane immersed in an outer reservoir of greater volume (Figure 1.5). In the latter 
system, passive diffusion acts to replenish the inner reaction vessel with low molecular 
weight cofactors whilst at the same time low molecular weight waste by-products are 
removed by dilution. In vitro protein biosynthesis by a continuous-flow approach can 
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typically be sustained for well over 16 h (up to 60 h).[93] For the batch set-up protein 
synthesis halts at approximately 2-4 h[94,95] however, recent advances and modifications have 
seen the duration prolonged to 10 h.[96,97] Although the lesser duration of protein 
biosynthesis in the batch approach results in lower protein production, this simple and 
rapid experimental setup is ideally suited for high-throughput applications. Continuous-
flow however provides higher protein yields and as such is generally employed where 
greater quantities of protein are desired.  
 
      
Figure 1.5 Typical experimental setup for continuous flow CFPS. 
 
CFPS for residue-specific incorporation offers several benefits over the conventional 
auxotroph approach: (i) CFPS systems are dedicated to the manufacture of a single protein 
since metabolic resources are not consumed for the physiological processes that are needed 
to sustain cell viability in in vivo systems; (ii) amino acid transport is not required since there 
is no cell barrier; (iii) the conditions under which proteins form can be precisely 
manipulated to minimise the formation of misfolded or aggregated proteins since the 
system has flexibility to accommodate additives that can mitigate the formation of inclusion 
bodies; (iv) post-translational metabolic modifications to the produced proteins are 
negligible (even with lysate based systems), which simplifies their analysis; (v) the 
translational machinery in CFPS makes more efficient use of the characteristically expensive 
non-proteinogenic amino acids and unlike auxotrophic cells,[98] which can be afflicted by the 
Inner reaction vessel contains 
translational machinery,  
DNA template and low 
molecular weight cofactors 
Dialysis membrane 
Outer reservoir  
contains low molecular  
weight cofactors 
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often toxic nature of the non-proteinogenic amino acids, cell-free systems are unaffected;[99] 
and (vi) accordingly this in vitro approach permits the production of cytotoxic proteins.  
 
To summarise, CFPS is an excellent method for preparing modified proteins since it 
enables rapid and efficient preparation of small quantities of proteins with unnatural amino 
acids or isotopic labels. This method is typically higher yielding than in vivo systems, 
making it a more economical choice when considering unnatural and isotopic labelled 
amino acids are expensive to prepare or purchase. 
 
Site-specific methods of amino acid misincorporation suffer from low yields due to 
low read-through of the stop codon (i.e., truncation can often occur rather than the desired 
misincorporation). While residue-specific methods are not limited in this way, they can be 
constrained by low replacement efficiency with incomplete replacement typically observed. 
This results from background levels of the proteinogenic amino acids being present during 
protein biosynthesis. These proteinogenic amino acids can accumulate in trace amounts 
from proteolysis[82] or can be introduced alongside the commercial amino acids that 
generally contain residual amounts of other foreign proteinogenic amino acids. As outlined 
previously, these low levels of proteinogenic amino acids are incorporated with higher 
efficiencies than any non-proteinogenic counterpart but depending on the unnatural amino 
acid and its concentration this background incorporation may be negligible. 
 
 
1.7  Variety of Unnatural Amino Acids Incorporated into Proteins 
and Peptides by Biosynthetic Methods  
A diverse range of unnatural amino acids comprising many different functionalities have 
been incorporated into proteins. Details regarding the range of amino acids incorporated by 
site-specific methods can be found elsewhere.[100,101] For the residue-specific approach, the 
unnatural amino acid targeted for incorporation must be structurally similar to its 
proteinogenic counterpart in order for it to escape discrimination by the translational 
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machinery and successfully incorporate. Although native translational machinery can 
effectively discriminate between the proteinogenic amino acids, a number of unnatural 
amino acids can be misincorporated. These can be loosely categorised based on their 
structural characteristics as isotopically labelled, atom added, atom removed or atom 
substituted. 
 
The protein biosynthetic machinery is unable to discriminate between isotopically 
labelled and non-labelled amino acids. Most commonly 15N-, 13C- and 2H-labelled versions of 
proteinogenic amino acids are incorporated for 2D NMR structural studies of proteins.[102,103] 
Members of the atom added group include examples such as (S)-homoisoleucine,[68] (S)-
photoleucine,[75] (S)-photomethionine[75] and (S)-ethionine.[104] The atom removed group 
includes (S)-3,4-dehydroproline[105,106] and the naturally occurring (S)-azetidine-2-carboxylic 
acid.[105,106] The atom substituted group is much larger and can be further subdivided into 
groups based on the specific substitution (e.g., Cl for a CH3,[82] O for CH2,[32,35] N for CH,[107,108] 
Se/Te for S[64,109,110] and most commonly F for H[111]). The incorporation of substituted non-
proteinogenic amino acids is dependent on the position of the substitution and similarity in 
respect to both size and polarity to the group being replaced. 
 
The incorporation of fluorine into proteins is particularly interesting due to the 
significant and unusual physicochemical properties of fluorine.[112] Fluorinated compounds 
tend to be more hydrophobic than their non-fluorinated counterparts[113] and there is 
significant interest in utilising them to increase protein stability.[114,115] In addition, 19F is an 
excellent NMR probe for monitoring protein structure and dynamics. This is due to the 
complete absence of 19F in native proteins, the small and non-perturbing effects of 19F on 
protein structure combined with its extreme resonance sensitivity to the local molecular 
environment and 100% natural abundance of the highly sensitive 19F nucleus (only 17% less 
sensitive than 1H). Accordingly, the incorporation of fluorinated amino acids into peptides 
and proteins with both native and engineered translational systems has been extensively 
investigated. Following is a publication that summarises the current literature with respect 
to the incorporation of fluorinated amino acids with these translational systems.  
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Introduction
It is generally understood that ribosome-derived peptides and
proteins are comprised of twenty a-amino acids and, indeed, life
depends on the fidelity of their incorporation. Nevertheless,
many others are also incorporated. Usually this only occurs
when those other amino acids are structurally similar to, and
compete for incorporation with, one normally found in proteins
and in this regard amino acids having fluorine in place of
hydrogen often satisfy this criterion. Although the earlier mis-
conception that fluorine is similar in size to hydrogen has now
been largely dispelled,[1] often the fluorine–hydrogen substitu-
tion has negligible impact on the binding of compounds to
enzymes and other proteins[2] including those involved in pep-
tide biosynthesis. Accordingly, peptides and proteins containing
fluorinated amino acids can be prepared using natural protein
biosynthetic machinery as an alternative to more conventional
solid- and solution-phase peptide synthesis techniques. Through
bioengineering the scope of this method has been greatly
extended. This article provides an overview of those fluorinated
amino acids that are incorporated, biochemical methods of
peptide and protein synthesis that favour this, and properties of
the fluorinated products.
Incorporation in Natural Systems
Fluorinated compounds are very rare in nature and, to the best of
our knowledge, (2S,3S)-4-fluorothreonine (1) (Fig. 1) which has
been isolated from Streptomyces cattleya is the only a-amino
acid in this group.[3] Naturally occurring fluorinated peptides
and proteins are unknown. Even so, numerous methods have
been developed for the synthesis of a wide range of fluorinated
amino acids,[4,5] and the incorporation ofmany of these has been
investigated (Figs 2–4). Those substituted with fluorine at either
the a- or b-position are relatively difficult to prepare due to their
propensity to undergo dehydrofluorination and, even though
methods have been developed for chemical synthesis of corre-
sponding peptides,[6,7] these amino acids are unsuitable for
biochemical approaches.
Fluoroaromatic amino acids are arguably the easiest to
prepare and the most stable (many of these are now commer-
cially available), which is probably one reason why 4-fluoro-
phenylalanine (2a) (Fig. 2) was the first to be studied as a
substitute for a normal amino acid in its biosynthetic incorpo-
ration into proteins in natural systems. In the early reports the
evidence of incorporation was only indirect. Thus, the fluoride
2a was first investigated as a replacement for (S)-phenylalanine
(Phe) by monitoring its effects on the growth of Lactobacillus
arabinosus.[8] Direct analytical methods and 19F NMR spec-
troscopy in particular were used later, to establish, for example,
that feeding rabbits with the fluoride 2a resulted in the produc-
tion of carbonic anhydrase in which each of the Phe residues was
partially (,5%) replaced,[9] and that egg white lysozyme
isolated from birds fed with the 4-, 3-, and 2-fluorophenyalanines
(2a–c) and the 4-, 5-, and 6-fluorotryptophans (3a–c) partly
incorporated those amino acids in place of each Phe and
(S)-tryptophan, respectively.[10]
CO2!
OH
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F
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Fig. 1. The only known naturally occurring fluorinated a-amino acid.
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Use of Amino Acid Auxotrophic Bacteria
For practical peptide and protein synthesis, higher yields of
materials that are more easily isolated and purified are obtained
through overexpression in bacteria. When auxotrophic strains
that lack the ability to synthesise one or more of the amino acids
normally found in proteins are used for this purpose, there is the
added advantage of much greater levels of incorporation of
other structurally similar amino acids due to reduced competi-
tion. Accordingly, (S)-tyrosine (Tyr), (S)-methionine (Met),
(S)-leucine (Leu), (S)-proline (Pro), and (S)-histidine Escher-
ichia coli auxotrophs have been used to produce peptides con-
taining high levels of the fluorinated amino acids 4,[11] 5a,[12]
5b,[13] (2S,4S)- and (2S,4R)-6a,[14] (2S,4S)- and (2S,4R)-
7a,[15,16] and 8a, b,[17] respectively.
For ribosomal peptide synthesis, amino acids are first acti-
vated by corresponding aminoacyl-tRNA synthetases for attach-
ment to their cognate tRNAs. Whether or not fluorinated amino
acids are incorporated depends directly on the extent of their
activation and several strategies have been developed to
increase this. One is to exploit mutant synthetases that have
been identified through screening as having greater activity for
the fluorides. This has been demonstrated through the use of an
Escherichia coli strain that co-expresses aMet-tRNA synthetase
variant, to facilitate protein synthesis with the trifluoronorleu-
cine 9 as a Met replacement.[18] This substitution does not occur
in the absence of the unusual synthetase. Another approach is to
use bacterial hosts engineered to produce enhanced levels of
wild-type synthetase, as illustrated with hexafluoroleucine
6b,[19] trifluoroisoleucine 10,[20] and difluoroproline 7b.[21]
These were only activated efficiently enough to support protein
synthesis in systems co-expressing Leu-, (2S,3S)-isoleucine-
(Ile-), and Pro-tRNA synthetase, respectively. Even with addi-
tional Leu-tRNA synthetase, the level of activation of the
trifluoroisoleucine 13 (Fig. 3) remained insufficient.
(2S,3R)-4,4,4-Trifluorovaline (11) does not substitute for
(S)-valine (Val) during protein synthesis with conventional
Escherichia coli auxotrophs. In an unusual twist on the strategy
of addressing this with enhanced levels of synthetase, through
co-expression of Val-tRNA synthetase the fluoride 11 replaces
Val, but with additional Ile-tRNA synthetase it substitutes for
Ile.[22] That is, the synthetase determines which of the two
normal amino acids is replaced. (2S,3S)-4,4,4-Trifluorovaline
(14) does not incorporate instead of either Val or Ile, even with
co-expression of either Val- or Ile-tRNA synthetase. This shows
that not all those analogues of the amino acids normally found in
proteins having fluorine in place of hydrogen are suitable for
biochemical protein synthesis, yet the examples of the fluorides
9 and 11 replacing Met and Ile, respectively, demonstrate that
the method is not limited to that substitution. In the former case,
fluoride 9 differs fromMet by having a CH2CF3 group instead of
SCH3 and, in the latter, in place of CH2CH3 there is CF3.
Use of Cell-Free Peptide and Protein Synthesis
More recently, cell-free expression has emerged as a useful tool
for peptide and protein synthesis. By comparison with cellular
expression systems, the cell-free approach involves the prior
extraction and partial purification of cellular material, which is
then supplemented with the necessary DNA, amino acids, and
other ingredients to enable the synthesis. The cell-free expres-
sion systems can be biased towards incorporation of amino acids
normally not found in proteins bywithholding the normal amino
acids with which they compete,[23,24] such that fluorinated
amino acids processed through cellular expression are also taken
up by the cell-free method, often to greater extents. Cellular
extracts used for cell-free expression also contain enzymes that
catalyse the removal of a wide range of the protecting groups
employed in the synthesis of amino acids, so the deprotection of
an amino acid to be incorporated can be carried out in situ to
avoid separate processing steps.[25,26] This is particularly useful
with unstable amino acids, such as fluoroleucine 12. It rapidly
decomposes through lactone formation but this can be avoided
5 6
7 9∗
10 1211∗
CO2!
CF3
CF3
F
CO2!NH2
CF3
a X # CF3
b X # CHF2
a X # CH3, X$ # CF3∗
b X # X$ # CF3
a X # H, X$ # F∗
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by generating it in situ from the corresponding amino acid
hydrazide, whereupon it substitutes for Leu in peptides and
proteins.
Site-Specific Incorporation
When a fluoride competes for incorporation with an amino acid
normally found in proteins, as is the case in the examples dis-
cussed above, substitution occurs whenever the mRNA encodes
the normal amino acid. This is said to be residue-specific.
Alternatively, various molecular engineering strategies such as
supplementation of cell-free systemswith an appropriatemutant
aminoacyl-tRNA synthetase and cognate suppressor tRNA
allow incorporation of an unnatural amino acid in addition to the
normal ones, at a single site or in a site-specific manner.[27,28]
Fluoro amino acids 15–23 that have been introduced into pro-
teins in this manner are illustrated in Fig. 4.[29–36] An added
advantage of this method is that the unnatural amino acid does
not need to structurally resemble any normal one. Indeed, it
should be dissimilar so as to avoid any background residue-
specific incorporation. In this regard, the nitrobenzyltyrosines
23a–cwere developed as photolabile, masked fluorotyrosines in
order to accomplish site-specific incorporation while prevent-
ing substitution of other Tyr residues.[36] A complementary
approach for site-specific incorporation in large peptides and
proteins is to prepare a fragment peptide comprising the
unnatural amino acid through conventional solid- or solution-
phase synthesis, then use chemical ligation to fuse this to the
remainder of the target produced biosynthetically.[37]
Applications
A major impetus for producing peptides and proteins compris-
ing fluorinated amino acids is their utility in 19F NMR spec-
troscopy, for determining structures and probing conformational
changes and ligand binding,[38,39] and many of the examples
discussed above were developed for this purpose. The intro-
duction of fluorine also increases the resistance of peptides to
thermal and chemical denaturation,[20,40–43] oxidation,[44] and
proteolysis.[45,46] Fluorinated amino acids can also be used to
manipulate hydrophobicity[47] and local electronic environ-
ments,[36,48] as well as alter the reactivity of catalytic
groups.[49,50] For example, the kinetics of an isomerase enzyme
have been modified by replacing the active site, catalytic tyro-
sine with fluorinated analogues having altered acidities.[50]
Fluorine (18F) is used as a tracer in positron emission tomog-
raphy (PET) and amino acids labelled with fluorine have been
employed to monitor protein synthesis by this method.[51]
Incorporation of fluorinated amino acids also offers possibilities
for the redesign of ribosomally-derived antibiotics[52,53] and
hormones[54,55] having modified activities. Further information
on the uses and applications of peptides prepared from fluori-
nated amino acids is provided in recent articles by Merkel and
Budisa[56] and Marsh.[57]
Conclusions
It follows that there is very broad scope to use native and
engineered protein biosyntheticmachinery to incorporate awide
range of fluorinated amino acids into peptides, for diverse
applications. This approach is not without limitations. Conse-
quently, traditional solid- and solution-phase peptide synthesis
is likely to remain the method of choice for synthesis of short
peptides, particularly those containing backbone-modified
amino acids, but for larger sequences biochemical methods are
much more convenient, because they are efficient, scalable, and
provide complete control over amino acid sequence. The bio-
synthetic reagents are now commercially available or easily
prepared, and their use is straightforward, to the extent that the
viability of using them in any planned synthesis of a peptide is
worthy of consideration.
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1.9 Expanding the Range of Unnatural Amino Acids Incorporated 
with the Residue-Specific Approach 
To enable the incorporation of a wider array of non-proteinogenic amino acids using 
residue-specific systems, aaRSs which regulate amino acid activation for protein synthesis 
can be overexpressed or modified. Providing additional copies of an aaRS into the 
expression system has been demonstrated as an effective method to incorporate non-
proteinogenic amino acids that are otherwise incapable of producing substituted protein 
with the endogenous levels of aaRS.[116-118] This approach is successful for non-proteinogenic 
amino acids that are loaded onto tRNAs at extremely low rates. Increasing the aaRS 
concentration overcomes this poor activation to provide satisfactory amounts of the 
aminoacylated tRNA. Altering the binding pocket of an aaRS is another effective strategy to 
increase the rate of non-proteinogenic amino acid aminoacylation to tRNA.[119-121] By 
enlarging this pocket the structural diversity of non-proteinogenic amino acids that can 
replace their proteinogenic counterparts is expanded.[122-125] Alternatively, decreasing the 
proof-editing function of an aaRS increases the number of aminoacylated tRNAs that 
survive,[126] in turn increasing the range of non-proteinogenic amino acids that can be 
incorporated into proteins.[127,128] 
 
 Although these techniques have proven successful, they are not applicable to the 
work presented in this Thesis. This Thesis is concerned purely with the misincorporation of 
amino acids by native cellular machinery. 
 
 
1.10 Outlook for Preparation of Unnatural Proteins 
As described above, a wide assortment of strategies and methods have been developed to 
incorporate non-proteinogenic amino acids into proteins.[40,129] Whilst solution or solid-phase 
peptide synthesis might be ideal for the preparation of short unnatural peptides and site-
specific approaches are suitable for preparation of proteins with only a few functionalised 
unnatural amino acids inserted into targeted positions,[130] the residue-specific approach is 
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an arguably better and more powerful alternative. It is not restricted in the length of the 
polypeptides that can be manufactured and highly functionalised amino acids can be 
incorporated into peptides at numerous positions. If alternative unnatural amino acids are 
desired, the biosynthetic machinery can be simply mutated to permit their incorporation.  
 
Both auxotrophic and CFPS methods employed for the residue-specific incorporation 
of unnatural amino acids into proteins can be readily up- or down-scaled, with both utilising 
inexpensive starting materials and no specialist knowledge or equipment necessary, unlike 
site-specific approaches. Additionally, compared to synthetic methods, these are a much 
more sustainable approach to the synthesis of polypeptides and align with many of the 
twelve principles of green chemistry.[131] CFPS is however invariably a more versatile and 
adaptable method compared to the use of auxotrophic cells. 
 
The residue-specific approach is the only means available to investigate the natural 
misincorporation of non-proteinogenic amino acids for proteinogenic amino acids. 
Misincorporation of modified amino acids during protein biosynthesis is of significant 
importance since numerous diseases have been associated with the replacement of the usual 
twenty proteinogenic amino acids with modified variants in proteins.[69,132-135] Regardless of 
the approach employed, incorporation of non-proteinogenic amino acids remains an 
exciting and burgeoning field of research. 
 
 
1.11 Research Objectives and Thesis Outline 
To investigate the incorporation of unnatural amino acids into proteins these amino acids 
must first be acquired. While some unnatural amino acids are commercially available, most 
need to be prepared and this is almost exclusively by organic synthesis. The majority of 
these synthetic strategies require the use of protecting groups in order to mask reactive 
functionalities to achieve chemoselectivity. The removal of most protecting groups requires 
the use of harsh reagents, high temperatures and even prolonged reaction times.[136] This can 
be problematic when synthesising unnatural amino acids since many possess sensitive side 
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chains and consequently degrade under these conditions. Enzymes are an excellent 
alternative to traditional chemical approaches for the removal of protecting groups to 
prepare unstable amino acids since they can stereospecifically catalyse reactions under mild 
conditions. Purified enzymes have been employed previously to remove only simple 
protecting groups from both proteinogenic and unnatural amino acids.[136-142] Additionally 
these enzymes are purified which significantly increases their associated cost. To address 
these limitations the native enzymes from the cellular extract employed for the in vitro 
biosynthesis of proteins have been investigated for their ability to remove a range of 
protecting groups from a variety of amino acids. This study is described in Chapter 2. 
 
Protein oxidation has been strongly implicated in the progression of a variety of age-
related diseases.[143-147] Although this oxidation is generally understood to arise from 
reactions of proteins with reactive oxygen species, it has been postulated that protein 
oxidation can also occur pre-translationally through the misincorporation of oxidised amino 
acids.[148] To further examine this possibility the full range of unsaturated amino acid 
analogues of the aliphatic amino acids, except for the α,β-unsaturated derivatives, have been 
investigated as replacements of their proteinogenic counterparts utilising an in vitro 
approach with native translational machinery. This work is reported in Chapter 3.  
 
Peptide hormones are traditionally prepared by chemical synthesis employing either 
solution- or solid-phase peptide synthesis or a combination of the two.[149] However in 
contrast to recombinant approaches, chemical methods cannot be used to prepare longer or 
more complex peptide hormones. In most cases peptides produced by recombinant methods 
must be expressed as fusion proteins (e.g., by tethering the peptide to a longer carrier 
protein).[150] To liberate the peptide, selective cleavage is require between the carrier protein 
and peptide hormone which can be performed either enzymatically or chemically. Chemical 
methods are ideal for this cleavage since they can proceed under denaturing conditions 
utilising inexpensive reagents.[151-153] However, few chemical methods exist and the yields in 
most cases are poor. Part of the work described in this thesis has involved an examination of 
several dehydro amino acids as suitable handles for the mild targeted chemical cleavage of 
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the protein backbone. This has been investigated as a more efficient alternative to the 
existing methods to prepare peptide hormones. These results and relevant discussion are 
contained in Chapter 4. 
 
Expanding the range of unnatural amino acids with different functionality to that of 
the proteinogenic amino acids is of interest since it broadens the toolkit by which proteins 
can be modified. Accordingly, a trifluoromethylalkene, three vinyl halides and a diene were 
additionally investigated as replacements for (S)-leucine. Efforts have been made towards 
the modification of functionalised protein by cross-coupling chemistry. This work is 
reported in Chapter 5. 
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In situ Deprotection and Incorporation of 
Unnatural Amino Acids 
 
  
2.1 Introduction  
Unnatural amino acids are used extensively in biological chemistry to produce proteins with 
enhanced physical properties or altered catalytic function.[1-3] They have also been used for 
the development of peptides with increased biological activity, selectivity and metabolic 
stability.[4-7] Before such investigations can begin, these unnatural amino acids must first be 
acquired but while some are commercially available, in many cases they must be prepared 
by chemical synthesis. For most synthetic strategies the use of protecting groups is required 
in order to mask any reactive functionalities (e.g., amino and carboxyl groups) and obtain 
chemoselectivity.[8,9] Removal of these protecting groups usually requires harsh hazardous 
reagents, elevated temperatures and even prolonged reaction times.[10] This can be 
problematic in the preparation of unnatural amino acids since many possess reactive side 
chains. Often these unnatural amino acid derivatives are chemically intractable and as such 
their propensity for incorporation into biological systems is limited. 
 
Purified enzymes are often employed to remove simple protecting groups from both 
proteinogenic and unnatural amino acids.[10-16] This alternative method alleviates the issues 
! 26 
associated with traditional chemical approaches to the removal of protecting groups. 
However, these commercially available enzymes have significant cost associated with them 
due mainly to the purification process. Additionally due to the characteristically high level 
of specificity associated with enzyme catalysis, the use of a single enzyme limits the range of 
protecting groups that can be removed. To address these limitations the cell extract of E.coli 
BL21 (DE3) star, typically employed for in vivo protein synthesis, was investigated to 
remove protecting groups from proteinogenic and unnatural amino acids. Also of interest 
was studying whether amino acid deprotection could be accompanied by incorporation for 
the production of proteins in vitro, since the cell extract contains active translational 
machinery. 
 
 
2.2 Summary of the Published Article 
The majority of this work has been published in an article reproduced below. 
 
The E.coli BL21 (DE3) star cellular extract employed in this study was able to 
efficiently remove an extensive range of protecting groups from amino acids under mild 
conditions. Not only was the cell extract able to remove protecting groups from the !-amino 
and !-carboxyl sites but also from the amino acid side chains. Examples of the types of 
removable groups range from hydrazides and methyl esters to the more complex 
trifluoroacetamides and adamantyl esters among others. In addition to the removal of 
protecting groups from amino acids this cellular extract was utilised for the production of 
proteins in vitro, since it contains active translational machinery. The rate of deprotection of 
a number of protected amino acids was found to be compatible with supporting protein 
overexpression. 
 
This approach is more convenient than traditional chemical deprotection methods 
since the extract can remove a wide variety of protecting groups under mild conditions 
without the use of multiple or hazardous reagents. Unnatural amino acid derivatives in 
addition to the proteinogenic amino acids are recognised and deprotected in situ. As such, 
!27 
their deprotection can be coupled to protein biosynthesis resulting in the expression of 
modified protein. The particular unnatural amino acid derivatives evaluated are inherently 
unstable and this approach bypasses the issues associated with their chemical deprotection. 
Whilst in the examples provided in the publication, the protected amino acids have been 
incorporated by a residue-specific approach, this cellular extract could in principle also be 
utilised for site-specific incorporation of unnatural amino acids.    
 
 
2.3 Reproduction of the Published Article 
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Introduction
Cell-free synthesis[1–9] has emerged as a useful tool for the
controlled incorporation of unnatural amino acids into pro-
teins.[6–14] Relative to expression systems in vivo,[15–18] cell-
free synthesis involves the prior extraction and partial purifi-
cation of cellular material. The extract is then supplemented
with the necessary DNA, amino acids, and other ingredients
to enable protein synthesis in vitro under fully controlled
conditions. Cell-free synthesis allows the substitution of a
natural amino acid with an unnatural one. Incorporation of
the unnatural amino acid then depends upon it being struc-
turally similar to the one that is normally encoded and com-
peting for loading onto the corresponding tRNA by the cog-
nate aminoacyl tRNA synthetase. The cell-free system pro-
vides a method to bias this competition in favour of the un-
natural amino acid by supplementing it in place of the
normal one. By using this approach, proteins containing
high levels of isotopically labelled amino acids[2,8] selenome-
thionine,[6,7] 3,4-dihydroxyphenylalanine,[10] and chlorinated
amino acids[11] have been synthesized. Alternatively, the
cell-free system allows for the incorporation of an unnatural
amino acid in addition to the normal ones through supple-
mentation with an appropriate mutant aminoacyl tRNA syn-
thetase and cognate suppressor tRNA.[12–14]
The unnatural amino acids are prepared through synthe-
sis, often by using routes in which the final steps involve re-
moval of amino and carboxyl protecting groups.[19] Our ser-
endipitous observation that (S)-4-fluoroleucine hydrazide
(23) was cleaved to (S)-4-fluoroleucine (26), which was in-
corporated into a protein in place of (S)-leucine during cell-
free synthesis with the S30 extract of E. coli BL21 Star
(DE3)[20] prompted us to explore the scope of this in situ de-
protection and incorporation of amino acids. The obvious
advantage of this approach of deprotecting the amino acids
in situ is that it avoids separate processing steps that are
sometimes challenging, particularly with free amino acids
that are chemically labile.
Herein, we report our studies of a variety of backbone-
and side-chain-protected amino acids and related com-
pounds. Esters and amides were used in addition to hydra-
zides to investigate carboxyl protecting groups, while a
range of amides and carbamates were employed as protect-
ed amines. This initial screen was carried out with protected
forms of those amino acids typically found in proteins and
Abstract: The S30 extract from E. coli
BL21 Star (DE3) used for cell-free
protein synthesis removes a wide range
of a-amino acid protecting groups by
cleaving a-carboxyl hydrazides;
methyl, benzyl, tert-butyl, and adaman-
tyl esters; tert-butyl and adamantyl car-
boxamides; a-amino form-, acet-, tri-
fluoroacet-, and benzamides; and side-
chain hydrazides and esters. The free
amino acids are produced and incorpo-
rated into a protein under standard
conditions. This approach allows the
deprotection of amino acids to be car-
ried out in situ to avoid separate proc-
essing steps. The advantages of this ap-
proach are demonstrated by the effi-
cient incorporation of the chemically
intractable (S)-4-fluoroleucine, (S)-4,5-
dehydroleucine, and (2S,3R)-4-chloro-
valine into a protein through the direct
use of their respective precursors,
namely, (S)-4-fluoroleucine hydrazide,
(S)-4,5-dehydroleucine hydrazide, and
(2S,3R)-4-chlorovaline methyl ester.
These results also show that the fluoro-
and dehydroleucine and the chlorova-
line are incorporated into a protein by
the normal biosynthetic machinery as
substitutes for leucine and isoleucine,
respectively.
Keywords: amino acids · cell-free
synthesis · enzyme catalysis · pro-
tecting groups · protein expression
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shows that the S30 extract of E. coli BL21 Star (DE3) has
the capacity to deprotect a wide range of amino acid deriva-
tives with various a-amino, a-carboxyl and side-chain pro-
tecting groups. In many cases, the deprotection process is
sufficiently facile that the rate of production of the free
amino acid does not limit the quantity of protein formed
through cell-free synthesis under standard conditions. In ad-
dition to the initial assessment of the reactivity of various
protecting groups, we demonstrate the use of this methodol-
ogy for the deprotection of chemically intractable unnatural
amino acids in situ for their direct incorporation into a pro-
tein.
Results and Discussion
The compounds used in the initial screening phase of this
study are illustrated in Figures 1–3. Compounds 1a–f, 2, 8,
9a–c, 15a,b, and 16 were selected to investigate the scope of
cleavage of amino acid hydrazides. Amino acid esters 3a–g,
10a,c, and 13b,c, and amides 4 and 10b, were used to exam-
ine the removal of other carboxylic acid protecting groups.
Ester 13a was chosen as a protected alcohol. The ability of
S30 to unmask amino acid amino groups was also studied by
using acetamides 5a–c and 11a–d, trifluoroacetamides 6a,b,
formamides 7a,b, benzamide 12, and other N-substituted
amino acid derivatives 17a–c. Compounds 14 and 18 were
included in the study as amino acids with both their amino
and carboxyl groups protected. Each of these compounds
was incubated with the E. coli S30 extract for six hours at
37 8C at a concentration of 2 mm under the standard condi-
tions used for cell-free protein synthesis,[8,10, 21,22] except in
the absence of the DNA required to produce aprotein. The
mixtures were monitored by using HPLC for the consump-
tion of the starting materials and formation of the corre-
sponding deprotected products. Under these conditions,
compounds 1a–f, 2, 3a–g, 4, 5a–c, 6a,b, 7a,b, and 8 illustrat-
ed in Figure 1 were all completely deprotected (>90%) in
this assay. Compounds 9a–c, 10a–c, 11a–d, 12, 13a–c, and
14 shown in Figure 2 were partially deprotected (>20–<
80%), but underwent complete reaction when the incuba-
tion time was extended to 24 hours or when proportionately
more of the S30 extract was added to the mixture, whereas
compounds 15a,b, 16, 17a–c, and 18 (Figure 3) were unaf-
fected (<10% reaction).
The deprotection of 1a–f and 9a–c establishes the broad
substrate specificity of the S30 extract towards cleavage of
amino acid hydrazides, while, to the extent that they are
representative, the inertness of the R enantiomers 15a,b of
the (S)-leucine and (S)-valine derivatives 1a and 1c shows
the reactions are stereoselective and therefore likely to be
enzyme catalysed. The N-substituted derivative 2 of hydra-
zide 1a is also processed, but the des-amino analogue 16 of
the phenylalanine derivative 1b is not. This reaction is not
limited to hydrazides. Amino acid esters and amides are
also converted, as shown with methyl esters 3a–c, benzyl
esters 3d–f and 13b,c, tert-butyl esters 3g and 10a and
amide 10b, and the adamantyl amide 4 and ester 10c. The
reactions of esters 3d–g, 10a, and 13b,c are particularly
noteworthy given the common usage of benzyl and tert-
butyl ester protecting groups in amino acid and peptide
chemistry.[19]
The turnover of acetamides 5a–c and 11a–d,
trifluoroacetACHTUNGTRENNUNGamides 6a,b, formamides 7a,b, and benzamide
12 demonstrates the activity of the S30 extract with some of
the commonly used amino protecting groups.[19,23–27] Al-
Figure 1. Amino acid derivatives fully deprotected (>90%) by E. coli S30 extract under standard conditions for cell-free protein synthesis.
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though acetamides are more common, a trifluoroacetamide
functionality offers some specific advantages in synthesis be-
cause incorporation of the trifluoroacetyl group deactivates
the amino acid a-position towards radical reactions.[26,27] It is
apparent that there are limitations to the removal of amino
protecting groups by the S30 extract, however, as illustrated
by the lack of reaction of carbamate 17a, sulfonamide 17b,
and N-decanoylleucine 17c.
Most of the compounds examined had either the a-amino
or a-carboxyl group protected, but the reactions of glutamyl
hydrazide 8, serine acetate 13a, and aspartate and glutamate
benzyl esters 13b,c, respectively, demonstrate that side-
chain carboxylic acid derivatives are also cleaved. As for
doubly protected amino acids, both protecting groups are re-
moved from the N-acetylated leucine methyl ester 14, but
the corresponding hydrazide 18 is inert.
It does not affect the utility of the results, but it is none-
theless interesting to consider the enzymes likely to be in
the S30 extract and responsible for the reactions observed.
Leucine aminopeptidases (LAP, E.C. 3.4.11.1) are known to
hydrolyse hydrazide 1a[28] and the presence of this enzyme
in E. coli probably contributes to its cleavage by S30. This
enzyme is also known to catalyse reactions of other protect-
ed amino acids, such as phenylalanine hydrazide 1b and
ester 3b,[28] but in separate studies with this enzyme we
found it does not show activity for other protected amino
acids, such as valine hydrazide 1c and ester 3c. Therefore
other enzymes, such as aminopeptidase N (PepN, E.C.
3.4.11.2), which is known to have broad substrate specifici-
ty,[29–31] are also likely to be involved, as well as those en-
zymes with amino acid selectivity, such as methionine ami-
nopeptidase Type 1 (MAP 1, E.C. 3.4.11.18);[32] aminopepti-
dase B (PepB, E.C. 3.4.11.23), which is selective for acidic
amino acids;[33] and oligopeptidase B (Protease II, E.C.
3.4.21.83), which shows selectivity for basic amino acids.[34,35]
Hydrazide cleavage appears to be dependent on enzymes
that require their substrates to have a free amino group,
such as LAP,[28] because 1a and 2 react, whereas the des-
amino hydrazide 16 and N-acetylated leucine hydrazide 18
do not react. Ester cleavage is not limited in this way, how-
ever, as shown by the reaction of the acetylated leucine
methyl ester 14. b-Aspartyl peptidase (E.C. 3.4.19.5),[36,37] g-
glutamyl transpeptidase (E.C. 2.3.2.2),[38, 39] and glutaminase
A (E.C. 3.5.1.2)[40] are likely to be involved with the removal
of side-chain protecting groups, whereas carboxypeptidases
probably account for the amino acid deacylation reactions.
In any event, given the large number of enzymes expected
to be in the S30 extract, there is likely to be redundancy.
Having determined the scope of the deprotection of
amino acid derivatives by the S30 extract, examples of those
shown in Figures 1 and 2 were tested for deprotection and
incorporation into peptidyl-Pro cis–trans isomerase B
(PpiB) in situ through cell-free protein synthesis.[8,10,21, 22]
Figure 4 shows a representative SDS-PAGE analysis of the
purified proteins: lane B shows the PpiB produced when
each of the twenty normal amino acids (1 mm) was added,
lane C shows a decreased amount of that protein when (S)-
leucine was not added and only the background concentra-
tion of this amino acid was present (shown through separate
HPLC analyses to increase from negligible to around
0.01 mm during the course of the experiment), and lanes D
and E show the PpiB formed when hydrazide 1a (2 mm)
and methyl ester 3a (2 mm) were added, respectively, in-
stead of (S)-leucine. Mass-spectrometric analysis confirmed
the native sequence of the PpiB that formed. These results
Figure 2. Amino acid derivatives partially deprotected (>20–<80%) by E. coli S30 extract under standard conditions for cell-free protein synthesis.
Figure 3. Amino acid derivatives unaffected (<10% reaction) by the E.
coli S30 extract under standard conditions for cell-free protein synthesis.
Boc= tert-butyloxycarbonyl.
www.chemeurj.org ! 2013 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Chem. Eur. J. 2013, 19, 6824 – 68306826
C. J. Easton et al.
illustrate that PpiB is efficiently produced by using either
(S)-leucine, hydrazide 1a, or ester 3a and that conversion of
hydrazide 1a and ester 3a into the free amino acid occurs
sufficiently easily that it does not limit cell-free protein syn-
thesis under the standard conditions. In identical fashion, it
was demonstrated that ester 3d, amide 4, acetamide 5a, tri-
fluoroacetamide 6a, and the doubly protected N-acetyl-(S)-
leucine methyl ester 14 resulted in unrestricted synthesis of
PpiB. Less protein formed with hydrazides 1b and 9a, ester
10a, and amide 10b, but even in those cases unrestricted
PpiB production was achieved by adding more of the S30
extract, by preincubating the mixture before finally adding
the PpiB DNA, or by increasing the assay time to 24 hours.
In this context it is relevant to note that cell-free protein
synthesis occurs continuously throughout the experiment
(6 h) performed under standard conditions (as evident from
the SDS-PAGE analysis provided in the Supporting Infor-
mation), whereas 50 and 75% of methyl ester 3a had hydro-
lysed after 0.5 and 1 h, respectively, whereas only 50% of
tert-butyl ester 10a was converted into free (S)-Leu after
6 h. Irrespective of this, the reactions carried out in situ
were shown to be compatible with the cell-free protein syn-
thesis for a variety of carboxylic acid derivatives including
hydrazides, methyl esters, benzyl esters, tert-butyl esters and
amides, and amino protecting acetamides and trifluoroaceta-
mides.
The utility of these observations is demonstrated by the
incorporation of the unnatural amino acids (S)-4-fluoroleu-
cine (26), (S)-4,5-dehydroleucine (27), and (2S,3R)-4-chloro-
valine (29) into PpiB through the direct use of their respec-
tive protected forms 23, 25, and 28 in the cell-free system.
The latter compounds were prepared through side-chain
elaboration of (S)-leucine and (S)-valine[20,41–43] (Schemes 1
and 2, respectively). All attempts to prepare the free amino
acids 26 and 27 by deprotection of the corresponding leu-
cine derivatives 21 and 22 were frustrated by formation of
lactone 24. Eventually, removal of the phthaloyl group from
fluoride 21 was achieved by treatment with hydrazine to
give hydrazide 23, which underwent oxidative cleavage with
NBS to give amino acid 26 in addition to lactone 24. Even
by using this approach, the protected alkene 22 afforded hy-
drazide 25, but treatment of it with NBS gave only lactone
24. Nevertheless, as shown by the SDS-PAGE analysis illus-
trated in Figure 5, PpiB was efficiently produced through
cell-free synthesis by using hydrazides 23 and 25 (lanes G
and H, respectively), as substitutes for (S)-leucine (lane E).
The most abundant peak at 19340 Da in the mass spectrum
Figure 4. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) analysis of synthesized His6-PpiB with A) no DNA, B)
DNA, C) no (S)-leucine, D) no (S)-leucine but with hydrazide 1a, and
E) no (S)-leucine but with methyl ester 3a.
Scheme 1. Side-chain elaboration of (S)-leucine. Leu= leucine, NBS=N-
bromosuccinimide.
Scheme 2. Side-chain elaboration of (S)-valine.
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of the protein formed from hydrazide 23 (Figure 6b) corre-
sponds to substitution of fluoride 26 for all five of the (S)-
leucine residues found in native PpiB (Figure 6a), while the
next most abundant peak at 19321 Da in Figure 6b corre-
sponds to substitution of four of the five (S)-leucine resi-
dues. (Each substitution increases the mass by 18 Da. How-
ever, due to the natural 13C isotope abundance, PpiB gives
four dominant peaks 1 Da apart, which differ in intensity by
less than 15%. These peaks were not resolved and any one
may be labelled by the spectrometer, so the mass difference
indicated for one substitution is 18!4 Da.) Based on the
mass-spectrometric data, the average degree of incorpora-
tion of fluoride 26 is approximately 90%. In the case of hy-
drazide 25, the mass spectrum (Figure 6c) shows that four
or five of the (S)-leucine residues are replaced with alkene
27 (in this case, each substitution decreases the mass by
2 Da). This extent of incorporation was confirmed through
amino acid analysis of the PpiB. There has been an earlier
report of the incorporation of alkene 27 into leucine zipper
peptides,[44] although no details of that study have been pub-
lished.
Previously, we had found that chloride 29 is not incorpo-
rated into PpiB in place of (2S,3S)-isoleucine, despite sever-
al other chlorides proving to be suitable substitutes for ali-
phatic amino acids.[11] These studies had been based on the
use of a crude mixture of chloride 29, its 2S,3S diastereomer,
(S)-3-chlorovaline, and recovered starting material, obtained
by chlorination of (S)-valine,[43] because it had not been
practical to separate and test the pure material. Close analy-
sis of the mixture showed that chloride 29 is unstable and
converts into lactone 30 under the conditions of cell-free
protein expression (i.e. , pH 7.5, 37 8C), with a half-life of ap-
proximately 15 minutes. By comparison, when the valine
methyl ester 3c was chlorinated, the chloride 28 that formed
was sufficiently stable for it to be separated through HPLC
without lactonization. With the cell-free system, this materi-
al underwent deprotection in situ and product 29 was incor-
porated into PpiB (Figure 5, lane D) as a substitute for
(2S,3S)-isoleucine (Figure 5, lane C). With chloride 28, the
most abundant peak in the mass spectrum of the PpiB at
Figure 5. SDS-PAGE analysis of synthesized His6-PpiB with A) no DNA,
B) DNA, C) no (2S,3S)-isoleucine, D) no (2S,3S)-isoleucine but with
chloride 28, E) DNA, F) no (S)-leucine, G) no (S)-leucine but with hy-
drazide 23, and H) no (S)-leucine but with hydrazide 25.
Figure 6. Mass spectra of a) native PpiB, b) PpiB produced using hydrazide 23 in place of (S)-leucine, c) PpiB produced by using hydrazide 25 in place of
(S)-leucine, and d) PpiB produced by using chloride 28 in place of (2S,3S)-isoleucine.
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19455 Da (Figure 6d) corresponds to substitution of the
chlorinated free amino acid 29 for all ten of the (2S,3S)-iso-
leucine residues found in native PpiB (Figure 6a), while the
next most abundant peak at 19431 Da results from nine re-
placements (each substitution that corresponds to replacing
a methyl group with chlorine increases the mass by an aver-
age of 20.5 Da, although the natural carbon and chlorine
isotope abundance in each of these chlorinated PpiBs results
in five dominant ions 1 Da apart, differing in intensity by
15% or less, so the difference indicated by the spectrometer
is (20!5) Da). With chloride 29, the mass spectrum shows
that the average degree of incorporation is above 90%. For
hydrazides 23 and 25, the S30 extract simply provides a way
to avoid having to carry out problematic deprotection as a
separate step; however, for chloride 28 the S30 extract also
continuously replenishes the free amino acid 29 as it is con-
sumed through lactonization. As a result, incorporation is
observed by using ester 28, but not with the same initial con-
centration of the free amino acid 29.
Conclusion
This study has demonstrated the ability of the S30 extract to
remove a range of protecting groups for direct incorporation
of the resulting amino acids into a protein. This approach is
more efficient because it not only decreases the number of
synthetic steps required in the preparation of unnatural
amino acids, but also provides a versatile method to circum-
vent problems associated with chemical instability of amino
acids during both their deprotection and protein synthesis.
The method has been demonstrated to be suitable for the
incorporation of the fluoro- and dehydroleucines 26 and 27
and chlorovaline 29 as substitutes for leucine and isoleucine,
respectively, at levels of 90% or above. These high levels
are more than adequate for applications such as isotopic la-
belling or the fluorination of proteins, for use in spectro-
scopic studies for example, in which the unmodified protein
is not detectable. These levels are also suitable to investigate
general rather than specific effects of amino acid modifica-
tions on protein structure and function. Further, the cell-
free system with the S30 extract allows for a complete site-
specific incorporation of an unnatural amino acid through
the addition of a mutant aminoacyl tRNA synthetase and
cognate suppressor tRNA, under which conditions the incor-
poration levels would be expected to be quantitative.
Experimental Section
Amino acid derivatives : With the exception of hydrazides 2 and 9a and
ester 10c, all the amino acids illustrated in Figures 1–3 are available from
Sigma–Aldrich, Merck Pty. Ltd., Auspep, TCI Chemicals, or Aurora Fine
Chemicals LLC, although for the purposes of this investigation many
were prepared from the corresponding free amino acids (see the Support-
ing Information). Phenylhydrazide 2 was synthesized from methyl ester
3a by using phenylhydrazine.[45] Hydrazide 9a was prepared from (S)-
lysine by esterification with thionyl chloride in methanol, followed by
treatment of the corresponding ester with hydrazine hydrate.[46,47] Ester
10c was prepared by the treatment of (S)-leucine with 1-adamantanol, di-
methyl sulfite, and para-toluenesulfonic acid.[48]
(S)-4-Fluoroleucine hydrazide (23) was prepared by the protection of
(S)-leucine, bromination of phthalimide 19, treatment of bromide 20 with
silver fluoride, and reaction of fluoride 21 with hydrazine hydrate.[20] (S)-
4,5-Dehydroleucine hydrazide (25) was prepared from N-phthaloyl-4,5-
dehydroleucine methyl ester (22)[49] by reaction with hydrazine hy-
drate.[20] M.p. 130–132 8C; 1H NMR (300 MHz, D2O): d=5.06 (m, 1H),
4.93 (m, 1H), 4.15 (dd, J=9, 6 Hz, 1H), 2.62 (dd, J=14, 6 Hz, 1H), 2.54
(dd, J=14, 9 Hz, 1H), 1.78 ppm (s, 3H); 13C NMR (100 MHz, D2O): d=
168.9, 138.5, 116.9, 50.8, 39.8, 21.0 ppm; HRMS (ESI, +ve) m/z : calcd for
C6H14N3O: 144.1137; found: 144.1140 [M+H]+ .ACHTUNGTRENNUNG(2S,3R)-4-Chlorovaline methyl ester (28) was isolated through HPLC
from the mixture obtained by chlorination of ester 3c.[43] 1H NMR
(400 MHz, CD3OD): d=4.27 (d, J=4 Hz, 1H), 3.87 (s, 3H), 3.74 (dd, J=
12, 8 Hz, 1H), 3.66 (dd, J=12, 6 Hz, 1H), 2.35–2.45 (m, 1H), 1.10 ppm
(d, J=8 Hz, 3H); 13C NMR (100 MHz, CD3OD): d=170.2, 55.7, 53.8,
47.0, 39.5, 13.5 ppm; HRMS (ESI, +ve) m/z : calcd for C6H13NO2Cl:
166.0635 and 168.0605; found: 166.0633 and 168.0610 [M+H]+ ; m/z :
calcd for C6H12NO2ClNa: 188.0454 and 190.0425; found: 188.0452 and
190.0428 [M+Na]+ ; further details are provided in the Supporting Infor-
mation.
Treatment of amino acid derivatives with S30 extract from E. coli BL21
Star (DE3): S30 extract from E. coli BL21 Star (DE3) was prepared as
previously reported.[22] Stock solutions of the amino acid derivatives 1a–f,
2, 3a–g, 4, 5a–c, 6a,b, 7a,b, 8, 9a–c, 10a–c, 11a–d, 12, 13a–c, 14, 15a,b,
16, 17a–c, and 18 were prepared in water, ethanol, or dimethyl sulfoxide
(DMSO) according to solubility. An aliquot (4 mL) of each stock solution
was diluted to a final concentration of 2 mm with 4-(2-hydroxyethyl)-1-pi-
perazineethanesulfonic acid (HEPES) buffer (116 mL, 50 mm, pH 7.5)
and the S30 extract (80 mL). The mixtures were incubated at 37 8C for 6 h
and centrifuged at 12000 rpm for 10 min. Each supernatant was passed
through an Amicon Ultra-4 (YM-10) centrifugal filter device, and the fil-
trates were analysed with HPLC by using the Waters AccQ.Tag method,
with reference to amino acid standard solutions and the background
amino acid concentration of the S30 extract. Accordingly, a sample of
each filtrate (20 mL) was treated with AccQ.Fluor borate buffer (80 mL)
and reconstituted AccQ.Fluor reagent (20 mL). The mixtures were ana-
lysed by using an AccQ.Tag column (C18, 4 mm, 150"3.9 mm), eluting
with a gradient of acetonitrile in AccQ.Tag eluent. Representative HPLC
traces are provided in the Supporting Information.
Cell-free protein synthesis: Plasmid DNA encoding for His6-PpiB with
expression under control of the phage T7 promoter (pND1098) was car-
ried out according to a previous report.[10] Plasmid DNA was prepared
from E. coli DH5a/pND1098 with the Qiagen Plasmid Maxi kit. T7
RNA polymerase (50000 U mL"1) was obtained from New England Bi-
oLabs Inc. (MA, USA). Cell-free protein synthesis was carried out by
using a reported procedure[8,10,21, 22] with the following few modifications.
(S)-Alanine and RNasin were not added to the inner mixture (500 mL).
T7 RNA polymerase (2 mL) was added to each reaction mixture instead
of the plasmid encoding for this enzyme. An aliquot of tRNA solution of
5 mL was added instead of 10 mL. The final concentration of the solvent
(ethanol or DMSO) used to dissolve some of the amino acid derivatives
1a–f, 2, 3a–g, 4, 5a–c, 6a,b, 7a,b, 8, 9a–c, 10a–c, 11a–d, 12, 13a–c, 14,
15a,b, 16, 17a–c, and 18 was #2%, which was established through con-
trol experiments to have no effect on protein synthesis. The His6-PpiB se-
quence (with an additional C-terminal asparagine residue;[10] mass=
19221 Da, N-formyl-His6-PpiB=19250 Da) is MHHHHHHMVT
FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR
VINGFMIQGG GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL
AMARTQAPHS ATAQFFINVV DNDFLNFSGE SLQGWGYCVF
AEVVDGMDVV DKIKGVATGR SGMHQDVPKE DVIIESVTVS
EN. The in vitro cell-free reaction mixture containing expressed His6-
PpiB was centrifuged at 12000 rpm for 2 min and the supernatant was ap-
plied to a Ni-ion affinity column equilibrated with 20 mm sodium phos-
phate, 0.5m NaCl, and 20 mm imidazole at pH 7.5 and 4 8C. Bound pro-
teins were eluted by application of 20 mm sodium phosphate, 0.5m NaCl,
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and 500 mm imidazole at pH 7.5 and 4 8C. The eluted protein fractions
were concentrated using an Amicon Ultra-4 (YM-10) centrifugal filter
device and analysed by 20% SDS-PAGE and mass spectrometry (see the
Supporting Information for further details).
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1. General Experimental 
Nuclear Magnetic Resonance (NMR) spectra were recorded on Varian Mercury 300 and 
MR400 spectrometers operating at 300 MHz and 400 MHz respectively for 1H, and 100 MHz 
for 13C. The multiplicity of signals is abbreviated as follows: d = doublet, dd = doublet of 
doublets, m = multiplet, s = singlet. NMR solvents with purity of at least 99.8% were 
purchased from Cambridge Isotope Laboratories Inc. High resolution mass spectrometry was 
conducted using a Brucker Apex 4.7T FTICR spectrometer and a Waters LCT Premier XE 
spectrometer. Protein mass spectrometry was carried out by direct injection onto an Agilent 
1100 series LC/MSD TOF instrument. HPLC was carried out using a Waters Alliance 
Separation Module 2695 with a Waters 2996 photodiode array detector. LC/MSD and HPLC 
solvents were purchased from Merck and ultrapure water (resistivity >15 MΩ cm–1) was 
prepared using a Milli-Q® reagent system. Spectra/Por® dialysis membrane (#2, MWCO: 12-
14,000) was purchased from Spectrum Laboratories Inc. SDS-PAGE gels were run on a 
Mini-PROTEIN® Tetra system and stained with Bio-Safe® Coomassie Blue stain from Bio-
Rad with reference to molecular weight standards (low range) purchased from Bio-Rad. 
Proteins were purified with a His GraviTrap® Kit from GE Healthcare and concentrated with 
Amicon® Ultra-4 (YM-10) centrifugal devices purchased from Millipore.  
 
2. Syntheses 
With the exception of the hydrazides 2 and 9a, and the ester 10c, all the amino acids 
illustrated in Figures 1-3 are available from Sigma-Aldrich®, Merck Pty. Ltd., Auspep, TCI 
Chemicals or Aurora Fine Chemicals LLC. For the purposes of this investigation, the 
hydrazides 1a-f, 9b-c and 15a,b were prepared from the free amino acids by esterification 
with thionyl chloride in methanol,[1] followed by treatment of the corresponding product 
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esters (including the leucine, phenylalanine and valine derivatives 3a-c) with hydrazine 
hydrate.[1b, 2] The phenylhydrazide 16 was synthesised from methyl 3-phenylpropanoate, 
using phenylhydrazine.[3] N-Boc-(S)-leucine 17a was prepared by treatment of (S)-leucine 
with di-tert-butyl dicarbonate.[4] Reaction of N-Boc-(S)-leucine 17a with benzyl bromide 
followed by treatment with trifluoroacetic acid gave the benzyl ester 3d, with the same 
method being used to generate the benzyl esters 3e and 3f.[4-5] Reaction of N-Boc-(S)-leucine 
17a with BOP and 1-aminoadamantane and tert-butylamine, respectively, followed by 
deprotection with trifluoroacetic acid, gave the amides 4 and 10b.[6] The acetamides 5a,b and 
11a,b were obtained by acetylation of their respective free amino acids using acetic 
anhydride.[7] Treatment of (S)-leucine and (S)-valine with ethyl trifluoroacetate yielded 
compounds 6a and 6b, respectively.[8] The benzamide 12 and the sulfonamide 17b were 
synthesised from the ester 3a using benzoyl chloride[9] and methanesulfonyl chloride,[9-10] 
respectively, followed by ester cleavage using lithium hydroxide. BOP coupling of the ester 
3a with decanoic acid then treatment with base yielded compound 17c.[11] The hydrazide 8 
was prepared by selective side chain esterification of (S)-glutamic acid using sulfuric acid in 
methanol, followed by reaction with hydrazine hydrate.[12] Acetylation of the ester 3a using 
acetic anhydride yielded the diprotected leucine 14,[13] which reacted with hydrazine hydrate 
to give the corresponding hydrazide 18.[14] The amides 5c, 7a,b and 11c,d, the esters 3g and 
10a and the side chain protected amino acids 13a-c were purchased from Sigma-Aldrich®, 
Merck Pty. Ltd., Auspep or TCI Chemicals. 
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(S)-4,5-Dehydroleucine hydrazide 25. 
 
N-Phthaloyl-(S)-γ,δ-dehydroleucine methyl ester 22[15] (8 mg, 0.029 mmol) was dissolved in 
2 mL ethanol, followed by addition of 80% hydrazine hydrate (17.8 µL, 0.29 mmol). The 
resultant solution was heated at reflux for 1 h. After cooling and evaporation of the solvent, 
the colourless residue was subjected to reverse phase HPLC (YMC-Pack ODS-AQ, 250 x 4.6 
mm, 5 µm) running a mobile phase of 20% acetonitrile in 0.1% aqueous trifluoroacetic acid 
at a flow rate of 1 mL per minute. Upon evaporation of the solvent, white needles of the title 
compound as the TFA salt were obtained (1.9 mg, 25%). M.P. 130-132 °C. HPLC tR = 2.8 
minutes. [α]20D  -19.3 (c =  0.8, H2O). 1H NMR (300 MHz, D2O): δ 1.78 (s, 3H), 2.54 (dd, J 
=14, 9 Hz, 1H), 2.62 (dd, J = 14, 6 Hz, 1H), 4.15 (dd, J = 9, 6 Hz, 1H), 4.93 (s, 1H), 5.06 (s, 
1H). 13C NMR (100 MHz, D2O) δ 21.0, 39.8, 50.8, 116.9, 138.5, 168.9. HRMS (ESI) calcd. 
for C6H14N3O [M+H]+ m/z 144.1137; found 144.1140. 
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(2S,3R)-4-Chlorovaline methyl ester 28 
 
(S)-Valine methyl ester 3a[15] (2.0 g, 11.9 mmol (hydrochloride salt)) was dissolved in 
trifluoroacetic acid (20 mL) and chlorine gas was bubbled through the solution for 5 minutes 
whilst it was irradiated with a 300 W sunlamp. After evaporation of the solvent, a sample of 
this reaction mixture was subjected to reverse phase HPLC (Atlantis, 150 x 4.6 mm, 3µm, in 
tandem with Atlantis, 250 x 4.6 mm, 5 µm) running a mobile phase of 20% acetonitrile in 
100 mM NaClO4, pH 2.1, at a flow rate of 0.8 mL per minute. Counter-ion exchange by 
HPLC (Primesep 100, 150 x 4.6 mm, 5 µm) running a mobile phase of 20% methanol in 
0.4% aqueous trifluoroacetic acid at a flow rate of 1 mL per minute, followed by evaporation 
of the solvent gave the TFA salt of the title compound as colourless powder. HPLC (Atlantis) 
tR = 15.6 minutes. HPLC (Primesep) tR = 5.4 minutes. 1H NMR (400 MHz, CD3OD) δ 1.10 
(d, J = 8 Hz, 3H), 2.35-2.45 (m, 1H), 3.66 (dd, J = 12, 6 Hz, 1H), 3.74 (dd, J = 12, 8 Hz, 1H), 
3.87 (s, 3H), 4.27 (d, J = 4 Hz, 1H). 13C NMR (100 MHz, CD3OD) δ 13.5, 39.5, 47.0, 53.8, 
55.7, 170.2. HRMS (ESI) calcd. for C6H13NO235Cl [M+H]+ m/z 166.0635, 168.0605; found 
166.0633, 168.0610; calcd. for C6H12NO235ClNa [M+Na]+ m/z 188.0454, 190.0425; found 
188.0452, 190.0428.  
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3. Compound Characterisations 
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4. Representative HPLC analyses of the deprotection of amino acid derivatives 
Analysis of the deprotection of amino acid derivatives by S30 was carried out using the 
Waters AccQ.Tag™ method as described in the Experimental Section of the manuscript. 
Below are representative analyses used to determine the extents of deprotection of the 
hydrazides 1b and 1c by S30. 
     
Figure S1. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized S30 extract incubated at 37 °C for 6 h. 
 
 
Figure S2. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-phenylalanine. 
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Figure S3. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-phenylalanine hydrazide 1b. 
 
 
 
Figure S4. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-phenylalanine hydrazide 1b incubated with S30 extract at 37 °C for 6 h. 
 
 
!
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Figure S5. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-valine. 
 
 
 
Figure S6. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-valine hydrazide 1c. 
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Figure S7. Chromatogram obtained through reverse phase HPLC of AccQ.Tag™ 
derivatized (S)-valine hydrazide 1c incubated with S30 extract at 37 °C for 6 h. 
 
5. SDS-PAGE analyses  
!
 
Figure S8.!20% SDS-PAGE of synthesised His6-PpiB with: a) no DNA; b) DNA; c) no 
(S)-leucine; d) no (S)-leucine but with the hydrazide 1a; e) no (S)-leucine but with the 
methyl ester 3a; and f) no (S)-leucine but with the ester 10a. 
!!!!!a! !!!!!!!!b!!!!!!!!!!!!!!!!c!!!!!!!!!!!!!!!!d!!!!!!!!!!!!!!!!e! !!!!!!!!f! !
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Figure S9.!20% SDS-PAGE of synthesised His6-PpiB with: a) DNA; b) no DNA; c) no 
(S)-leucine; d) no (S)-leucine but with the amide 10b; e) no (S)-leucine but with the 
amide 4; and f) no (S)-leucine but with the ester 3d. 
 
 
 
Figure S10.!20% SDS-PAGE of synthesised His6-PpiB with: a) DNA; b) no DNA; c) no 
(S)-leucine; d) no (S)-leucine but with the acetamide 5a; and e) no (S)-leucine but with 
the trifluoroacetamide 6a. 
!!!!!!a! !!!!!!!!b!!!!!!!!!!!!!!!c!!!!!!!!!!!!!!!!!!!!!!!d!!!!!!!!!!!!!!e! !!!!!!!!!!!f! !
!!!!!a! !!!!!!!!!!!!!!!!!b!!!!!!!!!!!!!!!!!!!!!!c!!!!!!!!!!!!!!!!!!d! !!!!!!!!!e! !
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Figure S11.!20% SDS-PAGE of synthesised His6-PpiB with: a) DNA; b) no DNA; c) no 
(S)-leucine; d) no (S)-leucine but with the ester 3a; e) no (S)-leucine but with the 
acetamide 5a; and f) no (S)-leucine but with the diprotected leucine 14. 
 
 
Figure S12.!20% SDS-PAGE of synthesised His6-PpiB with: a) DNA; b) no DNA; c) no 
(S)-phenylalanine but with the hydrazide 1b; d) no (S)-phenylalanine; e) no (S)-lysine but 
with the hydrazide 9a; and f) no (S)-lysine. 
!!!!!a! !!!!!!!!!!b!!!!!!!!!!!!!!!!!c!!!!!!!!!!!!!!!!d!!!!!!!!!!!!!!!!!e!!!!!!!!!!!!!!!!!f
! !
!!!!a! !!!!!!!!!b!!!!!!!!!!!!!!!!!!c!!!!!!!!!!!!!!!!!d! !!!!!!!!e! !!!!!!!!!!!!!f!
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Figure S13.!Time-dependent wild-type PpiB synthesis (19250 Da) illustrated by 20% 
SDS-PAGE of unpurified proteins after a) 10 mins; b) 20 mins; c) 30 mins; d) 40 mins; 
e) 50 mins; f) 60 mins; g) 90 mins; h) 120 mins; i) 150 mins; j) 180 mins; k) 240 mins; l) 
300 mins; and m) 360 mins incubation at 37 °C.  
 
 
Figure S14.!PpiB synthesised using the chloride 28 in place of (2S,3S)-isoleucine, 
before Ni ion affinity chromatography, illustrated by 20% SDS-PAGE showing His6-
PpiB (19250 Da) synthesised with: a) no DNA; b) DNA; c) no (S)-leucine; d) no 
(2S,3S)-isoleucine; and e) no (2S,3S)-isoleucine but with the chloride 28. 
 
 
!!!!!!!!!!a! !!!!!b!!!!!!c!!!!!!d! !!e!!!!!!!f!!!!!!!g!!!!!!h!!!!!!i!!!!!!!!j!!!!!!!k!!!!!!!l!!!!!!!!!m
! !
Marker!!!!!
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!
!!!!!!!!!!!!
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!
!!!!!!!!!!!!
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6. ESI Mass spectrometry of purified proteins 
Purified protein solutions (50 µL) were analysed by ESI mass spectrometry by direct 
injection into the spectrometer running a mobile phase of a 50:50 (v/v) solution of 0.1% 
formic acid in acetonitrile:0.1% aqueous formic acid. Deconvoluted mass spectra of native 
PpiB and PpiB synthesised in the presence of the hydrazides 23 and 25, and the chloride 28, 
are shown below.    
 
 
 
 
 Figure S15. Deconvoluted mass spectrum of native PpiB 
Mass reconstruction of  +TOF MS: 0.108 to 0.198 min from 26_03_12 Sam Karine Mantas.wiff Agilent Max. 4.6e5 cps.
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Figure S16. Deconvoluted mass spectrum of PpiB synthesised using the hydrazide 23.  
 
Figure S17. Deconvoluted mass spectrum of PpiB synthesised using the hydrazide 25. 
Mass reconstruction of  +TOF MS: 0.084 to 0.445 min from Sample 1 (Sam 7) of 25_05_12 Sam ZQ Ma... Max. 4.1e4 cps.
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Figure S18. Deconvoluted mass spectrum of PpiB synthesised using the chloride 28. 
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2.4 Additional Experimental Details 
The Supporting Information in the published article did not cover the synthesis of the 
precursors for the preparation of the (S)-4,5-dehydroleucine hydrazine (27).* Although these 
compounds had been reported previously,[17] some changes to the experimental method 
were made. The precise synthetic details used in this case have been provided below. 
 
(S)-N-Phthaloylleucine Methyl Ester (19) A mixture of (S)-leucine (8.6 g, 66 
mmol) and phthalic anhydride (9.7 g, 66 mmol) was heated for 
approximately 0.5 h at 140 °C. After cooling to 0 °C the resultant solid was 
dissolved in MeOH (100 mL) and SOCl2 (6.0 mL, 83 mmol) was added dropwise. The 
solution was stirred at RT for 18 h before it was concentrated under reduced pressure. The 
residue was dissolved in DCM and the solution was washed with saturated aqueous 
Na2CO3 twice and then H2O. The solution was then dried (MgSO4) and concentrated under 
reduced pressure to afford the title compound as a colourless oil. Yield 16.3 g (91%). ¹H 
NMR (300 MHz, CDCl3): !=7.99-7.61 (m, 4H), 4.95 (dd, 3J=11.6, 3J=4.3 Hz, 1H), 3.72 (s, 3H), 
2.33 (ddd, 2J=14.3, 3J=11.6, 3J=4.0 Hz, 1H), 1.95 (ddd, 2J=14.3, 3J=10.3, 3J=4.3 Hz, 1H), 1.48 (m, 
1H), 0.95 (d, 3J=6.6 Hz, 3H), 0.92 ppm (d, 3J=6.6 Hz, 3H); HRMS (ESI): m/z calcd for 
C15H17NO4: 276.1236 [M+H]+; found: 276.1237. These spectral data are consistent with 
reported values.[18] 
 
(S)-N-Phthaloyl-4-bromoleucine Methyl Ester (20) NBS (0.84 g, 4.7 
mmol) was added to a solution of (S)-N-phthaloylleucine methyl ester 
(19)  (1.2 g, 4.3 mmol) in CCl4 (6 mL). The resultant mixture was heated at 
reflux whilst being irradiated with a 300 W sunlamp for 2 h, before it was cooled and 
filtered. The filtrate was collected and concentrated under reduced pressure to give a yellow 
residue. Flash chromatography eluting with EtOAc/PET provided the title compound as 
off-white crystals. Yield 0.75 g (49%). M.p. 60-62 °C; ¹H NMR (300 MHz, CDCl3): !=7.95-7.65 
(m, 4H) 5.24, (dd, 3J=8.2, 3J=4.2 Hz, 1H), 3.74 (s, 3H), 2.95-2.74 (m, 2H), 1.83 (s, 3H), 1.75 ppm 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"!Compound numbering is consistent with that in the published article 
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(s, 3H); HRMS (ESI): m/z calcd for C15H1679BrNO4: 354.0341 [M+H]+; found: 354.0348. These 
spectral data are consistent with reported values.[19] 
 
(S)-N-Phthaloyl-4,5-dehydroleucine Methyl Ester (22) AgNO3 (110 mg, 
0.62 mmol) was added to a solution of (S)-N-phthaloyl-4-bromoleucine 
methyl ester (20) (130 mg, 0.37 mmol) in dry MeCN (40 mL) and the 
resultant mixture was stirred in the dark at RT for 24 h under N2, before brine was added 
and the mixture was filtered through celite. The filtrate was concentrated under reduced 
pressure and the residue dissolved in EtOAc and washed with saturated NH4Cl solution. 
The organic layer was dried (MgSO4) and concentrated under reduced pressure. HPLC 
(Grace Altima C18 250x22 mm, 5 µm) of the residue using a MeCN/H2O (40:60) at a flow rate 
15 mL min-1, gave (S)-N-phthaloyl-4,5-dehydroleucine methyl ester (22) as colourless 
crystals. Yield 15 mg (15%); HPLC tR  = 58.7 min; M.p. 77-79 °C; ¹H NMR (300 MHz, CDCl3): 
!=7.93-7.67 (m, 4H), 5.09 (dd, 3J=12.1, 3J=4.2 Hz, 1H), 4.69 (m, 1H), 4.62 (m, 1H), 3.75 (s, 3H), 
3.07 (m, 1H), 2.85 (dd, 2J=14.2, 3J=4.2 Hz 1H), 1.75 ppm (s, 3H); HRMS (ESI): m/z calcd for 
C15H15NO4Na: 296.0899 [M+Na]+; found: 296.0899. These spectral data are consistent with 
reported values.[17] 
 
(2S)-Amino-4-hydroxyl-4-methylpentanol lactone (24) Treatment of (S)-N-
phthaloyl-4,5-dehydroleucine methyl ester (22) with hydrochloric acid (2 mL, 1 
M) and acetic acid (20 µL) at reflux for 18 h resulted in formation of the lactone 24. ¹H NMR 
(300 MHz, CD3OD): !=4.80 (dd, 3J=9.2, 3J=2.3 Hz, 1H), 2.50 (dd, 3J=12.3, 3J=9.2 Hz, 1H), 2.14 
(t, 3J=12.3 Hz, 1H), 1.52 (s, 3H), 1.46 ppm (s, 3H). These spectral data are consistent with 
reported values.[20] 
 
 (S)-4,5-Dehydroleucine Hydrazide (25) (S)-N-Phthaloyl-4,5-dehydroleucine 
methyl ester (22) (8 mg, 0.029 mmol) was dissolved in EtOH (2 mL) and 80% 
hydrazine hydrate (17.8 µL, 0.29 mmol) added. The resultant solution was 
heated at reflux for 1 h, after which it was concentrated under reduced pressure to give a 
colourless residue. HPLC (YMC-Pack ODS-AQ, 250 x 4.6 mm, 5 µm) of the residue using a 
N
O
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O
H3N
O
O
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O
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mobile phase of 0.1% TFA in H2O/MeCN (80:20) at a flow rate of 1 mL min-1, gave the TFA 
salt of the title compound as colourless needles. Yield 1.9 mg (25%). HPLC tR  = 2.8 min; M.p. 
130-132 °C (H2O 0.1% TFA/MeCN); 1H NMR (300 MHz, D2O): !=5.06 (s, 1H), 4.93 (s, 1H), 
4.15 (dd, 3J=9.6, 3J=6.5 Hz, 1H),  2.62 (dd, 2J=14.2, 3J=6.5 Hz, 1H), 2.54 (dd, 2J=14.2 Hz, , 
3J=9.6 Hz, 1H), 1.78 ppm (s, 3H); 13C NMR (100 MHz, D2O): !=168.9, 138.5, 116.9, 50.8, 39.8, 
21.0; HRMS (ESI): m/z calcd for C6H14N3O: 144.1137 [M+H]+; found: 144.1140.  
 
2.4.1  1H NMR Spectra of Selected Compounds 
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For 1H NMR, HMBC, HSQC and HRMS (ESI) spectra of (S)-4,5-dehydroleucine hydrazide 
(25) please refer to the Supporting Information of the publication included in this Chapter 
(Section 2.3). 
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3 
 
Translational Incorporation of Dehydro Amino 
Acids 
 
 
3.1 Introduction 
Protein structure and function are highly dependent upon the fidelity of protein 
biosynthesis and the susceptibility of proteins to chemical modifications. Alterations to the 
defined primary sequence of proteins or to amino acid residue side chains through chemical 
reactions have been implicated in the progression of numerous diseases.[1-5] Protein 
oxidation in particular has been strongly associated with the development of several 
degenerative conditions.[6-10] This oxidation has been previously postulated to occur post-
synthesis rather than pre-synthesis, resulting from reactions with free radicals commonly 
produced through normal cellular processes.[11-13] However, despite the highly 
discriminatory process through which amino acids are selected for protein synthesis, 
oxidised amino acids have been incorporated into proteins, suggesting that this oxidation 
could also occur pre-translationally. For example, (S)-m-hydroxytyrosine produced under 
normal cellular conditions is an effective surrogate of (S)-tyrosine and is incorporated by the 
native translational machinery to produce oxidised proteins.[14] 
 
! 34 
The aliphatic amino acids (S)-valine, (S)-leucine and (2S,3S)-isoleucine are highly 
susceptible to side chain modification and in particular oxidation.[15-19] Of interest in this 
present work was the possibility that unsaturated analogues of the aliphatic amino acids 
would be misincorporated during protein biosynthesis resulting in oxidised protein. The 
seven compounds assessed represent all possible alkene analogues of (S)-valine, (S)-leucine 
and (2S,3S)-isoleucine, other than the hydrolytically labile α,β-unsaturated amino acids 
(Figure 3.1).[20] Their misincorporation was assessed in vitro using cell-free protein synthesis 
(CFPS) with translational machinery sourced from native E. coli cellular lysate.  
 
 
Figure 3.1 Dehydro amino acids under investigation in this chapter. 
 
 
3.2 Synthesis of Dehydro Amino Acids  
A literature search revealed that of the seven dehydro amino acids 1-7 of interest, the (S)-4,5-
dehydroleucine (2) and (2S,3S)-4,5-dehydroisoleucine (4) had been previously reported as 
replacements for (S)-leucine and (2S,3S)-isoleucine respectively, during protein synthesis in 
bacterial auxotrophs.[21,22] None of the other dehydro amino acids 1, 3, 5-7 had been studied 
in this context, although the dehydro amino acids 5-6 are naturally occurring.[23,24]  
 
Only the (S)-4,5-dehydroleucine (2) was commercially available and was purchased, 
while the other dehydro amino acids were synthesised. Synthetic routes to prepare each of 
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the amino acids 1, 3-7 were selected based on the number of steps and common 
methodologies. The chosen synthetic approaches reflect what was considered to be the most 
time efficient method for preparation. The dehydro amino acids 1, 3-7 were prepared as 
racemates. The use of racemic material is common for this type of incorporation study as 
there is negligible misreading of (2R)-amino acids.[22,25,26]  
 
3.2.1 Synthesis of 3,4-Dehydrovaline 
It was anticipated that deprotection of N-phthaloyl-3,4-dehydrovaline methyl ester[27] would 
provide the desired dehydrovaline 1 (Scheme 3.1). N-Phthaloyl-3,4-dehydrovaline methyl 
ester was prepared as described previously.[27]  
 
 
Scheme 3.1 Synthesis of 3,4-dehydrovaline 1. 
 
The two protecting groups of N-phthaloyl-3,4-dehydrovaline methyl ester were 
successfully removed by acid-hydrolysis to give 3,4-dehydrovaline 1. The amino acid was 
purified by precipitation upon the addition of propylene oxide to a solution of the amino 
acid 1 in hydrochloric acid and ethanol. The spectral characteristics of the 3,4-dehydrovaline 
1 are consistent with those previously reported for this amino acid.[28] 
 
3.2.2 Synthesis of 3,4-Dehydroleucine 
3,4-Dehydroleucine 3 was synthesised by a reported approach (Scheme 3.2).[29] (E)-4-
Methylpent-2-enoic acid was brominated by treatment with N-bromosuccinimide to give 
(E)-4-bromo-4-methylpent-2-enoic acid. Analysis of the product by 1H NMR spectroscopy 
confirmed the synthesis of (E)-4-bromo-4-methylpent-2-enoic acid by the doublet signals at 
both 7.29 and 5.90 ppm integrating for one proton each and possessing matching coupling 
constants, which correspond to the olefinic protons. This reaction proceeds via the allyl 
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stabilised radical, due to the stability of the tertiary radical (the major resonance contributor) 
bromination was only observed at the 4- position. 
 
 
Scheme 3.2 Synthesis of 3,4-dehydroleucine 3. 
 
Treatment of (E)-4-bromo-4-methylpent-2-enoic acid with anhydrous ammonia in 
dry tetrahydrofuran gave a mixture of both 3,4-dehydroleucine 3 and (E)-4-amino-4-
methylpent-2-enoic acid. Separation of these α- and γ- amino acids was achieved by anion 
exchange chromatography. 1H NMR spectroscopy confirmed the identity of 3,4-
dehydroleucine 3 by the olefinic resonance at 5.22 ppm integrating for one proton and by the 
signal at 4.70 ppm corresponding to the α- proton. 3,4-Dehydroleucine 3 and (E)-4-amino-4-
methylpent-2-enoic acid are formed via SN2’ and SN1 nucleophilic substitution reactions 
respectively. 
 
3.2.3 Synthesis of 4,5-Dehydroisoleucine 
4,5-Dehydroisoleucine 4 was prepared by a similar method to that reported previously 
(Scheme 3.3).[22] The alkyne product of the Steglich esterification between 
N-carbobenzyloxyglycine and but-2-yn-1-ol was reduced stereoselectively to the (Z)-alkene 
with hydrogen in the presence of Lindlar’s catalyst. 1H NMR spectroscopy confirmed the 
identity of the product, (Z)-N-carbobenzyloxyglycine but-2-enyl ester by the olefinic signals 
at 5.60-5.45 ppm integrating for two protons.  
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Scheme 3.3 Synthesis of 4,5-Dehydroisoleucine 4. 
 
A [3,3]-sigmatropic rearrangement of the (Z)-alkenyl ester provided (2RS,3RS)-N-
carbobenzyloxyglycine-4,5-dehydroisoleucine (de = 78%). This reaction proceeds via the 
formation of a chelate-bridged metal enolate by treatment with lithium diisopropylamine 
and zinc chloride, which then undergoes rearrangement with high diastereoselectivity. This 
high selectivity results from the chair-like transition state of this rearrangement. The identity 
of (2RS,3RS)-N-carbobenzyloxyglycine-4,5-dehydroisoleucine was confirmed by 1H NMR 
spectroscopy, which revealed a distinctive multiplet at 5.70 ppm which corresponds to the 
olefinic methine proton.  
 
The carbamate protecting group of the monoprotected 4,5-dehydroisoleucine was 
removed by treatment with iodotrimethylsilane in anhydrous chloroform to give 4,5-
dehydroisoleucine 4. This was confirmed by 1H NMR spectroscopy as no signals 
corresponding to aromatic proton were observed.  The 1H NMR spectra of 4,5-
dehydroisoleucine 4 was consistent with that previously reported.[30] 
 
3.2.4 Synthesis of the 3,4-Dehydroisoleucines 
It was envisaged the 3,4-dehydroisoleucines 5-7 could be prepared by deprotection of the 
corresponding N-phthaloyl-3,4-dehydroisoleucine methyl esters[31] (Scheme 3.4 & 3.5), in the 
same manner as that described for the synthesis of 3,4-dehydrovaline 1 (Section 3.2.1). The 
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N-phthaloyl-3,4-dehydroisoleucine methyl esters were synthesised as described 
previously.[31] The alkene isomers of N-phthaloyl-3,4-dehydroisoleucine methyl ester were 
only partially resolved by reverse-phase HPLC and as such were collected in two fractions. 
One fraction consisted of (E)-N-phthaloyl-3,4-dehydroisoleucine and N-phthaloyl-3,4’-
dehydroisoleucine and the other of (Z)-N-phthaloyl-3,4-dehydroisoleucine.  
 
 
Scheme 3.4 Synthesis of the 3,4-dehydroisoleucines 5-6. 
 
 
 
 
Scheme 3.5 Synthesis of the 3,4-dehydroisoleucine 7. 
 
 
Acid-catalysed hydrolysis of the diprotected dehydroisoleucines gave the 
dehydroisoleucines 5-7, which were purified by reverse-phase HPLC. 1H NMR spectroscopy 
confirmed the identity of these dehydroisoleucines 5-7, with spectral characteristics 
consistent to those reported previously.[30] 
 
 
3.3 Evaluation of the Dehydro Amino Acids as Translational 
Replacements  
CFPS was chosen to evaluate the incorporation of the dehydro amino acids 1-7 into proteins 
because of the many advantages of this approach over the use of bacterial auxotrophs as 
highlighted in Chapter 1, Section 1.6. Translational machinery for CFPS was provided by 
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the highly active s30 cellular extract of E. coli BL21(DE3) star. As previous reports have 
demonstrated that peptidyl-prolyl cis-trans isomerase B (PpiB) can be synthesised in high 
yield during CFPS with this cellular extract, it was selected as the model protein for this 
investigation. Furthermore, in a previous study this protein remained mostly soluble when 
substituted with (S)-m-hydroxytyrosine, unlike the other proteins evaluated.[14] The 
synthesis of soluble protein is desirable as it is less complicated to analyse. 
 
CFPS of PpiB was carried out at 30 °C for 18 h following a literature procedure,[32-36] 
with each of the twenty proteinogenic amino acids, when either (S)-valine, (S)-leucine or 
(2S,3S)-isoleucine were withheld, and the appropriate corresponding dehydro amino acid 
(dehydrovaline 1, the dehydroleucines 2-3, or the dehydroisoleucines 4-7) was supplied 
instead.  
 
The soluble PpiB synthesised in these experiments was purified by immobilised 
metal affinity chromatography and analysed by SDS-PAGE (Figure 3.2). Supplementation 
with the dehydrovaline 1 produced insoluble protein, this was suspended with water, 
vortexed then pelleted by centrifugation. This washing process was repeated before the 
protein was solubilised in protein sample buffer and analysed by SDS-PAGE.  
 
 
Figure 3.2 SDS-PAGE of PpiB synthesised with: A) all 20 proteinogenic amino acids, B) no (S)-valine, 
C) no (S)-valine but with the dehydrovaline 1 (soluble fraction), D) no (S)-valine but with the 
dehydrovaline 1 (insoluble fraction), E) no (S)-leucine, F) no (S)-leucine but with the dehydroleucine 
3, G) no (S)-leucine but with the dehydroleucine 2, H) no (2S,3S)- isoleucine, I) no (2S,3S)-isoleucine 
but with the dehydroisoleucines 5-7,  J) no (2S,3S)-isoleucine but with the dehydroisoleucine 4. 
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Low background levels of PpiB were produced when either (S)-valine, (S)-leucine or 
(2S,3S)-isoleucine were withheld (Lanes B, E & H of Figure 3.2). This was attributed to low 
residual levels of these amino acids present in the S30 extract, as observed previously.[35,36] A 
similar low level of protein was formed when the dehydroisoleucines 5-7 were supplied in 
place of (2S,3S)-isoleucine, indicating that none of them act as a substitute for (2S,3S)-
isoleucine (Lanes H & I of Figure 3.2). This was corroborated by analysis of the protein 
formed by mass spectrometry. Strong signals were observed at 19250 and 19220 Da 
corresponding to unmodified N-formylated His6-PpiB and His6-PpiB (Figure 3.3 & 3.4). This 
suggests that these amino acids are unacceptable substrates for isoleucyl-tRNA synthetase, 
or are subjected to proof-editing preventing their incorporation. As isoleucyl-tRNA 
synthetase is particularly sensitive to the stereochemistry at the β- position and can 
effectively discriminate between (2S,3S)-isoleucine and allo-(2S,3R)-isoleucine,[22] it is 
unlikely that these residues are activated for protein synthesis. 
 
 
Figure 3.3 Deconvoluted mass spectrum of PpiB formed in the presence of 1 mM of all twenty 
proteinogenic amino acids. 
 
Mass reconstruction of  +TOF MS: 0.066 to 0.374 min from Sample 1 (A) of 211114Sam.wiff Agilent Max. 2.0e5 cps.
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Figure 3.4 Deconvoluted mass spectrum of PpiB formed in the presence of 4.4 mM, 16 mM, and 4.0 
mM of 3,4-dehydroisoleucines 5, 6 and 7 respectively without the supplementation of (2S,3S)-
isoleucine. 
 
  The level of PpiB synthesised when the dehydro amino acids 1-4 were supplied 
instead of their proteinogenic counterparts, was similar to the amount produced when all 
twenty of the proteinogenic amino acids were added (Lanes A, D, F, G & J of Figure 3.2). 
Analysis of the soluble proteins by mass spectrometry confirmed the incorporation of the 
unnatural amino acids 2-4 with dominant peaks corresponding to near full replacement 
observed in each case. Although analysis by SDS-PAGE indicated incorporation of the 
dehydrovaline 1, the protein formed was insoluble and thus it was impractical to obtain a 
suitable mass spectrum.  
 
Analysis of the mass spectrum for PpiB formed when the (S)-4,5-dehydroleucine (2) 
was supplied revealed both modified His6-PpiB and N-formylated His6-PpiB were prepared 
(Figure 3.5). The dominant signals at 19241 and 19214 Da correspond to N-formylated 
His6-PpiB and His6-PpiB respectively, each with full substitution of (S)-4,5-dehydroleucine 
(2) in place of (S)-leucine at the five possible sites. 
Mass reconstruction of  +TOF MS: 0.043 to 0.423 min from Sample 5 (SF_5) of 14_09_11 SF.wiff Agilen... Max. 1.1e5 cps.
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Figure 3.5 Deconvoluted mass spectrum of PpiB formed in the presence of 2 mM (S)-4,5-
dehydroleucine (2) instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
The mass spectrum for PpiB formed when the 3,4-dehydroleucine 3 was supplied 
showed dominant peaks at 19242 and 19215 Da (Figure 3.6). These correspond to N-
formylated His6-PpiB and His6-PpiB respectively, each with (S)-leucine replaced by the 3,4-
dehydroleucine 3 at four of the five possible sites.  
 
 
Figure 3.6 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 3,4-dehydroleucine 
3 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen proteinogenic amino 
acids. 
Mass reconstruction of  +TOF MS: 0.060 to 0.422 min from Sample 1 (SF_1) of 14_09_11 SF.wiff Agilen... Max. 1.9e5 cps.
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Analysis of the mass spectrum for His6-PpiB formed when 4,5-dehydroisoleucine 4 
was supplied revealed both modified His6-PpiB and N-formylated His6-PpiB were prepared 
(Figure 3.7). The dominant signals at 19231 and 19205 Da correspond to the most abundant 
proteins, which have replacement of (2S,3S)-isoleucine with the 4,5-dehydroisoleucine 4 at 
all ten of the ten possible sites in N-formylated His6-PpiB and His6-PpiB respectively. 
 
 
Figure 3.7 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM (2RS,3RS)-4,5-
dehydroisoleucine 4 instead of 1 mM (2S,3S)-isoleucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
The overall degree of substitution with the dehydro amino acids 1-4 could not be 
determined by mass spectroscopy since defined peaks in the mass spectra corresponding to 
incomplete misincorporation were not resolved as they only differ by two mass units 
(Figure 3.5-3.7). Analysis of the constituent amino acids of the hydrolysed protein was 
instead utilised to determine the overall degree of substitution as it is compatible with both 
soluble and insoluble proteins, unlike 1H NMR spectroscopy.[22] 
 
Amino acid analysis was conducted for the hydrolysed samples of unmodified and 
dehydro substituted PpiB (Figure 3.8). The dehydro amino acids 1-4 could not be directly 
measured as they are unstable under the conditions required for the protein hydrolysis. 
Mass reconstruction of  +TOF MS: 0.043 to 0.441 min from Sample 4 (SF_4) of 14_09_11 SF.wiff Agilen... Max. 2.6e5 cps.
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Instead from the reduction of the mol% values for the aliphatic amino acids (S)-valine, (S)-
leucine and (2S,3S)-isoleucine, the percentage replacement with the corresponding dehydro 
amino acids 1-4 was determined. The reduction in the mol% value is directly proportional to 
the replacement level with the corresponding dehydro amino acid.  
 
Figure 3.8 Aspartic acid normalised percentage amino acid values for (S)-valine, (S)-leucine 
and (2S,3S)-isoleucine: A) calculated from the PpiB amino acid sequence, and measured by hydrolysis 
of PpiB produced with B) all 20 proteinogenic amino acids, C) no (S)-valine but with the 
dehydrovaline 1 (insoluble fraction), D) no (S)-leucine  but with the dehydroleucine 2, E) no (S)-
leucine but with the dehydroleucine 3, and F) no (2S,3S)-isoleucine but with the dehydroisoleucine 4. 
 
Substitution with a dehydro amino acid reduced the mol% values for the 
corresponding aliphatic amino acid and this in turn artificially inflated the mol% values for 
the other acid stable proteinogenic amino acids. To correct for this, the amino acid mol% 
values were normalised relative to aspartic acid. Aspartic acid was chosen for normalisation 
since experimentally it is the most abundant amino acid present in the hydrolysate of PpiB 
and is considered a reliable amino acid to measure, thus likely to have the lowest associated 
error.[37] The level of aspartic acid determined by this analysis is high because its mol% is the 
sum of the amount of aspartic acid and asparagine present in the sample (asparagine is 
hydrolysed to aspartic acid during the protein hydrolysis step).   
 
This method underestimates the degree of replacement with the dehydro amino 
acids 1-4 as the PpiB analysed is likely contaminated with trace levels of other proteins from 
the cell lysate which contribute to the levels of the aliphatic amino acids (S)-valine, (S)-
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leucine and (2S,3S)-isoleucine. While the results show some experimental variability, the 
reduction of the corresponding proteinogenic amino acids (S)-valine, (S)-leucine or (2S,3S)-
isoleucine is between 75%-85%, indicating a high overall level of replacement with the 
dehydro amino acids 1-4. This is consistent with the degree of incorporation implied by the 
level of expression in comparison to unmodified PpiB and to the incorporation indicated by 
the mass spectra of the synthesised proteins.  
 
Of the dehydro amino acids 1-7 only the 3,4-dehydroisoleucines 5-7 were not 
incorporated into PpiB. This is attributable to them being the most geometrically dissimilar 
to the saturated analogue (2S,3S)-isoleucine. By contrast, the 4,5-dehydroisoleucine 4, which 
is readily incorporated, is more geometrically similar to (2S,3S)-isoleucine with a more 
remote and less substituted double bond than the unincorporated analogues 5-7. Another 
contributing factor may be that the isoleucyl-tRNA synthetase is more substrate specific. 
Comparison of the Km values for valyl- (1.0 x 10-4 M), leucyl- (5.6 x 10-5 M) and isoleucyl-
tRNA synthetases (5.0 x 10-6 M) from E. coli ML30 with their respective amino acids show 
that isoleucyl-tRNA synthetase has greater affinity toward its native substrate.[38] Therefore 
it can be deduced that, only the 4,5-dehydroisoleucine 4 is sufficiently similar in size and 
shape to be able to compete with (2S,3S)-isoleucine for binding to isoleucyl-tRNA 
synthetase. Conversely, the broader specificity of the leucyl- and valyl-tRNA synthetases 
likely enables activation of the 4,5-dehydroleucine 2, the 3,4-dehydroleucine 3 and the 3,4-
dehydrovaline 1, even though their double bonds are less remote and/or more substituted. 
 
3.3.1 Characterisation of the Modified Proteins 
PpiB modified with the dehydro amino acids 2-4 was characterised briefly to assess any 
changes to the structure or catalytic properties of the protein. Circular dichroism 
spectroscopy of PpiB substituted with the dehydro amino acids 2-4 revealed near identical 
spectra to unmodified PpiB, indicating the secondary and tertiary structures were 
unperturbed by the incorporation of these dehydro residues (Figure 3.9). These spectra are 
comparable to that obtained previously under similar conditions.[39] 
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Figure 3.9 Circular dichroism spectra of PpiB synthesised with: ❚) proteinogenic amino acids 
(unmodified), ❚) no (S)-leucine but with the dehydroleucine 2, ❚) no (S)-leucine but with the 
dehydroleucine 3, and ❚) no (2S,3S)-isoleucine but with the dehydroisoleucine 4. 
 
 
The catalytic activity of PpiB substituted with the dehydro amino acids 2-4 was 
assessed by monitoring the isomerisation of the peptide substrate N-succinyl-(S)-Ala-(S)-
Pro-(S)-Phe-4-nitroanilide (Figure 3.10).[40]  
 
Figure 3.10 Enzymatic activity of PpiB synthesised with: ❚) proteinogenic amino acids (unmodified), 
❚) no (S)-leucine but with the dehydroleucine 2, ❚) no (S)-leucine but with the dehydroleucine 3, and ❚) 
no (2S,3S)-isoleucine but with the dehydroisoleucine 5, compared to background substrate 
isomerisation without PpiB ❚. 
 
In the assay, PpiB catalyses the geometric interconversion between the cis- isomer 
and trans- isomer of the substrate, subsequently the trans isomer is hydrolysed by 
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chymotrypsin to produce p-nitroaniline. Although the isomerisation reaction catalysed by 
PpiB occurs at an observable rate without the enzyme, this step is rate limiting and thus the 
increase in absorbance at 390 nm due to formation of p-nitroaniline is directly proportional 
to the rate of isomersation. These modified proteins were catalytically active, with activities 
indistinguishable from the unmodified enzyme. 
 
3.3.2 Competition Studies 
The relative incorporation rates for the dehydro amino acids 1-4 were determined by 
analysis of the PpiB formed when known concentrations of both amino acids were supplied. 
To directly determine the incorporation rates for the dehydro amino acids 1-4 by mass 
spectrometry it was necessary to observe defined peaks corresponding to incomplete 
misincorporation. Mass spectrometric analysis of proteins synthesised with the dehydro 
amino acids 1-4 did not reveal any distinct peaks corresponding to incomplete replacement 
(Section 3.2). This is due to inadequate resolution of the two mass units difference between a 
proteinogenic amino acid and its dehydro counterpart. Through the use of per-deuterated 
amino acids, the mass differences could be increased to enable the resolution of distinct 
peaks.  
 
CFPS of PpiB was conducted with either (S)-[D8]valine, (S)-[D10]leucine or 
(2S,3S)-[D10]isoleucine in place of the respective proteinogenic amino acid, and with the 
other nineteen proteinogenic amino acids to confirm the incorporation of these per-
deuterated amino acids. The incorporation efficiencies for these per-deuterated amino acids 
relative to their unlabelled counterparts were then established to ensure they incorporate 
with equivalent efficiency. 
 
Analysis by mass spectrometry of the protein formed in the presence of nineteen 
proteinogenic amino acids and the respective deuterated amino acid, revealed that both 
His6-PpiB and N-formylated His6-PpiB were synthesised. In each case full replacement with 
the per-deuterated amino acid was observed (Figure 3.11). 
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Figure 3.11 Deconvoluted mass spectrum of PpiB formed in the presence of: A) 2 mM (S)-[D8]valine 
instead of (S)-valine, B) 2 mM (S)-[D10]leucine instead of (S)-leucine and C) 2 mM 
(2S,3S)-[D10]isoleucine instead of (2S,3S)-isoleucine, and 1 mM of each of the other nineteen 
proteinogenic amino acids. 
Mass reconstruction of  +TOF MS: 0.065 to 0.752 min from Sample 5 (Sam 5) of 25_05_12 Sam ZQ Ma... Max. 3.4e4 cps.
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The PpiB synthesised by CFPS when (S)-[D8]valine was supplied revealed signals at 
19377 and 19349 Da corresponding to full replacement of (S)-[D8]valine in place of (S)-valine 
at the sixteen possible sites in N-formylated His6-PpiB and His6-PpiB respectively. PpiB 
synthesised by CFPS when (S)-[D10]leucine was supplied revealed signals at 19299 and 19272 
Da corresponding to full replacement of (S)-[D10]leucine in place of (S)-leucine at the five 
possible sites in N-formylated His6-PpiB and His6-PpiB respectively. Similarly, for PpiB 
synthesised when (2S,3S)-[D10]isoleucine was supplied, signals were observed at 19348 and 
19321 Da corresponding to full replacement of (2S,3S)-[D10]isoleucine in place of 
(2S,3S)-isoleucine at the ten possible sites in N-formylated His6-PpiB and His6-PpiB 
respectively. 
 
CFPS of PpiB was conducted with equal concentrations of the corresponding labelled 
and unlabelled aliphatic amino acids alongside the other nineteen proteinogenic amino 
acids. Before using these per-deuterated amino acids in competition experiments it was 
crucial to ensure they undergo translation with equal efficiency to their unlabelled 
counterparts. The protein synthesised in each of these experiments was analysed by mass 
spectrometry (Figure 3.12). 
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Figure 3.12 Deconvoluted mass spectrum of PpiB formed in the presence of: A) 2 mM (S)-[D8]valine 
and 2 mM (S)-valine, B) 2 mM (S)-[D10]leucine and 2 mM (S)-leucine and C) 2 mM 
(2S,3S)-[D10]isoleucine and 2 mM (2S,3S)-isoleucine, with 1 mM each of the other nineteen 
proteinogenic amino acids. 
Mass reconstruction of  +TOF MS: 0.058 to 0.836 min from Sample 6 (Sam 6) of 25_05_12 Sam ZQ Ma... Max. 2.2e4 cps.
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Analysis of the mass spectrum of PpiB synthesised by CFPS when equal amounts of 
the labelled and unlabelled amino acids were supplied was complex in each case (Figure 
3.12). When (S)-[D8]valine and (S)-valine were supplied the dominant signal was at 19321 Da 
corresponding to replacement with (S)-[D8]valine in place of (S)-valine at nine of the sixteen 
possible sites in N-formylated His6-PpiB. When equal amounts of the (S)-[D10]leucine and 
(S)-leucine were supplied the mass spectrum of the resulting protein showed dominant 
signals at 19270 and 19279 Da corresponding to replacement with (S)-[D10]leucine in place of 
(S)-leucine at two and three of the five possible sites in N-formylated His6-PpiB respectively. 
Similarly, the mass spectrum for PpiB synthesised in the presence of equal amounts of 
(2S,3S)-[D10]isoleucine and (2S,3S)-isoleucine showed a dominant peak at 19301 Da 
corresponding to replacement of (2S,3S)-isoleucine with the per-deuterated counterpart at 
five out of the ten possible sites. These control experiments show equivalent incorporation of 
the labelled and unlabelled amino acids. This indicated that there was no discrimination 
between the labelled and non-labelled aliphatic amino acids. As such the per-deuterated 
amino acids are suitable for use in subsequent experiments investigating the competition 
between the dehydro amino acids and their proteinogenic counterparts. 
 
CFPS was then conducted with a high concentration of the dehydro amino acid and 
low concentration of the corresponding per-deuterated amino acid. Mass spectrometry was 
conducted on the synthesised protein and dominant peaks were identified corresponding to 
incomplete substitution (Figure 3.14, 3.16, 3.18, & 3.20). At these low concentrations of the 
per-deuterated amino acids, incorporation of the corresponding non-labelled amino acid 
was observed as these proteinogenic amino acids are present at trace levels during 
CFPS.[35,36] This background level of incorporation was taken into account when calculating 
the relative incorporation efficiencies. 
 
The mass spectrum for PpiB synthesised by CFPS when 0.03 mM (S)-[D8]valine  was 
supplied revealed a dominant peak at 19283 Da corresponding to incorporation of four (S)-
[D8]valine residues at the sixteen possible sites in N-formylated His6-PpiB (Figure 3.13). The 
incorporation of background (S)-valine is significant at this low concentration of (S)-
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[D8]valine. Analysis of the mass spectrum for PpiB synthesised by CFPS when 3,4-
dehydrovaline 1 and the same low level of (S)-[D8]valine were supplied revealed a shift of 
the dominant peak from 19283 to 19266 Da, resulting from incorporation of the  3,4-
dehydrovaline 1 (Figure 3.14). An average of two 3,4-dehydrovaline residues are 
incorporated at the sixteen possible sites, i.e., 12.5%. Taking the relative concentrations of the 
(S)-3,4-dehydrovaline (1) and (S)-[D8]valine into account, the relative rate of incorporation of 
(S)-3,4-dehydrovaline (1) compared to (S)-valine is ca. 0.2% (12.5/(2/0.03)). 
 
 
Figure 3.13 Deconvoluted mass spectrum of PpiB formed in the presence of 0.03 mM (S)-[D8]valine 
instead of (S)-valine, and with 1 mM of each of the other nineteen proteinogenic amino acids. 
 
 
Mass reconstruction of  +TOF MS: 0.057 to 0.455 min from Sample 20 (Sam 20) of 27_07_12 Sam Mant... Max. 2.1e4 cps.
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Figure 3.14 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 3,4-dehydrovaline 1 
and 0.03 mM (S)-[D8]valine instead of (S)-valine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
The mass spectrum for PpiB synthesised by CFPS when 0.015 mM (S)-[D10]leucine 
was supplied revealed a dominant peak at 19280 Da corresponding to incorporation of three 
(S)-[D10]leucine residues at the five possible sites in N-formylated His6-PpiB (Figure 3.15). 
Analysis of the mass spectrum for PpiB synthesised by CFPS when (S)-4,5-dehydroleucine 
(2) and the same low level of (S)-[D10]leucine were supplied revealed a shift of the dominant 
peak from 19280 to 19252 Da resulting from the incorporation of the (S)-4,5-dehydroleucine 
(2) (Figure 3.16). An average of two (S)-4,5-dehydroleucine (2) residues are incorporated at 
the five possible sites, i.e., 40%. Taking the relative concentrations of the (S)-4,5-
dehydroleucine (2) and (S)-[D10]leucine into account, the relative rate of incorporation of (S)-
4,5-dehydroleucine (2) compared to (S)-leucine is ca. 0.3% (40/(2/0.015)). 
 
Mass reconstruction of  +TOF MS: 0.058 to 0.438 min from Sample 19 (Sam 19) of 27_07_12 Sam Ma... Max. 2411.3 cps.
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Figure 3.15 Deconvoluted mass spectrum of PpiB formed in the presence of 0.015 mM (S)-[D10]leucine 
instead of (S)-leucine, and with 1 mM of each of the other nineteen proteinogenic amino acids. 
 
 
Figure 3.16 Deconvoluted mass spectrum of PpiB formed in the presence of 2 mM 
(S)-4,5-dehydroleucine (2) and 0.015 mM (S)-[D10]leucine instead of (S)-leucine, and with 1 mM of each 
of the other nineteen proteinogenic amino acids. 
 
The mass spectrum for PpiB synthesised by CFPS when 0.03 mM (S)-[D10]leucine was 
supplied revealed a dominant peak at 19300 Da corresponding to full incorporation of (S)-
[D10]leucine in N-formylated His6-PpiB (Figure 3.17). Analysis of the mass spectrum for PpiB 
synthesised by CFPS when 3,4-dehydroleucine 3 and the same low level of (S)-[D10]leucine 
were supplied revealed a shift of the dominant peak to 19291 Da, from the incorporation of 
Mass reconstruction of  +TOF MS: 0.063 to 0.352 min from Sample 15 (Sam B) of 20_04_12 ZQ Sam S... Max. 2.4e4 cps.
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the  3,4-dehydroleucine 3 (Figure 3.18). An average of one 3,4-dehydroleucine 3 residue is 
incorporated at the five possible sites, i.e., 20%. Taking the relative concentrations of the 
(S)-3,4-dehydroleucine (3) and (S)-[D10]leucine into account, the relative rate of incorporation 
of (S)-3,4-dehydroleucine (3) compared to (S)-leucine is ca. 0.3% (20/(2/0.03)). 
 
 
Figure 3.17 Deconvoluted mass spectrum of PpiB formed in the presence of 0.03 mM (S)-[D10]leucine 
without the supplementation of (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
 
Figure 3.18 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 3,4-dehydroleucine 
3 and 0.03 mM (S)-[D10]leucine, and with 1 mM of each of the other nineteen proteinogenic amino 
acids. 
Mass reconstruction of  +TOF MS: 0.059 to 0.620 min from Sample 2 (Sam 2) of 14_08_12 Sam.wiff Agil... Max. 7.9e4 cps.
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The mass spectrum for PpiB synthesised by CFPS when 0.03 mM (2S,3S)-
[D10]isoleucine was supplied revealed a dominant peak at 19329 Da corresponding to 
incorporation of eight (2S,3S)-[D10]isoleucine residues at the ten possible sites in N-
formylated His6-PpiB (Figure 3.19). Analysis of the mass spectrum of PpiB synthesised by 
CFPS when 4,5-dehydroisoleucine 4 and the same low level of (2S,3S)-[D10]isoleucine were 
supplied revealed a shift of the dominant peak from 19329 to 19291 Da, caused by the 
incorporation of the 4,5-dehydroisoleucine 4 (Figure 3.20). An average of four 4,5-
dehydroisoleucine residues are incorporated at the ten possible sites, i.e., 40%. Taking the 
relative concentrations of the (2S,3S)-4,5-dehydroisoleucine (4) and (2S,3S)-[D10]isoleucine 
into account, the relative rate of incorporation of (2S,3S)-4,5-dehydroisoleucine (4) compared 
to (2S,3S)-[D10]isoleucine is ca. 0.6% (40/(2/0.03)). The competition efficiency of the (2S,3S)-
4,5-dehydroisoleucine (4) is interesting given that a previous study reports that the 
activation of the (2S,3S)-4,5-dehydroisoleucine (4) for protein synthesis by isoleucyl-tRNA 
synthetase is 2.5 times that of (2S,3S)-isoleucine.[22] This suggests there is significant proof-
editing of (2S,3S)-4,5-dehydroisoleucine (4) once activated by isoleucyl-tRNA synthetase.  
 
 
Figure 3.19 Deconvoluted mass spectrum of PpiB formed in the presence of 0.03 mM (2S,3S)-
[D10]isoleucine instead of (2S,3S)-isoleucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
Mass reconstruction of  +TOF MS: 0.052 to 0.469 min from Sample 18 (Sam E) of 20_04_12 ZQ Sam S... Max. 8.4e4 cps.
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Figure 3.20 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM (2RS,3RS)-4,5-
dehydroisoleucine (4) and 0.03 mM (2S,3S)-[D10]isoleucine instead of (2S,3S)-isoleucine, and with 1 
mM of each of the other nineteen proteinogenic amino acids. 
 
The competition experiments, aided by use of per-deuterated amino acids, gave 
relative rates of incorporation for 3,4-dehydrovaline 1, (S)-4,5-dehydroleucine (2), 3,4-
dehydroleucine 3 and 4,5-dehydroisoleucine 4 of ca. 0.2, 0.3, 0.3 and 0.6% respectively. These 
levels of incorporation exceed those at which the aliphatic proteinogenic amino acids 
substitute for each other. This is apparent from observation of the diminutive levels of PpiB 
produced when either (S)-valine, (S)-leucine or (2S,3S)-isoleucine were withheld (Lanes B, E 
and H of Figure 3.2). However, supplementation with one of the dehydro amino acids 1-4 at 
comparable concentrations, allows PpiB synthesis to proceed with no observable constraint 
(Lanes D, F, G and J of Figure 3.2).  
 
Previous reports estimate the average rate of misincorporation in vivo between 
proteinogenic amino acids to be approximately one in every ten thousand (0.01 %),[41,42] and 
the error rate for incorporation of (S)-valine in place of (2S,3S)-isoleucine is at most 
0.03%.[43,44] Here the relative rates of incorporation for the dehydro amino acids 1-4 of 0.2-
0.6% significantly exceed these values. It is likely the greater misincorporation of the 
dehydro amino acids 1-4 reflects the evolutionary pressure applied to tRNA-synthetases and 
the relevant editing mechanisms to distinguish between the proteinogenic amino acids in 
Mass reconstruction of  +TOF MS: 0.138 to 0.247 min from Sample 15 (Sam E) of 13_04_12 Sam Lucy.... Max. 3.6e4 cps.
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order to maintain translational fidelity and protein integrity. By contrast, there has been 
much less stringent evolutionary pressure to discriminate against the oxidised amino acids 
1-4, at least under circumstances encountered by nature. 
 
 
3.4 Evaluation of the Antibiotic Activity of 3,4-Dehydrovaline 
The incorporation of dehydrovaline 1 into PpiB resulted in the production of only insoluble 
protein, unlike substitution with the other dehydro amino acids 2-4 where the resulting PpiB 
was soluble. Its potential antibiotic activity was therefore examined against E. coli BL21 star 
(DE3), the strain used as the source of the extract employed in the cell-free protein synthesis 
experiments (Figure 3.21). The IC50 of 3,4-dehydrovaline 1 was found to be approximately 
100 mM for E. coli grown in minimal media. Although this adverse effect on cell viability 
could be due to a variety of factors, one possibility is that the misincorporation of the 
dehydrovaline 1 into proteins is widespread and impacts on protein function in cells. Based 
on the normal cellular concentration of (S)-valine in E. coli of around 4 mM[45] and, as 
discussed previously (Section 3.3.2), the relative rate of incorporation of the dehydrovaline 1 
compared to (S)-valine into PpiB of 0.2%, the extent of misincorporation of the 
dehydrovaline 1 at its IC50 of 100 mM would be about 5% (100/4 x 0.2%). 
 
Figure 3.21 Cell growth of E.coli BL21 star (DE3) in minimal media doped with 3,4-dehydrovaline 1, 
monitored by the absorbance at 600 nm as a function of time. 
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3.5 Conclusions 
Of the seven dehydro analogues of (S)-valine, (S)-leucine and (2S,3S)-isoleucine evaluated, 
four dehydro amino acids 1-4 were found to be effective surrogates of their corresponding 
aliphatic amino acid counterparts in protein biosynthesis with native translational 
machinery. This incorporation of dehydro amino acids to produce oxidised protein 
demonstrates, together with a previous study,[14] that protein oxidation is not exclusively a 
post-translational process. Furthermore, protein oxidation was found to affect protein 
structure, which may lead to adverse cellular function as observed in the antibiotic activity 
of the 3,4-dehydrovaline 1. The rates of incorporation for the four dehydro amino acids 1-4 
in place of either (S)-valine, (S)-leucine or (2S,3S)-isoleucine ranged from ca. 0.2% to 0.6%. 
This is significantly higher than the in vivo misincorporation rate of proteinogenic amino 
acids, which is approximately 0.01%.[41,42] The lesser misincorporation of the proteinogenic 
amino acids relative to the dehydro amino acids 1-4 likely reflects the evolution of tRNA-
synthetases and editing mechanisms to distinguish between the normal amino acids, in 
order to maintain translational fidelity and protein integrity. Overall, seven dehydro amino 
acids have been evaluated, four of which incorporate into proteins utilising a readily 
adaptable, scalable and efficient approach.   
 
 
3.6 Experimental Details 
3.6.1 Syntheses of Dehydro Amino Acids 
Synthesis of 3,4-dehydrovaline 1 
3,4-Dehydrovaline 1 N-Phthaloyl-3,4-dehydrovaline methyl ester[27] (40 mg, 0.15 
mmol) was added to a solution of 4 M HCl (1 mL) and AcOH (0.2 mL). The 
mixture was heated at reflux for 7.5 h, after which it was concentrated under reduced 
pressure to give a colourless solid. The solid was purified by dissolution in EtOH/HCl 
followed by the addition of propylene oxide,[46] which produced a fine colourless precipitate 
of the title compound that was collected by centrifugation. Yield 13 mg (73%); M.p. >217 °C 
(decomp.); ¹H NMR (300 MHz, D2O): δ=5.22 (s, 1H), 5.20 (s, 1H), 4.25 (s, 1H), 1.77 ppm (s, 
H3N
O
O
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3H); HRMS (ESI): m/z calcd for C5H10NO2: 116.0712 [M+H]+; found: 116.0712. These spectral 
data are consistent with reported values.[28]  
 
Synthesis of 3,4-dehydroleucine 3 
(E)-4-Bromo-4-methylpent-2-enoic Acid NBS (0.86 g, 4.8 mmol) was added 
to a solution of (E)-4-methylpent-2-enoic acid (0.52 mL, 4.4 mmol) in 
α,α,α-trifluorotoluene (10 mL) and the resultant mixture was heated at reflux for 0.5 h, before 
it was cooled and filtered, and the filtrate was concentrated under reduced pressure. 
Crystallisation of the residue from α,α,α-trifluorotoluene afforded 
(E)-4-bromo-4-methylpent-2-enoic acid as a colourless solid. Yield 0.70 g (82%); M.p. 101-102 
°C; 1H NMR (300 MHz, CDCl3): δ=7.27 (d, 3J=15.3 Hz, 1H), 5.90 (d, 3J=15.3 Hz, 1H), 1.93 
ppm (s, 6H); HRMS (ESI): m/z calcd for C6H879BrO2: 190.9708 [M-H]-; found: 190.9709. These 
spectral data are consistent with reported values.[29]  
 
3,4-Dehydroleucine 3 Anhydrous NH3 (50 mL) was added to a solution of 
(E)-4-bromo-4-methylpent-2-enoic acid (75 mg, 0.39 mmol) in dry THF (2 mL) 
and the mixture was let stand for 16 h before it was concentrated under reduced 
pressure to give an off-white solid. HPLC ion-exchange chromatography (Waters Spherisorb 
SAX C18 250 x 1.6 mm, 5 µm) of this material using a mobile phase of 0.25% AcOH in H2O at 
a flow rate of 0.7 mL min-1, followed by HPLC (Alltech Prevail C18 250 x 10 mm, 5 µm) using 
a mobile phase of 0.1% TFA in H2O at a flow rate of 4 mL min-1, gave the TFA salt of 3,4-
dehydroleucine 3 as a colourless solid. Yield 7 mg (7%); HPLC tR = 14.9 min; M.p.  216-218 
°C (decomp.); 1H NMR (400 MHz, D2O): δ=5.22 (d, 3J=10.0 Hz, 1H), 4.70 (d, 3J=10.0 Hz, 1H), 
1.81 ppm (s, 6H); 13C NMR (101 MHz, CDCl3): δ=173.2, 145.5, 115.1, 52.4, 25.5, 18.2 ppm; 
HRMS (ESI): m/z calcd for C6H12NO2: 130.0868 [M+H]+; found: 130.0868. These spectral data 
are consistent with reported values.[29]  
 
 
 
OH
O
Br
H3N
O
O
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Synthesis of 4,5-dehydroisoleucine 4 
N-Cbz-glycine But-2-ynyl Ester A solution of N-Cbz-glycine (1.0 g, 4.8 
mmol), but-2-yn-1-ol (0.36 mL, 4.8 mmol) and DCM (11 mL) was added 
to a solution of DMAP (58 mg, 0.48 mmol) and DCC (0.99 g, 4.8 mmol) 
in DCM (8 mL) maintained at -20 °C, then the mixture was stirred and 
allowed to warm to RT over 3 h. The colourless precipitate that formed during this time was 
separated by filtration and washed with DCM. The combined filtrates were washed with 1 M 
HCl and saturated aqueous NaHCO3, and the washings were extracted with DCM. The 
combined organic phases were dried (MgSO4) and concentrated under reduced pressure. 
Flash chromatography of the residual oil on silica, eluting with EtOAc/hexane provided N-
Cbz-glycine but-2-ynyl ester as a colourless solid. Yield 1.1 g (91%); M.p. 52-54 °C; 1H NMR 
(300 MHz, CDCl3): δ=7.39-7.29 (m, 5H), 5.26 (br s, 1H), 5.13 (s, 2H), 4.72 (d, 4J=2.3 Hz, 2H), 
4.03 (m, 2H), 1.85 ppm (t, 5J=2.3 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ=169.6, 156.4, 136.1, 
128.5, 128.1, 128.0, 83.8, 72.5, 67.0, 53.6, 42.6, 3.6 ppm; HRMS (ESI): m/z calcd for 
C14H15NO4Na: 284.0899 [M+Na]+; found: 284.0899.  
 
(Z)-N-Cbz-glycine But-2-enyl Ester Lindlar’s catalyst (100 mg) was 
added to a solution of N-Cbz-glycine but-2-ynyl ester (1.1 g, 4.2 mmol) 
in dry MeOH (70 mL) and the mixture was stirred at RT under an 
atmosphere of H2 for 4 h, before it was filtered through celite, and the celite was washed 
with MeOH. The combined MeOH solutions were concentrated under reduced pressure to 
give (Z)-N-Cbz-glycine but-2-enyl ester as a colourless oil. Yield 1.1 g (97%); 1H NMR (300 
MHz, CDCl3): δ=7.39-7.29 (m, 5H), 5.82-5.65 (m, 1H), 5.60-5.45 (m, 2H), 5.11 (s, 2H), 4.70 (d, 
3J=6.9 Hz, 2H), 3.95 (d, 3J=5.6 Hz, 2H), 1.69 ppm (d, 3J=6.6 Hz, 3H); 13C NMR (75 MHz, 
CDCl3): δ=170.1, 156.4, 136.2, 130.3, 128.5, 128.1, 128.1, 123.5, 67.0, 60.9, 42.7, 13.1 ppm; 
HRMS (ESI): m/z calcd for C14H17NO4Na: 286.1055 [M+Na]+; found: 286.1055. An analytically 
pure sample was obtained by HPLC (Grace Altima C18 250 x 22 mm, 5 µm) using a mobile 
phase of 0.1% TFA in MeOH/H2O (65:35) at a flow rate of 10 mL min-1. HPLC tR  = 19.8 min; 
elemental analysis calcd (%) for C14H17NO4: C 63.87, H 6.51, N 5.32; found: C 64.18, H 6.82, N 
5.59. 
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(2RS,3RS)-N-Cbz-4,5-dehydroisoleucine nBuLi (3.6 mL, 5.8 mmol, 1.6 M 
in hexanes) was added slowly to a stirred solution of diisopropylamine 
(0.8 mL, 5.8 mmol) in dry THF (20 mL) maintained at -20 °C under an 
atmosphere of N2. After 20 min, the solution was cooled to -78 °C and (Z)-
N-Cbz-glycine but-2-enyl ester (0.51 g, 1.9 mmol) in dry THF (30 mL) was added. After 5 
min, ZnCl2 (0.32 g, 2.3 mmol) was added in portions, and the resulting mixture was allowed 
to warm to RT over 6 h, before 1 M HCl was added and the mixture was concentrated under 
reduced pressure. The oily residue was dissolved in Et2O and the solution washed with 1 M 
HCl and then twice with 1 M NaOH. The aqueous washings were combined, acidified to pH 
1 with HCl and extracted twice with Et2O. The combined organic phases were dried 
(MgSO4) and concentrated under reduced pressure. Flash chromatography of the residual 
yellow oil on silica, eluting with AcOH/EtOAc/hexane, afforded a ca. 4:1 mixture of 
diastereoisomers of N-Cbz-4,5-dehydroisoleucine as a colourless solid. Yield 0.35 g (68%); 1H 
NMR (300 MHz, CDCl3): δ=9.35 (br s, 1H), 7.39-7.29 (m, 5H), 5.70 (ddd, 3J=17.4, 3J=9.9, 
3J=6.9 Hz, 1H), 5.24-5.12 (m, 5H), 4.41 (dd, 1H, 3J=8.7, 3J=4.4 Hz, 0.8 x 1H), 4.24 (m, 0.2 x 
1H), 2.86 (m, 1H), 1.14 ppm (d, 3J=6.9 Hz, 3H); HRMS (ESI): m/z calcd for C14H18NO4: 
264.1236 [M+H]+; found: 264.1234. These spectral data are consistent with reported values.[47]  
 
(2RS,3RS)-4,5-Dehydroisoleucine 4 Iodotrimethylsilane (0.46 mL, 3.3 mmol) 
was added to a stirred solution of a ca. 4:1 mixture of the diastereoisomers of N-
Cbz-4,5-dehydroisoleucine (0.29 g, 1.1 mmol) in dry CHCl3 (10 mL). After 20 
min, MeOH (10 mL) was added and the solution was concentrated under 
reduced pressure, to give a colourless solid that was washed with Et2O. The solid was 
purified by dissolution in EtOH/HCl followed by the addition of propylene oxide,[46] to give 
colourless crystals of the (2RS,3RS)-4,5-dehydroisoleucine 4 together with ca. 5% of the 
diastereoisomer. Yield 60 mg (47%); M.p. 216-217°C (decomp.); 1H NMR (400 MHz, D2O): 
δ=5.77 (ddd, 3J=16.6, 3J=9.8, 3J=5.6 Hz, 1H), 5.28-5.24 (m, 2H), 3.77 (d, 2J=5.6 Hz, 0.05 x 1H), 
3.63 (d, 2J=5.6 Hz, 0.95 x 1H), 2.85-2.75 (m, 1H), 1.03 (d, 3J=7.2 Hz, 0.95 x 3H), 0.97 ppm (d, 
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3J=7.2 Hz, 0.05 x 3H); HRMS (ESI): m/z calcd for C6H10NO2: 128.0712 [M-H]-; found: 128.0713. 
These spectral data are consistent with reported values.[22] 
 
Synthesis of 3,4'-Dehydroisoleucine 5 and (E)-3,4-Dehydroisoleucine 6 
3,4'-Dehydroisoleucine 5 and (E)-3,4-Dehydroisoleucine 6 A solution of 4 M HCl 
(1 mL) and AcOH (60 µL) was added to a ca. 4:1 mixture of (E)-N-phthaloyl-3,4-
dehydroisoleucine methyl ester[31] and N-phthaloyl-3,4'-dehydroisoleucine 
methyl ester[31] (10 mg, 0.037 mmol). The mixture was heated at reflux for 3 h, 
after which it was concentrated under reduced pressure. HPLC (YMC-Pack 
ODS-AQ C18 250 x 4.6 mm, 5 µm) of the colourless solid using a mobile phase of 0.1% TFA 
in H2O/MeCN (97:3) at a flow rate of 1 mL min-1, gave the TFA salt of a ca. 4:1 mixture of 
(E)-3,4-dehydroisoleucine 6 and 3,4'-dehydroisoleucine 5 as a colourless solid. Yield 4 mg 
(45%); HPLC tR  = 3.55 min; ¹H NMR (400 MHz, D2O): δ=5.85 (q, 3J=6.8 Hz, 0.8 x 1H), 5.31 
(d, 2J=1.2 Hz, 0.2 x 2H), 4.45 (s, 0.2 x 1H), 4.42 (s, 0.8 x 1H), 2.27-2.05 (m, 0.2 x 2H), 1.70 (s, 0.8 
x 3H), 1.68 (t, 3J=1.8 Hz, 0.8 x 3H), 1.10 ppm (t, 3J=7.6 Hz, 0.2 x 3H); HRMS (ESI): m/z calcd 
for C6H11NO2Na: 152.0687 [M+Na]+; found: 152.0689. These spectral data are consistent with 
reported values.[30]  
 
Synthesis of 3,4-dehydroisoleucine 7 
 (Z)-3,4-Dehydroisoleucine 7 A solution of 4 M HCl (1 mL) and AcOH (60 µL) 
was added to (Z)-N-phthaloyl-3,4-dehydroisoleucine methyl ester[31] containing 
ca. 4% N-phthaloyl-3,4'-dehydroisoleucine methyl ester (5 mg, 0.070 mmol). The mixture 
was heated at reflux for 3 h, after which it was concentrated under reduced pressure. HPLC 
(YMC-Pack ODS-AQ C18 250x4.6 mm, 5 µm) of the colourless solid using a mobile phase of 
0.1% H2O/MeCN (97:3) at a flow rate of 1 mL min-1, gave the TFA salt of (Z)-3,4-
dehydroisoleucine 7 together with ca. 4% 3,4'-dehydroisoleucine 5 as a colourless solid. Yield 
3 mg (67%); HPLC tR  = 3.55 min; ¹H NMR (400 MHz, D2O): δ=5.83 (q 3J=7.1 Hz, 0.96 x 1H), 
4.93 (s, 0.96 x 1H), 1.75 (d, 3J=6.8, 0.96 x 3H), 1.71 (s, 0.96 x 3H); HRMS (ESI): m/z calcd for 
C6H12NO2: 130.0868 [M+H]+; found: 130.0866. These spectral data are consistent with 
reported values.[30]  
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3.6.2 NMR Spectra of Selected Compounds 
Spectra of samples recorded in D2O have been recorded with and without reference 
material. Both spectra have been provided for clarity. 
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3.6.3 Cell-Free Protein Synthesis 
Cell-free protein synthesis was carried out following a literature procedure at 30 °C for 18 
h.[32-36] The synthesis of unmodified PpiB was performed with supplementation of each of 
the twenty proteinogenic amino acids at a concentration of 1 mM. Misincorporation 
experiments were performed in the same manner but instead of supplementation with 
either (S)-valine, (S)-leucine or (2S,3S)-isoleucine, a 4 mM concentration of the racemic 3,4-
dehydrovaline 1, 3,4-dehydroleucine 3, 4,5-dehydroisoleucine 4 or a 2 mM concentration of 
the (S)-4,5-dehydroleucine (2) (Chem-Impex International, Inc.), or a mixture comprising 4, 
16 and 4 mM concentrations of the 3,4-dehydroisoleucines 5-7, respectively.  
 
The per-deuterated amino acids (S)-[D8]valine, (S)-[D10]leucine, and (2S,3S)-
[D10]isoleucine were purchased from Cambridge Isotope Laboratories, Inc. Experiments to 
evaluate the efficiencies of incorporation of the deuterated amino acids, and the dehydro 
amino acids 1-4, relative to (S)-valine, (S)-leucine or (2S,3S)-isoleucine, were performed in 
the same way as above but varying the concentration of the competing species (detailed in 
main text).  
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 Soluble proteins were purified at 4 °C on a 1 mL His-Trap HP column (GE 
Healthcare). The bound protein was washed with binding buffer 30 mL (0.5 M NaCl, 20 mM 
sodium phosphate, 32 mM imidazole, pH 7.4) and eluted with 5 mL (0.5 M NaCl, 20 mM 
sodium phosphate, 500 mM imidazole, pH 7.4).! Insoluble proteins were purified by 
suspension in Milli-Q water, pelleting the insoluble material by centrifugation and then 
removing the supernatant. This was repeated twice.! Soluble protein samples were 
concentrated at 4 °C with Amicon Ultra-4 (YM-10) centrifugal devices (EMD Millipore, 
Merck KGaA). 
 
3.6.4 Amino Acid Analysis 
Amino Acids analysis was performed by the Australian Proteome Analysis Facility, 
Macquarie University, NSW, Australia. Samples in Milli-Q water were subjected to gas 
phase hydrolysis with 6 M HCl at 110 °C for 24 h followed by analysis using Waters AccQ-
Tag Ultra chemistry. This was performed in duplicate and the results presented as an 
average. Cysteine and tryptophan were not analysed by this method. Asparagine and 
glutamine are hydrolysed in this process to aspartic acid and glutamic acid respectively and 
the amount of these amino acids given is the sum of their respective components. The 
results provided below are uncorrected percentage mole values (Table 3.1). 
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Table 3.1 Amino acid mole percentage values for PpiB. 
Amino Acid Theoretical Unmodified 3,4-Dehydrovaline 1 4,5-Dehydroleucine 2 3,4-Dehydroleucine 3 4,5-Dehydroisoleucine 4 
Histidine 6.4 6.5 6.5 6.8 6.7 6.8 
Serine 3.5 3.7 2.8 3 3.4 3 
Arginine 2.9 3.6 3.9 3.3 3.3 3.2 
Glycine 9.3 11.1 11.2 9.9 9.9 10.2 
Aspartic Acid 14 14.1 15.2 15.3 14.8 15.4 
Glutamic Acid 9.3 9.2 10.7 9.4 10.2 10 
Threonine 7 6.9 6.1 6.7 7.1 6.7 
Alanine 5.8 5.7 7.3 6.1 6.3 6.3 
Proline 2.9 3 3.7 3.8 3.1 3.4 
Lysine 6.4 6.4 7.2 6.9 6.8 7 
Tyrosine 1.7 1.7 2.2 1.9 2.5 2.4 
Methionine 4.1 4 3.4 2.1 4.2 3.2 
Valine 9.3 8.8 1.9 10.4 8.5 10.6 
Isoleucine 5.8 5.2 6.4 6.2 5.4 0.9 
Leucine 2.9 3 4.3 0.7 0.6 3.4 
 
 
3.6.5 Enzymatic Activity of PpiB 
Enzyme activity was determined using reported conditions.[40] UV/Vis spectrophotometric 
studies were conducted using a Shimadzu UV-2450 UV/Vis spectrophotometer with a 
Shimadzu CPS-temperature controller running with UV probe Version 2.0 software. The 
peptide substrate was dried in vacuo over P2O5 for 18 h. LiCl was dried in vacuo at 150 °C for 
18 h. Trifluoroethanol was dried over activated 4 Å molecular sieves for 48 h. Solutions were 
prepared under an atmosphere of dry N2. Peptide substrate (N-succinyl-(S)-Ala-(S)-Ala-(S)-
Pro-(S)-Phe-4-nitroanilide, 25 mg, 0.04 mmol) was dissolved in a solution of LiCl in dry 
trifluoroethanol (0.3 M, 16.5 mL). The assay buffer (800 µL, 50 mM HEPES, 100 mM NaCl, pH 
8.0) was added to a quartz cuvette and cooled to 0 °C, a chymotrypsin solution (10 µL, 50 mg 
mL-1 in 1 mM HCl) and 10 µL of PpiB buffer (20 mM NaH2PO4, 0.5 M NaCl, pH 7.4) was then 
added and a UV/Vis trace was recorded as a baseline. The peptide solution (25 µL) was then 
added and absorbance from 270 to 470 nm monitored until the reaction was complete. This 
was repeated with addition of PpiB (10 µL, 2.0 µM, 20 mM NaH2PO4, 0.5 M NaCl, pH 7.4).  
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3.6.6 Antibiotic Activity of 3,4-Dehydrovaline 
E.coli BL21 star (DE3) were grown in 56X minimal media overnight. 1023 mL of 56X minimal 
media consists of 50 mL of a (20 x) minimal media salt solution ((NH4)2SO4 20 g, K2HPO4 106 
g, pH 7.1 in 500 mL of H2O), Casein hydrolysate (CAS amino acids) 5 g, H2O 950 mL 
autoclaved. Glucose (2 M, 20 mL) and MgCl2 (1 M, 1 mL) are autoclaved and added 
separately, along with filtered vitamin B1 (1 mg mL-1, 1 mL), and adenosine monophosphate 
(100 mg mL-1, 1 mL). 150 µL of minimal 56X media with different concentrations of 
3,4-dehydrovaline 1 was pipetted in the wells of a 96 microtitre plate and were inoculated 
with 5 µL of E.coli BL21 star (DE3) in minimal 56X media. Cell growth at 37 °C was 
monitored by the change in absorbance at 600 nm on a Molecular Devices SpectraMax M2e 
microplatereader. The 96 microtitre plate was shaken for 20 s prior to the initial read and 
following this 30 s for the subsequent readings. 3,4-dehydrovaline 1 concentrations were 
assessed in triplicate and the results expressed as an average. 
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4 
 
Peptide Production by Chemical Cleavage of 
Dehydro Amino Acids 
 
 
4.1 Introduction 
The interest in peptides for material science applications and as potent pharmaceutical 
agents has increased exponentially in recent years.[1-6] As such the efficient and sustainable 
synthesis of peptides is of on-going importance.[6-8] Peptides can be prepared by either 
chemical synthesis or the use of recombinant systems. Chemical approaches to produce 
peptides are typically either: solution-phase synthesis (the method of choice for the 
preparation of peptides less than 15 amino acids in length) or solid-phase synthesis (which is 
ideally suited for peptides up to 50 amino acids long). These methods are well established 
and remain popular choices for both small and large-scale production of peptides despite 
characteristically suffering from poor atom economy and overall low efficiency. 
Furthermore, these methods are generally impractical for producing longer and more 
complex peptides due to peptide truncation and/or chain aggregation, both of which lead to 
complex impurity profiles and poor yields (Chapter 1, Section 1.5.1). These drawbacks can 
be partially overcome by hybrid approaches such as combinations of solid-phase peptide 
synthesis with solution-phase synthesis[9-11] or solid-phase peptide synthesis with native 
chemical ligation.[12-14] Chemoenzymatic methods can also be used to generate peptides by 
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employing enzymes under conditions in which aminolysis is favoured to create amide 
bonds between amino acids.[15] The major limitations of these methods are, reduced control 
over the final peptide sequence and difficulty in preparing longer sequences.[15]  
 
Recombinant methods are an attractive alternative to chemical methods for peptide 
production. The starting materials are typically cheaper than those required for chemical 
synthesis and the preparation of large complex peptides such as venom peptides is more 
readily achievable.[16] Whilst the method development costs for such systems are invariably 
greater than chemical approaches, recombinant systems are a more sustainable form of 
chemistry.[17]  
 
The overexpression of eukaryotic peptides in recombinant bacterial hosts is met with 
several challenges these include, their susceptibility to rapid proteolytic degradation,[18,19] the 
potential for insoluble expression leading to irreversible aggregation,[20] and the toxicity of 
some eukaryotic peptides (in particular antibiotic peptides) to bacterial cells.[21,22] These 
complications limit the diversity of peptides that can be simply expressed without the need 
for method modification. Generally, if the peptides are sufficiently large and promptly form 
inclusions bodies (providing these can be reconstituted into soluble peptides) they may be 
directly expressed since inclusion bodies are not susceptible to proteolysis.[23-25] CFPS is a 
more versatile method for the synthesis of peptides than in vivo systems since the conditions 
can be readily controlled and adapted. The synthesis of reasonable quantities of calcitonin 
(3.4 kDa) has been achieved using CFPS with continual removal of synthesised peptide to 
ensure minimal proteolytic degradation.[26] However typical CFPS systems do not allow 
ready removal of the product and such a setup is more complicated and is not feasible for 
large scale or high-throughput expressions without specialist equipment.  
 
To overcome the complications associated with the direct expression of peptides 
using recombinant technology, peptides can be expressed fused to a carrier protein. This is 
akin to the production of peptide hormones in nature where they are masked in a 
pro-hormone until hydrolytically activated.[27] Two types of carriers exist, 
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solubility-enhancing carriers or aggregation-promoting carriers. The former encourages 
overexpression of soluble fusion protein and can be utilised to purify the fusion product (e.g. 
thioredoxin).[28,29] Conversely, aggregation-promoting carriers encourage the formation of 
insoluble protein generally as inclusion bodies.[30,31] Insoluble proteins can be simply purified 
through centrifugation and washing steps before resolubilisation. Tethering a peptide to a 
carrier protein assists in prevention of proteolytic degradation of the peptide hormone and 
alleviates any toxic affects of the peptide.[20] An alternative fusion approach is the expression 
of the peptide as a polymer of tandem repeating peptide units in attempt to increase peptide 
yield.[32-35] For either method, cleavage of the protein backbone is required to release the 
peptide from the carrier protein or other peptide units.  
 
The protein backbone is comprised of amide bonds that are extremely resistant to 
hydrolytic cleavage under mild biological conditions. Whilst the spontaneous hydrolysis of 
amides is estimated to proceed on a timescale of hundreds of years,[36,37] heating at reflux in 
the presence of a strong acid or base will unselectively cleave amide bonds.[38] For the 
purposes of cleaving the protein backbone to produce peptides, cleavage needs to be highly 
selective. Several selective approaches exist and can be categorised as either self-cleaving, 
enzymatic or chemical.  
 
4.1.1 Self-Cleavage 
Proteins are able to site-specifically cut their own backbone if they possess an auto-
processing sequence. In nature, these self-cleaving elements exist to excise a section of the 
protein backbone and then rejoin the external flanking portions.[39] This cleavage can be 
induced by a change in temperature, shift in pH or the addition of a thiol reagent.[40] A 
number of examples exist where self-cleaving elements have been utilised in fusion proteins 
to prepare peptides.[41-49] Cleavage of the protein backbone by this approach is characterised 
by long reaction times and low yields as a result of premature or incomplete cleavage.  
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4.1.2 Enzymatic Cleavage 
Enzymatic methods are invariably faster and more versatile than self-cleaving methods. In 
nature rapid cleavage of the protein backbone is achieved enzymatically using proteases of 
which there are over 200 reported.[50] Proteases intended to cleave fusion proteins need to be 
carefully selected since they range from highly specific (i.e., trypsin which cleaves arginine 
or lysine residues at the carboxyl terminal side of the amide bond) to poorly specific (i.e., 
proteinase K that can digest an entire protein into its constituent amino acids).  
 
A number of enzymes have been employed to cleave fusion proteins, with 
enterokinase, thrombin and factor Xa the most commonly employed.[51,52] Cleavage 
efficiencies for these proteases can be very poor and in some cases this is due to steric 
hindrance.[53-56] More recent alternatives include the tobacco etch virus (TEV) and small 
ubiquitin modifier (SUMO) proteases, these display high specificity and are tolerant of a 
variety of conditions and can even function in the presence of low levels of urea.[52,57,58] 
SUMO protease is unique in that it recognises the tertiary structure of the SUMO carrier 
protein. This makes it more specific than proteases that identify the cleavage positions based 
a specific sequence motif.[58]  
 
Limitations to the employment of enzymatic cleavage methods vary with enzyme 
selection but can include: (i) the need for optimisation of reaction conditions to ensure only 
the desired cleavage occurs, (ii) incompatibility with residues that have been post-
translationally modified[59] or positions where non-proteinogenic amino acids have been 
introduced, (iii) restricted proteolytic activity at sterically hindered sites,[60] (iv) susceptibility 
of some proteases to autolysis (intermolecular digestion) leading to contamination of the 
cleavage products and (v) formation of truncated peptide due to the presence of an internal 
protease recognition site. Chemical cleavage methods, although less specific, are immune to 
several of the limitations (ii, iii and iv) applicable to enzymatic cleavage.[55]  
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4.1.3 Chemical Cleavage   
The use of chemical reagents is often preferential to enzymatic fragmentation since they can 
be used to cleave fusion proteins under both physiological and denaturing conditions,[61,62] 
and are more cost effective.[63]  
 
Metal complexes and metal ions have been extensively investigated as candidates for 
site-specific protein cleavage. Since the stability of amides derives from the resonance effect, 
apart from activating the bond by distortion,[64] metal ions can activate amides for hydrolysis 
by acting as Lewis acids. Metals shown to site-specifically cleave proteins include, Pt2+,[65,66] 
Pd2+,[67,68] Ni2+,[69,70] Co3+,[71] Mo6+,[72] Ce4+,[73] Fe2+[74-77] and Cu2+.[78-82] Although most of these 
reactions proceed with good selectivity, long reaction times are necessary at elevated 
temperatures, which is generally not compatible with proteins. Furthermore metals ions can 
induce protein aggregation, while Fe and Cu are known to catalyse the oxidation of several 
protein side chains.[83] To date metal complexes or ions have not been used for preparation of 
peptides from fusion proteins.  
 
Organic and non-metal based inorganic reagents are commonly employed to cleave 
fusion proteins to produce peptides these include; hydroxylamine,[84-87] formic acid,[31,63,88,89] 
acetic acid,[90] 2-(2-nitrophenylsulphenyl)-3-methyl-3’-bromoindolene,[91] o-iodosobenzoic 
acid[92] and cyanogen bromide.[93-98] Cyanogen bromide in 70% formic acid remains the most 
widely employed chemical cleavage method, which targets cleavage at the C-terminus of 
methionine. Its widespread use is due to the low abundance of methionine in peptides and 
the typically quantitative cleavage efficiency achieved – except where methionine is prior to 
a threonine or serine residue.[99]  
 
While these methods described thus far cleave the protein backbone at amide bonds 
akin to proteases (Section 4.1.1), cleavage between the amino group and α-carbon is also 
possible by the chemical modification of serine or cysteine to induce β-elimination to yield 
dehydroalanine.[100] This protein bound dehydroalanine is highly susceptible to hydrolytic or 
oxidative cleavage to produce fragments with a C-terminal amide and a N-terminal 
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(hydroxyl)pyruvyl group. Limitations to this niche cleavage method are typical of chemical 
methods requiring excess reagent, extreme pH, long reaction times and high temperatures.  
 
4.1.4 Unnatural Amino Acids as Targets for Protein Cleavage 
Incorporation of unnatural amino acids into proteins has been used in previous studies to 
provide a reactive handle for the cleavage of the polypeptide backbone. For example, 
N-bromosuccinimde has been reported to react with dipeptides containing either 
2-amino-4-pentenoic acid or 4,5-dehydroleucine leading to the hydrolysis of the peptide 
backbone in 60-80% yield.[101,102] 2-Amino-4-pentenoic acid has furthermore been 
incorporated site-specifically into proteins and then treated with iodine to induce 
iodolactonisation, which is proceeded by hydrolysis of the resulting lactone, site-specifically 
fragmenting the protein backbone.[103-105] This method has been used to generate active 
trypsin from trypsinogen and also by cleaving the enzyme-bound inhibitor ecotin.[104,105] The 
amounts of reagent as well as the reaction conditions need to be carefully controlled in these 
reactions, since these reagents can undergo a variety of undesirable side reactions with the 
numerous native side chains. These side reactions include oxidation of the sulphur atoms for 
both methionine and cysteine,[102] and also iodination of tryptophan, histidine and tyrosine 
residues,[106] which can lead to loss of protein function.[103] Of interest was the possibility that 
the dehydro amino acids 1-4, previously shown to be misincorporated in place of their 
respective proteinogenic counterparts of (S)-valine, (S)-leucine and (2S,3S)-isoleucine 
(Chapter 3) during protein biosynthesis, could be utilised for the chemical cleavage of fusion 
proteins to produce peptides. 
 
 
4.2 Suitability of Dehydro Amino Acids as Latent Sites for the 
Chemical Cleavage of Proteins  
The suitability of the four dehydro amino acids 1-4 (Figure 4.1) that are misincorporated into 
proteins (Chapter 3) as latent sites for the chemical cleavage of proteins was first assessed by 
treating the free amino acids 1-4 with excess iodine at 25 °C in D2O.  
 
! 86 
 
Figure 4.1 Dehydro Amino Acids under investigation. 
 
This initial assessment of the reactivity of the dehydro amino acids to iodine was 
evaluated by 1H NMR spectroscopy. 3,4-Dehydrovaline 1 was evaluated together with its 
(R)-stereoisomer and neither was found to react with iodine. 3,4-Dehydroleucine 3 was 
evaluated as a racemic mixture and reacted sluggishly with iodine, in contrast to the 
reaction of (S)-4,5-dehydroleucine (2) and 4,5-dehydroisoleucine 4 with iodine, which 
appeared to proceed more rapidly. 
 
4.2.1 Evaluation of Chemical Reagents to Promote Protein Cleavage 
A variety of chemical reagents were evaluated to assess whether they could mediate the 
fragmentation of protein substituted with the dehydro amino acids 1-4. Although the 
dehydrovaline 1 did not appear to undergo lactonisation after iodine treatment (Section 
4.2), for completeness it was not discounted during this assessment. The reagents evaluated 
were iodine as well as hydrochloric, hydrobromic and hydriodic acids. Iodine was evaluated 
as it has previously been shown to site-specifically cleave at 2-amino-4-pentenoic acid 
residues in proteins and has been demonstrated in the previous section to react with the free 
amino acids 2-4.[103-105] (S)-4,5-Dehydroleucine (2) is known to undergo rapid lactonisation 
under mild acidic conditions with dilute hydrochloric acid,[107-109] so accordingly this reagent 
has been evaluated. Hydrobromic and hydriodic acids were also evaluated since they are 
known to hydrohalogenate alkenes potentially leading to lactonisation under mild 
conditions.[110-113] The application of strong hydrohalide mineral acids to induce protein 
cleavage is particularly attractive since unlike N-bromosuccinimde and iodine these 
reagents are less prevalent to undergo undesired side reactions with native side chains 
under mild conditions. These reagents were screened at two different temperatures (4 and 
35 °C) with both unmodified PpiB and PpiB substituted with the dehydro amino acids 1-4. 
The effectiveness of the reagents was evaluated by SDS-PAGE (Figure 4.2-4.6). 
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Figure 4.2 SDS-PAGE of PpiB synthesised with the twenty proteinogenic amino acids treated with: A) 
H2O at 35 °C, B) 2500 eq. of hydriodic acid at 4 °C, C) 2500 eq. of hydriodic acid at 35 °C, D) 11000 eq. 
of hydriodic acid at 4 °C, E) 11000 eq. of hydriodic acid at 35 °C, F) 120 eq. of iodine at 4 °C, G) 120 eq. 
of iodine at 35 °C, H) 20000 eq. of hydrobromic acid at 4 °C, I) 20000 eq. of hydrobromic acid at 35 °C, 
J) 45000 eq. of hydrochloric acid at 4 °C, K) 45000 eq. of hydrochloric acid at 35 °C. 
 
PpiB synthesised with the twenty proteinogenic amino acids was treated with each 
of the four reagents to identify any undesired reactions with native protein side chains 
(Figure 4.2). The unmodified protein (19.3 kDa) appeared to partially react with both 
hydriodic acid and iodine to produce higher molecular weight species (Lanes B-G of Figure 
4.2). However, the amount of full length PpiB did not significantly decrease and remained at 
a similar level to the negative control (Lane A of Figure 4.2). Despite a near-colourless 
solution of hydriodic acid used in these preliminary studies, the possibility of trace iodine 
present in this solution could not be excluded (Scheme 4.1). When exposed to air hydriodic 
acid solutions will oxidise to generate iodine, which can undergo a further reaction with 
hydriodic acid to generate hydrogen triiodide. As such, the protein samples were treated 
with two different concentrations of hydriodic acid (1000 eq. and 5000 eq.) in order to vary 
the amount of background iodine present.  
 
4HI + O2 → 2H2O + 2I2 
HI + I2 → HI3 
 
Scheme 4.1 Top reaction: oxidation of hydriodic acid to give iodine. Bottom reaction: iodination of 
hydriodic acid to produce hydrogen triiodide. 
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Hydrobromic and hydrochloric acids did not appear to react with the native protein 
to produce any material with a different migration (Lanes H-K of Figure 4.2). Although the 
former reagents appeared to react undesirably with the native protein, all four were further 
investigated as mediators for site-specific protein cleavage utilising dehydro amino acids. 
However these preliminary results were taken into account while assessing the subsequent 
evaluations. 
 
Incorporation of 3,4-dehydrovaline 1 in place of (S)-valine produced insoluble PpiB, 
unlike the other dehydro amino acids 2-4 that incorporate to give soluble PpiB (Chapter 3). 
To assess the reaction between the four test reagents and the insoluble PpiB substituted with 
3,4-dehydrovaline 1, the protein was solubilised by denaturing using sodium dodecyl 
sulphate to a final concentration of 10% (w/v). 
 
 
Figure 4.3 SDS-PAGE of PpiB synthesised with 4 mM of 3,4-dehydrovaline 1 in place of 1 mM (S)-
valine, solubilised by SDS to a final concentration of 10% and treated with: A) H2O at 35 °C, B) 2500 
eq. of hydriodic acid at 4 °C, C) 2500 eq. of hydriodic acid at 35 °C, D) 11000 eq. of hydriodic acid at 4 
°C, E) 11000 eq. of hydriodic acid at 35 °C, F) 120 eq. of iodine at 4 °C, G) 120 eq. of iodine at 35 °C, H) 
20000 eq. of hydrobromic acid at 4 °C, I) 20000 eq. of hydrobromic acid at 35 °C, J) 45000 eq. of 
hydrochloric acid at 4 °C, K) 45000 eq. of hydrochloric acid at 35 °C. 
 
 Treatment of the solubilised protein with either hydriodic acid or iodine seemed to 
reduce the amount of full-length 3,4-dehydrovaline 1 substituted PpiB observed (Lanes B-G 
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of Figure 4.3). Treatment with either hydrobromic or hydrochloric acid however, did not 
appear to reduce the amount of modified PpiB (Lanes H-K of Figure 4.3). Given that as the 
free amino acid 3,4-dehydrovaline 1 was insensitive to iodine treatment, it appears that the 
protein is being oxidised or iodinated by these reagents under these denaturing conditions. 
Under such conditions the sensitive internal residues of the protein would likely be 
exposed[106] and modification of these residues would account for the high molecular weight 
smearing observed for these samples by SDS-PAGE (Figure 4.3). 
 
The levels of PpiB substituted with (S)-4,5-dehydroleucine (2) or 3,4-dehydroleucine 
3 were significantly reduced upon treatment with either hydriodic acid or iodine (Lanes B-G 
of Figure 4.4 & 4.5). Minor smearing at high molecular weights was observed in both cases. 
For PpiB modified with 3,4-dehydroleucine 3 there was a noticeable decrease in the amount 
of PpiB observed when the samples were incubated at elevated temperatures when exposed 
to either hydriodic acid or iodine (Lanes B-G of Figure 4.5) Neither of the 
dehydroleucine-modified proteins appeared to be affected by treatment with hydrobromic 
or hydrochloric acids (Lanes H-K of Figure 4.4 & 4.5). 
 
 
Figure 4.4 SDS-PAGE of PpiB synthesised with 2 mM of (S)-4,5-dehydroleucine (2) in place of 1 mM 
(S)-leucine treated with: A) H2O at 35 °C, B) 2500 eq. of hydriodic acid at 4 °C, C) 2500 eq. of hydriodic 
acid at 35 °C, D) 11000 eq. of hydriodic acid at 4 °C, E) 11000 eq. of hydriodic acid at 35 °C, F) 120 eq. 
of iodine at 4 °C, G) 120 eq. of iodine at 35 °C, H) 20000 eq. of hydrobromic acid at 4 °C, I) 20000 eq. of 
hydrobromic acid at 35 °C, J) 45000 eq. of hydrochloric acid at 4 °C, K) 45000 eq. of hydrochloric acid 
at 35 °C. 
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Figure 4.5 SDS-PAGE of PpiB synthesised with 4 mM of 3,4-dehydroleucine 3 in place of 1 mM 
(S)-leucine treated with: A) H2O at 35 °C, B) 2500 eq. of hydriodic acid at 4 °C, C) 2500 eq. of hydriodic 
acid at 35 °C, D) 11000 eq. of hydriodic acid at 4 °C, E) 11000 eq. of hydriodic acid at 35 °C, F) 120 eq. 
of iodine at 4 °C, G) 120 eq. of iodine at 35 °C, H) 20000 eq. of hydrobromic acid at 4 °C, I) 20000 eq. of 
hydrobromic acid at 35 °C, J) 45000 eq. of hydrochloric acid at 4 °C, K) 45000 eq. of hydrochloric acid 
at 35 °C. 
 
PpiB substituted with 4,5-dehydroisoleucine 4 in place of (2S,3S)-isoleucine was 
treated with the four chemical reagents and analysed by SDS-PAGE (Figure 4.6). Hydriodic 
acid and iodine both appeared to significantly reduce the amount of full-length protein 
(Lanes B-G of Figure 4.6). Treatment with the hydriodic acid produced proteinaceous 
material of lower molecular weight than the full-length protein, while higher molecular 
weight material was present in the iodine treated samples. Increasing the treatment 
temperature for either reagent resulted in increased interaction between protein and 
reagent, this is evident from the decreased amount of full-length protein. When the samples 
were treated with hydrobromic and hydrochloric acids there was no apparent reduction in 
the amount of full length PpiB (Lanes H-K of Figure 4.6). 
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Figure 4.6 SDS-PAGE of PpiB synthesised with 4 mM of (2RS,3RS)-4,5-dehydroisoleucine 4 in place of 
1 mM (2S,3S)-isoleucine treated with: A) H2O at 35 °C, B) 2500 eq. of hydriodic acid at 4 °C, C) 2500 eq. 
of hydriodic acid at 35 °C, D) 11000 eq. of hydriodic acid at 4 °C, E) 11000 eq. of hydriodic acid at 35 
°C, F) 120 eq. of iodine at 4 °C, G) 120 eq. of iodine at 35 °C, H) 20000 eq. of hydrobromic acid at 4 °C, 
I) 20000 eq. of hydrobromic acid at 35 °C, J) 45000 eq. of hydrochloric acid at 4 °C, K) 45000 eq. of 
hydrochloric acid at 35 °C. 
 
From these preliminary screens it appears that all the dehydro modified proteins 
reacted with hydriodic acid and iodine leading to a significant reduction of the amount of 
full length protein relative to the respective control lane (Lanes A-G of Figures 4.2-4.6). 
Some of these reactions appeared to result in the formation of small amounts of higher 
molecular weight material. If fragmentation had occurred it might be expected that lower 
molecular weight fragments for the treated dehydro modified proteins would be observed. 
This was only witnessed in one instance where 4,5-dehydroisoleucine 4 substituted PpiB 
was treated with hydriodic acid. The lack of evidence of fragmentation by SDS-PAGE 
analysis is not surprising since smaller fragments bind less dye making their visibility more 
difficult to detect. It seems reasonable to suggest from these experiments and previous 
studies with similar material,[103-105] that the residues of (S)-4,5-dehydroleucine (2), 3,4-
dehydroleucine 3 and 4,5-dehydroisoleucine 4 could lead to the discrete cleavage of the 
protein backbone by treatment with iodine or hydriodic acid.  
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4.3 Cleavage of Dehydro Amino Acids to Produce Human Peptide 
Hormones from Fusion Proteins 
(S)-4,5-Dehydroleucine (2) and the 4,5-dehydroisoleucine 4 were investigated as cleavable 
spacers to produce peptides from fusion proteins since as free amino acids they appeared to 
react rapidly with iodine (Section 4.2). The dehydroleucine 3 was not investigated since the 
regioisomer 2 seemed to react faster with iodine and the dehydrovaline 1 was not 
investigated since it was unreactive with iodine (Section 4.2).  
 
A carrier protein linked with a peptide hormone sequence was selected as the fusion 
strategy instead of a repeating peptide hormone sequence as the extent to which the latter 
would be overexpressed by the CFPS system was unknown. PpiB was chosen as the carrier 
protein as it is overexpressed during CFPS as soluble protein. It was envisaged that 
attachment of a linker sequence and peptide hormone to PpiB would have minimal affect on 
the expression level and the solubility of the protein.  
 
The proposed mechanism for lactonisation and subsequent hydrolytic cleavage of a 
dehydro amino acid sees cleavage at the C-terminus of the dehydro amino acid giving two 
fragments with the C-terminal fragment left unmodified at its N-terminus.[103] In order to 
faithfully produce peptides by the fusion carrier approach, the dehydro amino acid needs to 
be positioned directly before the N-terminal of the target peptide. For this study, the 
constructs were made with the peptide gene sequence and the cleavage site, fused to the 3’ 
(C-terminus) of the gene for the carrier protein with a flexible linker region (Figure 4.7).   
 
 
Figure 4.7 Generalised fusion protein construct; N-terminal hexahistidine-tag, PpiB sequence, linker 
region, cleavage position and a peptide hormone at the C-terminal. 
 
Carrier Protein (PpiB) 
linker 
Peptide Hormone His6 
Dehydro amino acid  
(Cleavage site) 
N C 
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Two different PpiB fusion protein constructs were used, each encoding a different 
dehydro amino acid ((2S,3S)-isoleucine or (S)-leucine) in the cleavable spacer immediately 
prior to the peptide sequence. The eight amino acid linker region between the carrier and 
the dehydro cleavage site consisted of primarily glycine residues to allow maximum solvent 
exposure to dehydro side chain for optimal accessibility and cleavage. The peptide 
hormones themselves were carefully selected based on their sequences, so that they lacked 
the amino acid encoded at the cleavage site. Human glycine extended gastrin-releasing 
peptide (GRPG) was selected for the dehydroisoleucine 4 cleavable fusion and human 
glycine extended prolactin-releasing peptide (PRPG) was selected as the fusion peptide 
where the dehydroleucine 2 was encoded at the cleavable position.  
 
4.3.1 Evaluation of 4,5-Dehydroisoleucine Cleavage for Peptide Production 
CFPS of PpiB-GRPG was carried out at 30 °C for 18 h with each of the twenty proteinogenic 
amino acids, when (2S,3S)-isoleucine was withheld, and 4,5-dehydroisoleucine 4 added 
instead. The synthesised proteins were purified by immobilised metal affinity 
chromatography, as the fusion proteins possessed an N-terminal polyhistidine-tag, and then 
analysed by SDS-PAGE to evaluate purity and level of expression (Figure 4.8). 
 
 
Figure 4.8 SDS-PAGE of synthesised PpiB-GRPG with: A) all twenty proteinogenic amino acids, B) no 
(2S,3S)-isoleucine, C) no (2S,3S)-isoleucine but with 4 mM (2RS,3RS)-4,5-dehydrosisoleucine 4. 
 
4,5-Dehydroisoleucine 4 was able to support the synthesis of the fusion protein to a 
level similar to that when all twenty proteinogenic amino acids were supplied (Lanes A & B 
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of Figure 4.8). A low level of PpiB-GRPG was produced when (2S,3S)-isoleucine was 
withheld, this is attributed to low residual levels of the amino acids present in the S30 
extract, as observed previously.[114,115] Two distinct protein bands were visible for these 
fusion proteins, with the lower band suspected to be the result of enzymatic degradation by 
the cell-lysate employed in CFPS. Mass spectroscopy confirmed that degradation had 
occurred between T12 and K13 of GRPG (residues 193 and 194 of the fusion complex) for 
both proteins (Figure 4.9 & 4.10). This truncation is likely the result of proteases (that exist in 
the crude cell lysate used to prepare the fusion protein) degrading the eukaryotic peptide, 
which is consistent with other reports.[18,19] Additionally, mass spectroscopy verified the 
majority of the PpiB-GRPG fusion protein formed in the presence of 4,5-dehydroisoleucine 4 
was fully substituted with this dehydro amino acid (Figure 4.10). 
 
 
Figure 4.9 Deconvoluted mass spectrum of PpiB-GRPG formed in the presence of 1 mM all of twenty 
proteinogenic amino acids. 
Mass reconstruction of  +TOF MS: 0.049 to 0.411 min from Sample 8 (GRPG 8) of 300514SAM.wiff Agil... Max. 7.0e5 cps.
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Figure 4.10 Deconvoluted mass spectrum of PpiB-GRPG formed in the presence of 4 mM (2RS,3RS)-
4,5-dehydroisoleucine 4 instead of 1 mM (2S,3S)-isoleucine, and with 1 mM of each of the other 
nineteen proteinogenic amino acids. 
 
 
Analysis of the mass spectrum of PpiB-GRPG synthesised with each of the twenty 
proteinogenic amino acids revealed strong signals at 22734 and 20897 Da (Figure 4.9). These 
signals correspond to full-length N-formylated His6-PpiB-GRPG and the N-formylated H1-
T193 fragment respectively. Analysis of the mass spectrum for PpiB-GRPG formed when the 
dehydroisoleucine 4 was supplied revealed signals at 22712 and 20875 Da that correspond to 
full replacement of 4,5-dehydroisoleucine 4 in place of (2S,3S)-isoleucine at the eleven 
possible sites in N-formylated His6-PpiB-GRPG and the N-formylated H1-T193 fragment 
respectively (Figure 4.10). 
 
Unmodified and dehydroisoleucine 4 substituted PpiB-GRPG were treated with 33 
equivalents of iodine (3 equivalents of iodine per alkene) in a solution with DMSO for 10 
min at 35 °C. The treated material was then analysed by SDS-PAGE, which indicated partial 
formation of a higher molecular weight species for unmodified PpiB-GRPG (Lane A of 
Figure 4.11). This was similar for the modified PpiB-GRPG except significantly less full-
length protein (22.7 kDa) was observed (Lane B of Figure 4.11).  
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1.9e4 2.0e4 2.1e4 2.2e4 2.3e4 2.4e4 2.5e4 2.6e4
Mass, Da
2.0e4
4.0e4
6.0e4
8.0e4
1.0e5
1.2e5
1.4e5
1.6e5
1.8e5
2.0e5
2.2e5
2.4e5
2.6e5
2.8e5
3.0e5
3.2e5
3.4e5
In
te
n
s
ity
, C
o
u
n
ts
22712.3621
22730.5192
20875.0376
22775.1816
23017.2473
20894.2904
22818.4047
22993.013720938.8747 22885.9360
19894.0800 21152.7039 23148.582419727.8955 25364.486223947.611121089.0224 24154.651121763.1504
! 96 
 
Figure 4.11 SDS-PAGE of synthesised PpiB-GRPG with: A) all twenty proteinogenic amino acids and 
treated with 33 equivalents of iodine at 35 °C for 10 min in 10% DMSO, B) no (2S,3S)-isoleucine but 
with (2RS,3RS)-4,5-dehydroisoleucine 4 and treated with 33 equivalents of iodine at 35 °C for 10 min 
in 10% DMSO. 
 
After treatment with iodine, the dehydroisoleucine 4 substituted PpiB-GRPG sample 
was subjected to reverse-phase analytical HPLC and an analyte with a matching retention 
time to synthetic GRPG was observed (Figure 4.12). The iodine treatment was also 
performed in the absence of 10% DMSO but no GRPG was observed by HPLC (data not 
shown). DMSO conceivably acts as a denaturant to enable the reactant iodine access to the 
hydrophobic side chain of dehydroisoleucine 4. 
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Figure 4.12 Reverse-phase analytical HPLC absorbance profile at 220 nm for iodine treated 4,5-
dehydroisoleucine 4 modified PpiB-GRPG. 
 
The peak corresponding to cleaved GRPG isolated by HPLC was collected and 
analysed LC-MS. Analysis by LC-MS verified the identity of the GRPG produced by CFPS 
and subsequent iodine facilitated cleavage at the dehydroisoleucine 4 spacer site. The 
dominant signals for the +5H+ (584), +4H+ (730) and +3H+ (973) ions of GRPG were consistent 
with a synthetic GRPG standard (Figure 4.13). 
 
 
Figure 4.13 ESI-MS of isolated GRPG prepared from 4,5-dehydroisoleucine 4 modified PpiB-GRPG. 
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The efficiency of the cleavage reaction was calculated by determining the amount of 
GRPG cleaved from a known amount of purified full-length dehydroisoleucine 4 modified 
PpiB-GRPG. The initial concentration of the fused protein-peptide was determined by 
absorbance at 280 nm, taking into account the prior degradation of the peptide in the fusion 
complex. This was achieved using ImageJ software with densitometric quantification of the 
purified sample analysed by SDS-PAGE. Following iodine cleavage, the molar amount of 
free peptide was determined using the GRPG absorbance peak area at 220 nm from 
analytical HPLC traces. The peak area was quantified based on a standard calibration using 
different concentrations of synthetic GRPG injected in the same manner (Figure 4.14). The 
efficiency of the conversion of dehydroisoleucine 4 modified PpiB-GRPG by treatment with 
iodine to GRPG was ca. 4%. 
 
 
Figure 4.14 Standard curve for the absorbance area of the peak at 220 nm corresponding to the 
amount of the GRPG. This was preformed in triplicate and the results expressed as an average with 
error bars two standard deviations from the mean. 
 
 
4.3.2 Evaluation of 4,5-Dehydroleucine Cleavage for Peptide Production 
Both the dehydroleucine regioisomers 2-3 appeared to undergo lactonisation to site-
specifically cleave the protein backbone. However, only the (S)-4,5-dehydroleucine (2) was 
further evaluated because iodolactonisation appeared to proceed faster with this amino acid 
than with the regioisomer 3,4-dehydroleucine 3. As with the preparation of the 4,5-
dehydroisoleucine 4 substituted fusion proteins, CFPS was used to prepare PpiB-PRPG 
substituted with (S)-4,5-dehydroleucine (2) in place of (S)-leucine. CFPS of PpiB-PRPG was 
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carried out with each of the twenty proteinogenic amino acids, when (S)-leucine was 
withheld, and (S)-4,5-dehydroleucine (2) was added instead. The synthesised proteins were 
purified by immobilised metal affinity chromatography and then analysed by SDS-PAGE to 
evaluate purity and level of expression (Figure 4.15). 
 
 
Figure 4.15 SDS-PAGE of synthesised PpiB-PRPG with: A) all twenty proteinogenic amino acids, B) 
no (S)-leucine, C) no (S)-leucine but with 2 mM (S)-4,5-dehydroleucine (2). 
 
(S)-4,5-Dehydroleucine (2) supported the synthesis of PpiB-PRPG as indicated by 
SDS-PAGE to a level similar to that when all twenty proteinogenic amino acids were 
supplied (Lanes A & B of Figure 4.15). A low level of PpiB-PRPG was produced when (S)-
leucine was withheld, this is attributed to low residual levels of the amino acids present in 
the S30 extract, as observed previously (Lane B of Figure 4.15).[114,115] Akin to the synthesis of 
PpiB-GRPG substituted with 4,5-dehydroisoleucine 4 (Figure 4.8), partial degradation was 
observed but in this case three distinct protein bands were observed (Lanes A-C of Figure 
4.15). Mass spectrometry confirmed the identity of the fragmented products and the level of 
substitution with (S)-4,5-dehydroleucine (2). Truncation was confirmed between residues 
S1-R2, E9-I10 and A21-S22 of PRPG (residues 182-183, 190-191 and 202-203 of the fusion 
complex) for both the unmodified and dehydro-substituted fusion proteins (Figure 4.16 & 
4.17). When synthesised in the presence of 4,5-dehydroleucine 2, the most abundant PpiB-
PRPG species was fully substituted.   
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Figure 4.16 Deconvoluted mass spectrum of PpiB-PRPG formed in the presence of 1 mM of all twenty 
proteinogenic amino acids. 
 
 
Figure 4.17 Deconvoluted mass spectrum of PpiB-PRPG formed in the presence of 2 mM (S)-4,5-
dehydroleucine (2) instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
 
Analysis of the mass spectrum of PpiB-PRPG synthesised with each of the twenty 
proteinogenic amino acids revealed strong signals at 23651, 23625, 22440, 21042, and 20006 
Da. These signals correspond to full-length N-formylated His6-PpiB-PRPG, full-length 
His6-PpiB-PRPG and the deformylated A202-S203, E190-I191, H1-T193 and S182-R183 
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fragments respectively (Figure 4.16). Analysis of the mass spectrum for PpiB-PRPG formed 
when (S)-4,5-dehydroleucine (2) was supplied revealed signals at 23640, 23613, 22430 and 
21032 Da corresponding to full replacement of the dehydro amino acid 2 in place of (S)-
leucine at the six possible sites in full-length N-formylated His6-PpiB-PRPG, full-length 
His6-PpiB-PRPG, and the deformylated A202-S203, E190-I191 and H1-T193 fragments 
respectively (Figure 4.17). 
 
Unmodified and (S)-4,5-dehydroleucine (2) substituted PpiB-PRPG were treated 
with 18 equivalents of iodine (3 equivalents of iodine per alkene) for 10 min at 35 °C. 
Analysis of the treated fusion proteins by SDS-PAGE indicated partial formation of a higher 
molecular weight species for the unmodified fusion product (Figure 4.18). For the (S)-4,5-
dehydroleucine (2) modified PpiB-PRPG treated with iodine a smear of proteinaceous 
material over a wide molecular weight range was observed.  
 
Figure 4.18 SDS-PAGE of synthesised PpiB-PRPG with: A) all twenty proteinogenic amino acids and 
treated with 18 equivalents of iodine at 35 °C for 10 min B) no (S)-leucine but with (S)-4,5-
dehydroleucine (2) and treated with 18 equivalents of iodine at 35 °C for 10 min. 
 
The substituted fusion protein was subjected to analytical reverse-phase HPLC and 
produced a peak with matching retention time to the synthetic standard PRPG (Figure 4.19). 
This peak was collected and subjected to LC-MS, which verified its identity as PRPG from 
the strong signals for the +7H+ (532),  +6H+ (621), +5H+ (745) and +4H+ (931) ions of PRPG 
that were consistent with the synthetic PRPG standard (Figure 4.20). 
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Figure 4.19 Reverse-phase analytical HPLC absorbance profile at 220 nm for iodine treated (S)-4,5-
dehydroleucine (2) substituted PpiB-PRPG. 
 
 
 
Figure 4.20 ESI-MS of isolated PRPG prepared from iodine treated (S)-4,5-dehydroleucine (2) 
substituted PpiB-PRPG. 
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The cleavage efficiency for the lactonisation and hydrolysis at the (S)-4,5-
dehydroleucine (2) site to produce free PRPG was assessed in the same manner as 
previously with the 4,5-dehydroisoleucine 4 (Section 4.3.2). The standard calibration of 
PRPG and peak area was prepared in the same manner as that for GRPG (Figure 4.21). For 
the previously examined system the cleavage efficiency was 4% and in this case, with the 
(S)-4,5-dehydroleucine (2) the conversion efficiency was similar at ca. 5%. 
 
 
Figure 4.21 Standard curve for the absorbance area of the peak at 220 nm corresponding the amount 
of the PRPG. This was preformed in triplicate and the results expressed as an average with error bars 
two standard deviations from the mean. 
 
After the successful release of the peptide hormone PRPG from the modified fusion 
protein upon treatment with iodine, hydriodic acid was also evaluated since it too appeared 
to react with dehydro modified protein during the preliminary evaluations (Section 4.2.1). 
(S)-4,5-Dehydroleucine (2) substituted PpiB-PRPG was treated with 18 equivalents of 
hydriodic acid (3 equivalents per alkene) for 10 min at 35 °C and analysed by reverse-phase 
analytical HPLC. An analyte with an identical retention time to the synthetic standard was 
observed but the conversion efficiency was significantly lower with more than a tenfold 
decrease. Subsequently no further efforts were conducted with hydriodic acid as the 
possibility that background iodine present in the hydriodic acid could not be excluded and 
may have been responsible for this observed fragmentation. 
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4.3.3 Optimisation of the Conversion Efficiency 
Treatment of the dehydro amino acid modified fusion proteins, PpiB-GRPG and PpiB-PRPG 
with 3 equivalents of iodine per alkene for 10 min at 35 °C was successful in producing the 
peptide hormones GRPG and PRPG. However since the conversion efficiencies were low, 
the reaction conditions were revised for optimal conversion efficiency. This optimisation 
was performed for the production of PRPG and was selected due to the excellent reactivity 
of (S)-4,5-dehydroleucine (2) with iodine, and unlike the GRPG fusion system with 4,5-
dehydroisoleucine 4 no further additives (DMSO) are required to assist peptide preparation. 
Furthermore the interest in the use of PRPG instead of GRPG for these optimisations is that 
the first amino acid is serine for PRPG. The proposed iodolactonisation and subsequent 
hydrolysis of the dehydro amino acids 2 and 4 proceeds via a comparable mechanism to that 
for the chemical cleavage of the carboxyl- terminus of methionine using cyanogen 
bromide.[103] The cleavage of methionine with cyanogen bromide proceeds in poor yield 
when adjacent to a serine or threonine residue due to the participation of the side chain in 
place of water to open the lactone preventing fragmentation.[99] Based on the results already 
shown, the presence of serine next to the dehydro amino acid 2 in PRPG does not appear to 
drastically reduce the conversion efficiency relative to GRPG (Section 4.3.2).  
 
The number of equivalents of the reagent iodine was considered the most important 
factor to increase the cleavage efficiency of the protein backbone. The amount of iodine 
needs to be carefully balanced to prevent the reaction of excess iodine with many other 
sensitive residues,[106] while diminutive amounts will lead to inefficient cleavage. 
Accordingly this was the first variable to be optimised, with 5 equivalents of iodine per 
alkene found to be optimal (Figure 4.22). Temperature was then optimised as it was shown 
to influence the amount of full-length protein in the preliminary studies (Section 4.2.1). 
Three temperatures 4, 35 and 70 °C were chosen as these encompass a wide range of 
reasonable temperatures. Using the optimised number of iodine equivalents (5 eq.), 4 °C 
provided the highest conversion efficiency. Lower temperatures were not investigated, as 
this is unfeasible with aqueous solvent. Lastly the reaction duration was investigated with 
10 min found to be ideal for maximal cleavage of intact PRPG. These conditions likely limit 
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side reactions of the oxidant iodine whilst maximising the production of the lactone leading 
to backbone cleavage. 
 
 
Figure 4.22 Optimisation process undertaken to improve the conversion efficiency for the production 
of PRPG. 
 
Intriguingly a similar investigation to the one contained in this chapter, where iodine 
was employed to cleave protein bound 2-amino-4-pentenoic acid, saw modified protein 
treated with 25,000-125,000 equivalents of iodine per residue at 25 °C for 30 min.[103] This 
resulted in cleavage efficiencies determined by SDS-PAGE to range from 55-61%.[103] Based 
on the optimisation for dehydro amino acid cleavage by treatment with iodine (Figure 4.22), 
application of similar harsh conditions (extreme iodine excess and longer reaction time) in 
this system would likely produce little to no peptide. 
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Although more rounds of optimisation may further increase the conversion 
efficiency, the purpose of this optimisation was to give an impression of the degree to which 
the conversion could be improved and this has been achieved. The optimised conversion is 
reasonable at ca. 38% especially considering this fragmentation occurs adjacent to a N-
terminal serine residue in which the hydroxyl side chain of this residue can react with the 
lactone preventing fragmentation. In fact this conversion efficiency is greater than a number 
of other chemical cleavage methods to prepare peptide hormones.[85,91,92] Iodine induced 
cleavage is preferable to the many other chemical methods for the cleavage of peptides from 
fusion proteins since other methods may require the use of protecting groups to prevent 
unwanted modification of certain residues,[92] costly reagents,[91,93,94] long reaction 
times,[84,85,88,90,92] elevated temperatures,[84,85,88] large molar excesses of reagent,[84,85,88,90-93] and 
can be low yielding.[84,85,91,92]  
 
 
4.4 Conclusions 
Dehydro amino acids analogues of (S)-leucine and (2S,3S)-isoleucine have been 
misincorporated into fusion proteins, using CFPS with translational machinery sourced 
from native bacterial s30 cellular extract, and exploited for the production of peptides. Since 
the protein is prepared in vitro, many issues associated with the in vivo synthesis of proteins 
are circumvented. Rapid peptide production has been accomplished by treating the dehydro 
residues 2 and 4 with iodine to cleave the proximal carboxyl peptide bond through 
iodolactonisation and subsequent hydrolysis. Although this reagent appears to undergo 
undesired side reactions with other protein residues, the cleavage conversion has been 
improved to ca. 38% by reducing the reaction temperature and limiting the reaction time. 
This conversion is in many cases superior to that for other chemical cleavage methods to 
prepare peptide hormones.[85,91,92] Unlike these other methods the cleavage proceeds 
extremely rapidly under very mild conditions and is not hindered by adjacent serine or 
threonine residues, whilst the reagent employed for this fragmentation is inexpensive and 
easy to handle. These convenient and versatile methods to cleave the protein backbone have 
been utilised for the production of the native human glycine extended peptides hormones, 
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PRPG and GRPG. The dehydro amino acids 2 and 4 can be incorporated efficiently as 
required with unmodified biosynthetic machinery as latent sites for protein fragmentation. 
These protocols for the rapid production of peptide hormones are an appealing alternative 
to the existing methods such as the isolation of peptides from natural sources, chemical 
synthesis and recombinant methods utilising other cleavage strategies. Whilst peptides in 
this case have been prepared on the analytical scale, this particular in vitro approach can be 
easily scaled up as required. 
 
 
4.5 Experimental Details 
4.5.1 Preliminary Screen of Various Reagents with Dehydro Modified PpiB 
Unmodified PpiB and PpiB substituted with the dehydro amino acids 1-4 were prepared as 
described previously (Chapter 3, Section 3.6.3). Either a solution of iodine (7.9 mM, 1.0 µL) 
in 50% THF, hydriodic acid (0.1 M or 0.8 M, 1.0 µL), hydrobromic acid (1.3 M, 1.0 µL), or 
hydrochloric acid (3 M, 1.0 µL) was added to a solution of purified PpiB in water (17 µM, 4.0 
µL). In the case of the 3,4-dehydrovaline 1 substituted PpiB, 20% was used to solubilise the 
protein SDS (giving a final concentration of 10% SDS). Water (3.0 µL) was then added to the 
samples which were gently mixed and incubated at either 4 °C or 35 °C for 10 min. Protein 
sample buffer (4.0 µL) was then added and the samples analysed immediately by 20% SDS-
PAGE.  
 
4.5.2 Preparation of the Protein-Peptide Fusion Constructs 
Genes encoding all fusion constructs were carried in the pETMCSIII plasmid with a N-
terminal His6-tag. All restriction enzymes were from New England BioLabs, Inc. and were 
used according to the manufacturers specifications. T4 DNA ligase and alkaline phosphatase 
were from F. Hoffman-La Roche, Ltd. The AN1459 E.coli strain was used during the cloning 
stages with bacterial transformation done by the heat shock method. All primers and 
peptide sequences were ordered from Integrated DNA Technologies, Inc. PCR was 
performed on a C1000 Touch thermal cycler from Bio-Rad Laboratories, Inc. The fusion 
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products were confirmed by DNA sequencing on an AB 3730xI DNA Analyzer from 
Applied Biosystems by the ACRF Biomolecular Resource Facility, John Curtin School of 
Medical Research, Australian National University before being expressed in the CFPS 
system.  
 
4.5.2.1 Preparation of the PpiB-GRPG DNA Construct 
The His6-PpiB-GRPG DNA construct was prepared by M. Liutkus using the antisense region 
of the gene as a primer to anneal the linker in place of bovine pancreatic trypsin inhibitor 
(BPTI) in a previously made PpiB-BPTI fusion construct. Flanking primers were used to 
amplify the final PpiB-GRPG construct.  
The His6-PpiB-GRPG amino acid sequence in the standard single letter amino acid code is: 
MHHHHHHMVTFHTNHGDIVIKTFDDKAPETVKNFLDYCREGFYNNTIFHRVINGFMIQ
GG GFEPGMKQKATKEPIKNEANNGLKNTRGTLAMARTQAPHSATAQFFINVVDNDFLN
FSGE SLQGWGYCVFAEVVDGMDVVDKIKGVATGRSGMHQDVPKEDVIIESVTVSENGGG
GGGGAIVPLPAGGGTVLTKMYPRGNHWAVGHLMG 
 
Mass is: 22705 Da, N-formylated is: 22732 Da 
 
 
4.5.2.2 Preparation of the PpiB-PRPG DNA Construct 
The His6-PpiB-PRPG construct was prepared from the pETMCSIII-His6-PpiB-GRPG 
construct by first inserting an XhoI restriction site into the linker region using the mutagenic 
primers F-XhoI and R-XhoI (Table 4.1) and whole plasmid PCR. The PCR product was 
digested with DpnI, XhoI, and EcoRI, then dephosphorylated with alkaline phosphatase and 
gel purified (Figure 4.23). 
 
Table 4.1 Mutagenic primers used during the construction of PpiB-PRPG.  
Primer Sequence 
F-XhoI 5’- AAT GGT GGA GCT CGA GGT GGA GGT GCA ATT GTT CC – 3’ 
R-XhoI 3’- G CAA TCG CTC TTA CCA CCT CGA GCT CCA CCT – 5’ 
F-tail-
XhoI 5’- GT GGA GCT CGA GGT GGA GGT GCA CTG – 3’ 
R-D4K 3’- GAT GAT GAT AAA – 5’ 
 Note: Underlined sections encode for the amino acid mutations and bold indicates the restriction site. 
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Figure 4.23 Preparation of the pETMCSIII vector with XhoI restriction site. A) Whole plasmid PCR 
with offset mutagenic primers to introduce mutation in the linker (in bold). B) Double digestion with 
XhoI and EcoRI enzymes and DpnI to remove methylated DNA. The vector was then 
dephosphorylated to prevent self-ligation and gel purified. 
 
The PRPG gene containing a 3’ EcoRI restriction site (Figure 4.24) was PCR amplified 
using the F-tail-XhoI forward primer with a tail containing an XhoI restriction site and the R-
D4K reverse primer (Table 4.1 and Figure 4.24). The product was digested with XhoI and 
EcoRI restriction enzymes (Figure 4.25) and ligated into the prepared plasmid-PpiB 
construct (Figure 4.23) at these sites.   
 
 
Figure 4.24 Sequence of PRPG with partial linker region and D4K primer.  
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5’ - A GGT GGA GGT GCA CTG AGC CGT ACC CAC CGC CAT AGC ATG GAA ATT CGC ACC CCG 
GAT ATT AAC CCG GCC TGG TAT GCA AGC CGC GGT ATT CGT CCG GTT GGT CGT TTC GGT TAA 
TAA GAA TTC TTT ATC ATC ATC – 3’             !
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Figure 4.25 Preparation of double stranded PRPG ready for ligation into the XhoI/ EcoRI cut 
pETMCSIII vector. A) PCR to prepare double stranded DNA and to insert the “tail” containing the 
rest of the linker with the XhoI restriction site to the PRPG gene. B) Digestion with EcoRI and XhoI 
restriction enzymes. 
 
The His6-PpiB-PRPG amino acid sequence in the standard single letter amino acid code is: 
MHHHHHHMVTFHTNHGDIVIKTFDDKAPETVKNFLDYCREGFYNNTIFHRVINGFMIQ
GGGFEPGMKQKATKEPIKNEANNGLKNTRGTLAMARTQAPHSATAQFFINVVDNDFLN
FSGESLQGWGYCVFAEVVDGMDVVDKIKGVATGRSGMHQDVPKEDVIIESVTVSENGGA
RGGGALSRTHRHSMEIRTPDINPAWYASRGIRPVGRFG 
 
Mass is: 23623 Da, N-formylated is: 23650 Da 
 
4.5.3 Cell-Free Synthesis of Fusion Proteins and Cleavage for Peptide 
Production  
CFPS and subsequent protein purification was carried out as detailed in Chapter 3, Section 
3.6.3 except for two minor differences. His-SpinTrap columns (GE Healthcare) were used for 
the purification and soluble proteins were concentrated using Amicon Ultra 0.5 mL (YM-3) 
centrifugal devices from EMD Millipore, Merck KGaA. 
 
4.5.3.1 Instrumentation for Peptide Analysis  
Analytical reverse-phase HPLC of the crude iodine treated mixture was carried out on a 
Waters Alliance e2695 separation module with a Waters 2996 photodiode array detector and 
processed with Waters Empower 2 software. LC-MS was conducted on a Waters Alliance 
e2695 separation module connected to a Waters TQ detector with the cone voltage set to 40 
V and the capillary voltage set to 1.00 kV. LC-MS data was processed with Waters 
MassLynx V4.1 software. 
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4.5.3.2 Preparation of GRPG from 4,5-Dehydroisoleucine Modified 
PpiB-GRPG 
Iodine (7.9 mM, 10 µL) in a 50% solution of THF was added to a solution of PpiB-GRPG 
substituted with 4,5-dehydroisoleucine 4 (25 µM, 100 µL) and 11 µL DMSO. The resulting 
solution was gently mixed and incubated for 10 min at 35 °C before it was lyophilized. A 
solution of TFA (0.1%, 200 µL) was then added followed by centrifugation at 5000 x g for 2 
min at 4 °C. The colourless supernatant was subjected to reverse-phase HPLC (Waters 
Symmetry 300 C18 150 x 4.6 mm, 5 µm) using a gradient mobile phase of 0.1% TFA in 
H2O/MeCN (100:0) to (0:100) over 30 min at a flow rate of 1 mL min-1. The peak collected at 
tR = 14.3 min was then subjected to LC-MS (Waters Symmetry C8 150 x 4.6 mm, 5 µm) using 
a gradient mobile phase of 0.1% formic acid in MeCN/0.1% formic acid in H2O (5:95) 0 min 
! (5:95) 1 min ! (30:70) 10 min ! (30:70) 24 min ! (95:5) 25 min at a flow rate of 0.30 mL 
min-1. LC tR = 16.2 min. MS (40 eV): m/z (%): 584 (100) [+5H+], 730 (42) [+4H+], 973 (5) [+3H+]. 
From the standard curve, 0.068 nmol of GRPG had been produced indicating a ca. 3% 
conversion. This was corrected by densitometric analysis with ImageJ for only full-length 
protein to give a conversion of ca. 4%. 
 
4.5.3.3 Optimised Preparation of PRPG from 4,5-Dehydroleucine 
Modified PpiB-PRPG 
Iodine (7.9 mM, 8.0 µL) in a 50% solution of THF was added to PpiB-PRPG substituted with 
(S)-4,5-dehydroleucine (2) (28 µM, 75 µL). The resulting solution was gently mixed and 
incubated for 10 min at 4 °C, before it was lyophilized. A solution of TFA (0.1%, 200 µL) was 
then added followed by centrifugation at 5000 x g for 2 min at 4 °C. The colourless 
supernatant was subjected to reverse-phase HPLC (Waters Symmetry 300 C18 150 x 4.6 mm, 
5 µm) using a gradient mobile phase of 0.1% TFA in H2O/MeCN (100:0) to (0:100) over 30 
min at a flow rate of 1 mL min-1. The peak collected at tR = 13.2 min was then subjected to LC-
MS (Waters Symmetry C8 150 x 4.6 mm, 5 µm) using a gradient mobile phase of 0.1% formic 
acid in MeCN/0.1% formic acid in H2O (5:95) 0 min ! (5:95) 1 min ! (30:70) 10 min ! 
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(30:70) 24 min ! (95:5) 25 min at a flow rate of 0.30 mL min-1. LC tR = 14.8 min. MS (40 eV): 
m/z (%): 531 (21) [+7H+], 620 (100) [+6H+], 744 (18) [+5H+], 930 (6) [+4H+]. From the standard 
curve, 0.34 nmol of PRPG had been produced indicating a ca. 16% conversion. This was 
corrected by densitometric analysis with ImageJ for only full-length protein to give a 
conversion of ca. 38%. 
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5 
 
Investigation of Halogenated Amino Acids as 
Translational Surrogates of Leucine 
 
 
5.1 Introduction 
Expanding the range of unnatural amino acid analogues that efficiently incorporate in place 
of proteinogenic amino acids is an important endeavour. By incorporating unnatural amino 
acids with functional groups not represented by the twenty proteinogenic amino acids, 
proteins with enhanced properties and desirable reactivitives can be prepared. The 
applications are diverse; selenomethionine can be used for phase determination in 
crystallographic studies,[1] 15N-, 13C- and 2H-labelled derivatives of proteinogenic amino 
acids are useful for 2D NMR structural studies of proteins,[2,3] cross-linking of proteins can 
be accomplished through incorporation of amino acids with the diazirine functional group,[4] 
and with dehydro amino acids peptides can be prepared through protein fragmentation 
(Chapter 4). 
 
Previous studies have determined that 2-amino-4-chloropentanoic acid and (2S)-2-
amino-4-(trifluoromethyl)pentanoic acid are effective substitutes for (S)-leucine during 
protein biosynthesis.[5-7] From these reports, it seemed a logical progression to investigate 
whether amino acids with other halogen substituents would also be suitable translational 
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replacements of (S)-leucine. The 2-amino-4-halopent-4-enoic acid framework was selected 
over that of 2-amino-4-halopentanoic acid as it was envisaged that the bromide and iodide 
derivatives of the latter would be prone to lactonisation, and therefore difficult to prepare. 
The selected alkene framework does not preclude incorporation since the methyl derivative, 
(S)-4,5-dehydroleucine (2) is a translational replacement of (S)-leucine (Chapter 3). Hence, 
the unsaturated amino acids 8-11 were investigated with respect to their incorporation into 
proteins (Figure 5.1). Of these, the bromide 10 and iodide 11 possess synthetically useful 
moieties, which are known to participate in palladium-catalysed cross-coupling reactions 
under mild conditions compatible with proteins.[8-14] 
 
Figure 5.1 Halogenated amino acids investigated in this chapter. 
 
5.2  Comparison of Substituent Sizes 
In the previous investigation of 2-amino-4-chloropentanoic acid, the basis behind evaluating 
this compound was the similarity in size, as indicated by their van der Waals radii, between 
the chlorine and methyl substituents.[5] Accordingly, in the current study the van der Waals 
radii for the halogen substituents of 8-11 were compared with that of a methyl group (Table 
5.1). This revealed the van der Waals radius of an iodo substituent is more similar to that of 
a methyl group than those of either the trifluoromethyl, chloro or bromo substituents.[15,16] 
 
 
Table 5.1 Effective van der Waals radii of a methyl group, primary alkyl bound halogen atoms and a 
trifluoromethyl substituent. 
 
Substituent van der Waals radii[15,16] 
Methyl 2.00 
Trifluoromethyl 2.20 
Chloro 1.73 
Bromo 1.84 
Iodo 2.01 
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The van der Waals radii are however an inadequate measure of steric size for this 
purpose since the substituent is treated as an isolated sphere without considering the steric 
contributions of the neighbouring atoms.[15,16] As such, an approach reported previously was 
used to compare the sizes of the halogens as substituents.[17] This approach compares the 
total surface area of the free amino acids, unlike the van der Waals approach, where the 
radii of the individual atoms are compared. In addition to the comparison of the total 
surface area, total volume was also determined for the halogenated amino acids 8-11 as an 
indicator of similarity.  
 
The molecular volumes and surface areas of the 4-trifluoromethyl, 4-chloro, 4-bromo 
and 4-iodo substituted (S)-2-aminopent-4-enoic acids 8-11 were calculated and compared to 
that for (S)-4,5-dehydroleucine (2) (Table 5.2).  
 
Table 5.2 Calculated molecular volumes of (S)-2-amino-4-halopent-4-enoic acids 8-11 normalised 
relative to (S)-4,5-dehydroleucine (2). 
 
Amino Acid 
Difference relative to (S)-4,5-dehydroleucine (2) 
Surface area (Å2) Volume (Å3) 
(S)-2-amino-4-(trifluoromethyl)pent-4-enoic acid (8) +14.8 +13.2 
(S)-2-amino-4-chloropent-4-enoic acid (9) -2.5 -4.1 
(S)-2-amino-4-bromopent-4-enoic acid (10) +1.2 +0.3 
(S)-2-amino-4-iodopent-4-enoic acid (11) +8.7 +7.5 
 
 
From the values displayed in Table 5.2, the bromide 10 is most similar in both 
molecular volume and surface area to (S)-4,5-dehydroleucine (2). These comparisons of 
molecular volumes and surface areas are valid for unnatural amino acids that are 
structurally similar to the proteinogenic counterparts (i.e., a comparison of a γ-amino acid 
with (S)-4,5-dehydroleucine (2) would not be valid). To assess the best indicator of 
substituent size, the degree of incorporation for each of these halogenated amino acids 8-11 
in protein was evaluated experimentally.  
 
 
 
!119 
5.3 Synthesis of Unsaturated Amino Acids 
A literature search revealed that of the amino acids 8-11, the trifluoride 8 had not been 
reported, whilst the amino acids 9-11 had been prepared previously and studied as 
antibacterial agents.[18,19] Of these, the naturally occurring (S)-2-amino-4-chloropent-4-enoic 
acid (9) was the most potent antibiotic against Escherichia coli and displayed antibacterial 
activities against a number of other bacterial strains including, Alcaligenes faecalis, Bacillus 
subtilis, Pseudomonas aeruginosa and Pseudomonas fluorescens.[19,20] No literature was found to 
suggest the incorporation of amino acids 8-11 into proteins. 
 
None of the amino acids 8-11 under investigation were commercially available, and 
instead were obtained synthetically. Synthetic routes to prepare these amino acids were 
selected based on the number of steps, common methodologies and efficiency. Due to the 
similarity of these amino acids, a common approach was employed starting from diethyl 
acetamidomalonate. The trifluoride 8 was prepared as the single (S)- enantiomer, while the 
chloride 9, bromide 10 and iodide 11 were prepared as racemates. The use of racemic 
material is conventional for misincorporation studies as the misactivation of (2R)-amino 
acids is negligible.[7,17,21] The quantity of the racemic materials supplied is therefore doubled 
for incorporation experiments.  
 
An amino acid possessing a diene moiety was additionally prepared and evaluated 
alongside the halogenated amino acids 8-11. This non-proteinogenic amino acid, (S)-2-
amino-4-methylenehex-5-enoic acid (12) (Figure 5.2) could be conveniently synthesised in 
three steps from a synthetic intermediate in the preparation of the bromide 10. The (S)-diene 
12 was of interest as it is a functionalised variant of (2S)-2-amino-4-methylhexanoic acid, 
which has been previously demonstrated as an efficient surrogate of (S)-leucine in protein 
synthesis.[17] This amino acid 12 was not commercially available and has been prepared 
previously as a racemate by a different method to that described here.[22] No literature was 
found to suggest the incorporation of this amino acid into proteins. 
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Figure 5.2 (S)-2-Amino-4-methylenehex-5-enoic acid (12) investigated as a translational substitute for 
(S)-leucine in this chapter. 
 
5.3.1 Synthesis of (S)-2-Amino-4-(trifluoromethyl)pent-4-enoic Acid 
It was envisioned that (S)-2-amino-4-(trifluoromethyl)pent-4-enoic acid (8) could be 
prepared in three steps starting from diethyl acetamidomalonate (Scheme 5.1). Diethyl 
acetamidomalonate was alkylated with 3-bromo-2-(trifluoromethyl)prop-1-ene in a mixture 
of caesium carbonate and acetonitrile by heating with microwave irradiation. The alkylated 
product, diethyl (2-(trifluoromethyl)prop-2-enyl)acetamidomalonate was purified in good 
yield by flash chromatography on silica gel. 1H NMR spectroscopy of the fluorinated 
malonate revealed resonances at 5.83 and 5.37 ppm corresponding to the olefinic protons 
and a singlet at -71.5 ppm in the 19F NMR spectrum, which are consistent with the product. 
Furthermore, the characteristic resonance at 5.18 ppm for the methine proton of the starting 
material, diethyl acetamidomalonate, was not observed by 1H NMR spectroscopy. 
Nucleophilic substitution of 3-bromo-2-(trifluoromethyl)prop-1-ene by the diethyl malonate 
anion is possible by a SN2 or SN2’ reaction. In both reaction mechanisms the same product is 
formed. 
 
Scheme 5.1 Synthesis of (S)-2-amino-4-(trifluoromethyl)pent-4-enoic acid (8). 
 
Deprotection of diethyl (2-(trifluoromethyl)prop-2-enyl)acetamidomalonate by acid-
catalysed hydrolysis was avoided because it was anticipated that the trifluoride 8 would be 
unstable to these conditions akin to the similar 4,5-dehydroleucine 2.[23-25] Instead diethyl 
(2-(trifluoromethyl)prop-2-enyl)acetamidomalonate was base saponified and 
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decarboxylated by treatment with sodium carbonate and then hydrochloric acid 
respectively, to give the monoprotected amino acid. Stereospecific deprotection of the N-
acetyl amino acid was accomplished by treatment with acylase I activated with Co2+, which 
is known to greatly enhance acylase activity.[26] The 1H NMR spectrum of (S)-2-amino-4-
(trifluoromethyl)pent-4-enoic acid (8) revealed singlet resonances at 6.06 and 5.76 ppm for 
the olefinic protons and a distinctive ABX spin system for the α- and two β- protons at 4.22, 
3.06 and 2.83 ppm respectively. These spectral characteristics are consistent with the (S)-
trifluoride 8. 
 
5.3.2 Synthesis of 2-Amino-4-Chloropent-4-enoic Acid 
2-Amino-4-chloropent-4-enoic acid 9 was synthesised following the same strategy as 
reported previously[18] (Scheme 5.2). Diethyl acetamidomalonate was alkylated with 
2,3-dichloropropene by heating with microwave irradiation in a mixture of caesium 
carbonate and acetonitrile. Analysis of the product by 1H NMR spectroscopy confirmed the 
synthesis of diethyl (2-chloroprop-2-enyl)acetamidomalonate with a singlet integrating for 
two methylene protons observed at 3.34 ppm and singlet resonances at 5.22 and 5.11 ppm 
corresponding to the olefinic protons. As stated for the synthesis of diethyl 
(2-(trifluoromethyl)prop-2-enyl) acetamidomalonate, nucleophilic substitution is possible by 
a SN2 or SN2’  reaction, and both reactions mechanisms give the same product. 
 
 
Scheme 5.2 Synthesis of 2-amino-4-chloropent-4-enoic acid 9. 
 
The free amino acid 9 was prepared by acid-catalysed hydrolysis of the diethyl (2-
chloroprop-2-enyl)acetamidomalonate. 1H NMR spectroscopy of the chloride 9 revealed 
overlapping peaks at 5.46 and 5.45 ppm corresponding to the olefinic protons and a 
distinctive ABX spin system corresponding to the α- and two β- protons at 4.05, 3.03 and 2.89 
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ppm consistent with the product. The chloride 9 is not degraded during the acid-catalysed 
hydrolysis, unlike 4,5-dehydroleucine 2, presumably because it is unable to form a tertiary 
carbocation. 
 
5.3.3 Synthesis of 2-Amino-4-Bromopent-4-enoic Acid 
 2-Amino-4-bromopent-4-enoic acid 10 was prepared following a literature method (Scheme 
5.3).[18] Diethyl acetamidomalonate was alkylated by treatment with sodium ethoxide and 
2,3-dibromopropene. 1H NMR spectroscopy of the product, diethyl (2-bromoprop-2-
enyl)acetamidomalonate, revealed singlet resonances at 5.60 and 5.55 ppm corresponding to 
the olefinic protons, which is consistent with that described previously.[27] As stated for the 
synthesis of diethyl (2-chloroprop-2-enyl)acetamidomalonate, nucleophilic substitution can 
proceed via SN2 and SN2’ mechanisms, both of which give the same product. 
 
 
Scheme 5.3 Synthesis of 2-amino-4-bromopent-4-enoic acid 10. 
 
  Diethyl (2-bromoprop-2-enyl)acetamidomalonate was subjected to acid hydrolysis, 
which provided the free amino acid 10 that was purified by ion-exchange chromatography 
and crystallisation from a solution of ethanol and water. The 1H NMR spectral 
characteristics of 2-amino-4-bromopent-4-enoic acid 10 were akin to that for the fluorinated 
8 and chlorinated 9 amino acids with a distinctive ABX spin system corresponding to the α- 
and two β- protons at 4.26, 3.18 and 3.02 ppm and two distinct olefinic proton signals 
present at 5.94 and 5.75 ppm. Akin to the chloride 9, the bromide 10 is not degraded during 
the acid-catalysed hydrolysis step. 
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5.3.4 Synthesis of 2-Amino-4-Iodopent-4-enoic Acid 
2-Amino-4-iodopent-4-enoic acid 11 has been previously prepared by the hydroiodination of 
2-amino pent-4-ynoic acid with hydroiodic acid in acetic anhydride.[18] From the analysis of 
this reaction mixture by 1H NMR spectroscopy it appeared 2-amino-4-iodopent-4-enoic acid 
11 and the undesired regioisomer were formed. It was thought that these compounds would 
be difficult to separate by reverse-phase HPLC due to their similar hydrophobicity. Instead 
the iodide 11 was prepared from ethyl 2-acetamido-4-iodopent-4-enoate as it was 
anticipated that the protecting groups of this reported compound[28] could be simply 
removed in one step (Scheme 5.4). 
 
 
Scheme 5.4 Synthesis of 2-amino-4-iodopent-4-enoic acid 11. 
 
 
Diethyl (prop-2-ynyl)acetamidomalonate was prepared by alkylation of diethyl 
acetamidomalonate with 3-bromoprop-1-yne. Formation of the product was verified by 1H 
NMR spectroscopy by the distinctive triplet corresponding to the alkynyl proton at 1.97 
ppm. Krapcho decarboxylation of diethyl (prop-2-ynyl)acetamidomalonate with lithium 
bromide and water in DMF gave ethyl 2-acetamidopent-4-ynoate. This was confirmed by 
with the appearance of a multiplet at 4.72 ppm corresponding to the α- proton of the 
diprotected amino acid. Ethyl 2-acetamidopent-4-ynoate was hydrostannylated by treatment 
with tributyltin hydride and a catalytic amount of tetrakis(triphenylphosphine)palladium. 
This reaction favours formation of the desired regioisomer, as confirmed by 1H NMR 
spectroscopy, which was subsequently purified by flash chromatography on silica gel. 
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Singlet resonances at 5.73 and 5.25 ppm for the olefinic protons with the neighbouring Sn-H 
satellites confirm the preparation of ethyl 2-acetamido-4-(tributylstannyl)pent-4-enoate. 
 
Ethyl 2-acetamido-4-iodopent-4-enoate was prepared by treating ethyl 
2-acetamido-4-(tributylstannyl)pent-4-enoate with iodine. This tin-iodine exchange reaction 
gave the diprotected vinyl iodide that was purified by reverse-phase HPLC. Its identity was 
verified by 1H NMR spectroscopy from singlet resonances at 6.09 and 5.83 ppm for the 
olefinic protons and the ABX spin system corresponding to the α- and two β- protons at 4.73, 
3.01 and 2.86 ppm. Additionally, the lack of signals between 1.40–1.25 ppm in the spectrum 
of the diprotected vinyl iodide verified the tributyltin moiety had been removed. 
 
Both N-acetyl and ethyl ester protecting groups of ethyl 2-acetamido-4-iodopent-4-
enoate were removed by acid-catalysed hydrolysis. Colourless crystals of 2-amino-4-
iodopent-4-enoic acid 11 as the hydrochloride salt formed upon concentration of the 
solution. The spectral details of 2-amino-4-iodopent-4-enoic acid 11 were similar to the 
analogous compounds 8-10, and the elemental analysis of this compound was near identical 
to the theoretical percentages. 
 
5.3.5 Synthesis of (S)-2-Amino-4-methylenehex-5-enoic Acid 
It was envisaged that (S)-2-amino-4-methylenehex-5-enoic acid (12) could be prepared in 
three straightforward steps from diethyl (2-bromoprop-2-enyl)acetamidomalonate (Scheme 
5.5). Diethyl (2-bromoprop-2-enyl)acetamidomalonate was selected as the starting material 
as it had been prepared previously from commercially available material in one step 
(Scheme 5.3). Additionally, this starting material was favoured over the chloride derivative 
since bromides are generally observed to be more reactive in cross couplings reactions.[11] 
Tributyl(vinyl)tin was added to a solution of the brominated malonate and 
tetrakis(triphenylphosphine) palladium in benzene before the reaction was heated under an 
inert atmosphere to give the diethyl (2-methylene but-3-enyl)acetamidomalonate. 1H NMR 
spectroscopy revealed a doublet of doublets at 6.29 ppm, characteristic for the methine 
olefinic proton of the product. 
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Scheme 5.5 Synthesis of (S)-2-amino-4-methylenehex-5-enoic acid (12). 
 
It has been reported previously that the protected derivatives of 2-amino-4-
methylenehex-5-enoic acid 12 are extremely sensitive to acidic conditions,[22] accordingly the 
deprotection of diethyl (2-bromoprop-2-enyl)acetamidomalonate was conducted to avoid 
prolonged treatment under acidic conditions (Scheme 5.5). Diethyl (2-bromoprop-2-enyl) 
acetamidomalonate was saponified with sodium carbonate and then decarboxylated upon 
acidification of the solution to give 2-acetamido-4-methylenehex-5-enoic acid. 1H NMR 
spectroscopy confirmed the identity of the product by a doublet of doublets at 4.57 ppm 
corresponding to the α- proton of the monoprotected amino acid spilt in an ABX spin 
system. Stereospecific deprotection of the N-acetyl amino acid was accomplished by 
treatment with acylase I activated with Co2+. 1H NMR spectroscopy confirmed the identity of 
the (S)-diene 12 following deprotection, by the distinctive ABX spin system for the α- and 
two β- protons at 4.14, 3.10 and 2.71 ppm respectively and the absence of a singlet at 2.00 
ppm corresponding to the N-acetyl methyl group of the precursor 2-acetamido-4-
methylenehex-5-enoic acid.  
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5.4 Evaluation of the Incorporation of Unsaturated Amino Acids 
into PpiB during CFPS 
The unsaturated amino acids 8-12 were evaluated as substitutes of (S)-leucine during the 
CFPS of PpiB. The S30 cellular extract of E. coli BL21 star (DE3) was used to provide the 
translational machinery for protein synthesis conducted at 30 °C for 18 h in the same manner 
as detailed previously (Chapter 2-4).[5,29-32] Unmodified PpiB was prepared by cell-free 
protein synthesis with each of the twenty proteinogenic amino acids and was compared 
with the protein formed when (S)-leucine was withheld and the unsaturated amino acids 8-
12 supplemented instead. PpiB synthesised in these experiments was purified by 
immobilised metal affinity chromatography as the protein possessed an N- terminal 
polyhistidine-tag. The purified proteins were analysed by 20% SDS-PAGE (Figure 5.3 & 5.4) 
and mass spectroscopy (Figure 5.5-5.11).  
 
 
Figure 5.3 SDS-PAGE of PpiB synthesised with: A) all 20 proteinogenic amino acids, B) no (S)-leucine, 
C) no (S)-leucine but with the (S)-trifluoride 8, D) no (S)-leucine but with the chloride 9, E) no (S)-
leucine but with the bromide 10, F) no (S)-leucine but with the iodide 11. 
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Figure 5.4 SDS-PAGE of PpiB synthesised with: A) all 20 proteinogenic amino acids, B) no (S)-leucine, 
C) no (S)-leucine but with the (S)-diene 12. 
 
 
A large amount of PpiB was synthesised when each of the twenty proteinogenic 
amino acids were supplied (Lane A of Figure 5.3 & 5.4). Diminutive levels of protein were 
produced when (S)-leucine was withheld and the other nineteen proteinogenic amino acids 
were supplied (Lane B of Figure 5.3 & 5.4). This was attributed to background levels of (S)-
leucine present in the S30 extract, as observed previously.[5,32] Mass spectrometry verified 
this background level of protein formed was unmodified by the strong signals at 19220 and 
19250 Da corresponding to full-length His6-PpiB and N-formylated His6-PpiB (Figure 5.5 & 
5.6). A similar low level of protein was formed when (S)-2-amino-4-(trifluoromethyl)pent-4-
enoic acid (8), 2-amino-4-iodopent-4-enoic acid 11 and (S)-2-amino-4-methylenehex-5-enoic 
acid (12) were supplied in place of (S)-leucine (Lanes C & F of Figure 5.3 and Lane C of 
Figure 5.4). However, supplementation with the chloride 9 and the bromide 10 supported 
the synthesis of PpiB to levels comparable to that when all twenty proteinogenic amino 
acids were supplied (Lane D & E of Figure 5.3).  
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Figure 5.5 Deconvoluted mass spectrum of PpiB formed in the presence of 1 mM of each of the twenty 
proteinogenic amino acids.  
 
 
Figure 5.6 Deconvoluted mass spectrum of PpiB formed without the addition of (S)-leucine but with 1 
mM of each of the other nineteen proteinogenic amino acids. 
 
Further to the preliminary analysis of incorporation by SDS-PAGE, the protein 
formed in the presence of each of the unnatural amino acids was analysed by mass 
spectrometry (Figure 5.7-5.11).    
 
Mass reconstruction of  +TOF MS: 0.071 to 0.252 min from Sample 1 (1) of 280613 Sam.wiff Agilent Max. 3.6e5 cps.
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Figure 5.7 Deconvoluted mass spectrum of PpiB formed in the presence of 2 mM (S)-2-amino-4-
methylenehex-5-enoic acid (12) instead of 1 mM (S)-leucine, and with 1 mM of each of the other 
nineteen proteinogenic amino acids. 
 
Mass spectrometry confirmed the (S)-diene 12 was not incorporated as only signals 
corresponding to unmodified His6-PpiB and N-formylated His6-PpiB at 19222 and 19250 Da 
respectively were observed (Figure 5.7).  
 
While analysis by SDS-PAGE did not indicate incorporation of the (S)-trifluoride 8, 
analysis of the protein formed by mass spectrometry revealed both modified His6-PpiB and 
N-formylated His6-PpiB were prepared (Figure 5.8). Signals at 19433, 19380, 19329 and 19277 
Da correspond to replacement with four, three, two and one of the (S)-trifluoride 8 
respectively in place of (S)-leucine at the five possible sites in His6-PpiB. The other series of 
signals at 19409, 19356 and 19304 Da correspond to replacement with three, two and one of 
the (S)-trifluoride 8 respectively in place of (S)-leucine at the five possible sites of N-
formylated His6-PpiB. The average level of replacement with the (S)-trifluoride 8 in place of 
(S)-leucine is ca. 39%. This was determined by the comparison of the peak heights of the 
variously substituted proteins in the deconvoluted spectrum, since these are directly 
proportional to their respective abundance. Distinct peaks can be observed because of the 
sufficient mass difference between the amino acid 8 and (S)-leucine. The level of 
replacement represented by each peak was determined from the mass. This was then 
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multiplied by the ratio of that particular peak height to the sum of all peak heights 
representing all levels of replacements.  
 
 
Figure 5.8 Deconvoluted mass spectrum of PpiB formed in the presence of 2 mM (S)-2-amino-4-
(trifluoromethyl)pent-4-enoic acid (8) instead of 1 mM (S)-leucine, and with 1 mM of each of the other 
nineteen proteinogenic amino acids. 
 
Previous studies have shown that the saturated amino acid analogues, (2S)-2-amino-
4-(trifluoromethyl)pentanoic acid and (2S)-2-amino-4-methylhexanoic acid, of the (S)-
trifluoride 8 and (S)-diene 12 are efficient replacements of (S)-leucine.[5-7] In contrast, the (S)-
trifluoride 8 was an inefficient substitute and the (S)-diene 12 was not incorporated in place 
of (S)-leucine. The lack of substitutability of these unsaturated counterparts indicates the 
importance of the side chain projection for the misincorporation of unnatural amino acids. 
 
Analysis of the mass spectrum for PpiB formed when the iodide 12 was supplied 
revealed both modified His6-PpiB and N-formylated His6-PpiB were prepared (Figure 5.9). 
Signals at 19551, 19442 and 19331 Da correspond to replacement with three, two and one of 
the iodide 11 respectively in place of (S)-leucine at the five possible sites in His6-PpiB. The 
other series of signals at 19576, 19467 and 19359 Da correspond to replacement with three, 
two and one of the iodide 11 respectively in place of (S)-leucine at the five possible sites of 
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N-formylated His6-PpiB. The average level of replacement with the iodide 11 in place of 
(S)-leucine is ca. 21%. 
 
 
Figure 5.9 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 2-amino-4-iodopent-
4-enoic acid 11 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen proteinogenic 
amino acids.  
 
Analysis of the mass spectrum for PpiB formed when the chloride 9 was supplied 
revealed both modified His6-PpiB and N-formylated His6-PpiB were synthesised (Figure 
5.10). Signals at 19317, 19297 and 19279 Da correspond to replacement with five, four and 
three of the chloride 9 respectively in place of (S)-leucine at the five possible sites in 
His6-PpiB. The other major signal at 19341 Da corresponds to full replacement with the 
chloride 9 in place of (S)-leucine in N-formylated His6-PpiB. The average level of 
replacement with the chloride 9 in place of (S)-leucine is ca. 89%. 
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Figure 5.10 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 2-amino-4-
chloropent-4-enoic acid 9 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
Analysis of the mass spectrum for PpiB formed when the bromide 10 was supplied 
revealed both modified His6-PpiB and N-formylated His6-PpiB were synthesised (Figure 
5.11). Signals at 19533, 19471 and 19411 Da correspond to replacement with five, four and 
three of the bromide 10 respectively in place of (S)-leucine at the five possible sites in 
His6-PpiB. The other signals at 19564, 19502, 19439, 19376 and 19312 Da correspond to 
replacement with five, four, three, two and one of the bromide 10 respectively in place of 
(S)-leucine at the five possible sites of N-formylated His6-PpiB. The average level of 
replacement with the bromide 10 in place of (S)-leucine is ca. 76%.  
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Figure 5.11 Deconvoluted mass spectrum of PpiB formed in the presence of 4 mM 2-amino-4-
bromopent-4-enoic acid 10 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
The unnatural amino acids 8-11 have been found to be substitutes for (S)-leucine to 
varying degrees in protein biosynthesis. For misincorporation to occur an unnatural amino 
acid must be activated by an aminoacyl-tRNA synthetase and go undistinguished from its 
proteinogenic counterpart by editing mechanisms set in place to uphold the fidelity of 
protein synthesis. The poor incorporation of the (S)-trifluoride 8 and iodide 11 in place of 
(S)-leucine, is perhaps due to limited amino acid activation or partial discrimination by the 
proof-editing system or a combination of both. Whereas for the (S)-diene 12, which is not 
incorporated, it is either not activated by leucyl-tRNA synthetase or is discriminated against 
by the proof-editing system. Conversely, the chloride 9 and bromide 10 are readily 
incorporated and for such to occur, they must be activated by the leucyl-tRNA synthetase 
and by-pass the editing mechanisms.  
 
5.4.1 Characterisation of Modified Proteins 
The secondary and tertiary structure of the proteins highly substituted with the chloride 9 
and bromide 10 residues were investigated using circular dichroism spectroscopy to identify 
any changes in the physical properties caused by the incorporation of these vinyl halides. 
The circular dichroism spectra for these modified proteins were near identical to that of the 
Mass reconstruction of  +TOF MS: 0.070 to 0.233 min from Sample 5 (5) of 280613 Sam.wiff Agilent Max. 5.0e4 cps.
1.90e4 1.91e4 1.92e4 1.93e4 1.94e4 1.95e4 1.96e4 1.97e4 1.98e4 1.99e4 2.00e4
Mass, Da
5000.0
1.0e4
1.5e4
2.0e4
2.5e4
3.0e4
3.5e4
4.0e4
4.5e4
5.0e4
In
te
n
s
ity
, C
o
u
n
ts
19501.4845
19564.3521
19438.5155
19532.6344
19471.1002
19375.4878
19588.6038
19604.693919411.2637
19635.2879
19664.165419311.7727 19398.4607
19701.8004 19683.753319359.187219221.8207
19765.0429
19860.665919177.1346 19163.3547
! 134 
unmodified protein, indicating there was no significant structural change upon 
incorporation of these unnatural amino acids 9 and 10. (Figure 5.12) However, the 
incorporation of the vinyl halides 9 and 10 lowered the melting temperature of PpiB from TM 
= 54 ± 1 °C, to TM = 43 ± 2 °C and TM = 41 ± 2 °C respectively (Figure 5.13). This 11 and 13 °C 
decrease in melting temperature is perhaps related to the increasing electron density of the 
residues, leading to increased unfavourable interactions. Intriguingly, peptides and proteins 
containing fluorinated aliphatic amino acids typically display enhanced thermal stabilities 
due to the reinforcement of the internal hydrophobic interactions.[7,33-36]  
 
 
 
Figure 5.12 Circular dichroism spectra for PpiB synthesised with: ❚) proteinogenic amino acids, ❚) no 
(S)-leucine but with the chloride 9, and ❚) no (S)-leucine but with the bromide 10. 
 
 
 
Figure 5.13 Thermal stability assessed by circular dichromism spectroscopy for PpiB synthesised 
with: !) proteinogenic amino acids, !) no (S)-leucine but with the chloride 9, and !) no (S)-leucine 
but with the bromide 10, monitored at a wavelength of 222 nm. 
 
-250 
-150 
-50 
50 
150 
250 
350 
190 200 210 220 230 240 250 260 
El
lip
tic
ity
 (1
03
 d
eg
 c
m
2  m
ol
-1
)  
 
Wavelength (nm) 
-240 
-230 
-220 
-210 
-200 
-190 
-180 
-170 
-160 
-150 
-140 
0 10 20 30 40 50 60 70 
El
lip
tic
ity
 (1
03
 d
eg
 c
m
2 
dm
ol
-1
)  
   
   
Temperature (°C)   
!135 
5.5 Comparison of the Calculated Substituent Sizes with the Extent 
of Incorporation 
The calculated molecular volumes and surface areas for amino acids 8-11 with the 
trifluoromethyl, chloro, bromo and iodo substituents relative to a methyl group and the van 
der Waals radii of these substituents were compared with experimental data to assess the 
best indicator of substituent size. The experimental data chosen was the degree of 
substitution observed with the 4-trifluoromethyl, 4-chloro, 4-bromo and 4-iodo substituted 
2-aminopent-4-enoic acids 8-11 in PpiB (Section 5.4). The level of substitution of (S)-leucine 
with these amino acids 8-11 was 39%, 89%, 76% and 21% respectively. The normalised 
molecular volumes for the trifluoromethyl, chloro, bromo and iodo substituents of the 
amino acids 8-11 are 13.2 Å3, -4.1 Å3, 0.3 Å3 and 7.5 Å3, respectively. These values do not 
correlate as well with the experimental data as the normalised surface areas for the 
trifluoromethyl, chloro, bromo and iodo substituents of 14.8 Å2, -2.5 Å2, 1.2 Å2 and 8.7 Å2 
respectively (Table 5.2). Even more poorly correlated with the observed experimental level 
of replacement are the van der Waal radii for the trifluoromethyl, chloro, bromo, iodo, and 
methyl substituents of 2.20 Å, 1.73 Å, 1.84 Å, 2.01 Å and 2.00 Å, respectively (Table 5.1). This 
comparison suggests that surface area is the best indicator of substitutability of those 
evaluated for these purposes.  
 
 
5.6 Towards the Modification of Halogenated Protein by a 
Palladium-Catalysed Cross-Coupling Reaction 
Previous studies have introduced aryl halides and alkynes into proteins for palladium-
catalysed cross-coupling reactions. These reactions include Suzuki,[11,37] Sonogashira[8,38] and 
Mizoroki-Heck[38,39] catalysed cross-couplings. Of interest was whether a protein possessing 
the vinyl halide moiety could participate in a metal catalysed cross-coupling reaction. The 
vinyl bromide 10 was selected for further investigation as this amino acid supported 
efficient protein synthesis leading to highly substituted protein (Section 5.4). Furthermore, 
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the vinyl bromide functional group is known to participate in palladium-catalysed cross-
coupling reactions under mild conditions compatible with proteins.[8-14] 
 
5.6.1 Suzuki Cross-Coupling with 2-Acetamido-4-bromopent-4-enoic Acid  
2-Acetamido-4-bromopent-4-enoic acid (13) was selected instead of 2-amino-4-bromopent-4-
enoic acid 10 to assess the reactivity of their common side chain in a Suzuki cross-coupling 
reaction under conditions compatible with proteins and peptides. This test substrate was 
chosen because it possesses the side chain of interest and while it is soluble in water, it can 
also be simply extracted into the organic phase (from the various salts present in the 
aqueous solution by acidification of this latter solution), which facilitates rapid analysis of 
the reaction. 
 
2-Acetamido-4-bromopent-4-enoic acid (13) was prepared by base saponification of 
diethyl (2-bromoprop-2-enyl)acetamidomalonate (Synthesis described in Section 5.3.3) 
followed by decarboxylation through treatment with hydrochloric acid (Scheme 5.6). The 
identity of the bromide 13 was confirmed by the distinctive ABX system of the α- and β- 
protons at 4.78, 3.10 and 2.96 ppm respectively, and by the singlet resonance of the N-acetyl 
methyl group at 2.06 ppm, integrating for 3 protons in the 1H NMR spectrum of this 
compound. 
 
Scheme 5.6 Synthesis of 2-acetamido-4-bromopent-4-enoic acid (13) from diethyl  
(2-bromoprop-2-enyl)acetamidomalonate. 
 
The palladium catalyst selected to investigate the reactivity of the vinyl bromide side 
chain was the complex of palladium acetate with the sodium salt of 2-amino-4,6-
dihydroxypyrimidine,[11] as this catalyst has successfully been used for Suzuki cross-
coupling reactions with protein bound aryl iodides at mild temperatures.[11,37] 2-Acetamido-
4-bromopent-4-enoic acid (13) was treated with the palladium pyrimidine catalyst,[11] 
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4-fluorophenylboronic acid and sodium hydrogen phosphate in water and the resultant 
solution was stirred at room temperature overnight (Scheme 5.7). The 1H NMR spectrum of 
the crude reaction mixture revealed conversion to the cross-coupled product 14 had 
occurred. This was indicated by the appearance of two distinct olefinic singlets at 5.33 and 
5.15 ppm. Integration of these olefinic signals and comparison with the integration of the 
olefinic signals of the starting material 13 at 5.70 and 5.57 ppm indicated ca. 90% conversion 
to the cross-coupled product, 2-acetamido-4-(4-fluorophenyl)pent-4-enoic acid (14). The 
vinyl bromide side chain of 2-acetamido-4-bromopent-4-enoic acid (13) appears sufficiently 
reactive to undergo a Suzuki cross-coupling reaction under these mild conditions with this 
palladium catalyst. 
 
Scheme 5.7 Synthesis of 2-acetamido-4-(4-fluorophenyl)pent-4-enoic acid (14).  
 
5.6.2 Compatibility of PpiB with Suzuki Cross-Coupling Reaction 
Conditions 
A method has been previously developed to analyse proteins by mass spectrometry after 
their subjection to conditions required for the Suzuki cross-coupling reaction.[37] This method 
relies upon the use of 3-mercaptopropionic acid which acts as a scavenger to remove 
palladium from protein by chelation. Palladium ions are believed to non-specifically co-
ordinate to protein leading to the formation of many adduct isoforms and this results in the 
loss of signals corresponding to protein when analysed by mass spectrometry.[37] Proteins 
investigated in palladium-catalysed cross-coupling reactions are selected based upon their 
stablity and robustness.[37,40]  PpiB was intially assessed because the purified vinyl bromide 
10 substituted protein was avaliable from a previous investigation (Section 5.4). This protein 
sample was dialysed with a 5 mM solution of 3-mercaptopropionic acid at 4 °C for 24 h. The 
soluble and insoluble fractions were then analysed by SDS-PAGE (Figure  5.14). 
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Figure 5.14 SDS-PAGE of purified PpiB synthesised with no (S)-leucine but with 4 mM of the bromide 
10 dialysed with 5 mM 3-mercaptoethanol at 4 °C for 24 h. A) Soluble fraction, B) insoluble fraction. 
 
No protein bands corresponding to PpiB (19.2 kDa) were apparent in the soluble 
fraction, whereas for the insoluble fraction a number of bands of higher and lower molecular 
weight than that of PpiB were observed. It appears that 3-mercaptopropionic acid reacts 
with the substituted PpiB to give rise to these proteinaceous materials of varying molecular 
weights. Given these observations ubiquitin was selected as the test protein instead of PpiB 
because the protein fold is robust and the protein is known to be compatible with 3-
mercaptopropionic acid and the conditions required for the Sonogashira reaction.[40] 
 
5.6.3 Preparation of Ubiquitin Substituted with Halogenated Amino Acids 
To investigate a Suzuki cross-coupling reaction of ubiquitin substituted with 2-amino-4-
bromopent-4-enoic acid 10, this material needed to be prepared. In addition to the synthesis 
of this material, for completeness the synthesis of ubiquitin when supplementing with either 
(S)-2-amino-4-(trifluoromethyl)pent-4-enoic acid (8), 2-amino-4-chloropent-4-enoic acid 9 or 
2-amino-4-iodopent-4-enoic acid 11 instead of (S)-leucine was also conducted to validate 
that misincorporation of these unnatural amino acids 8-11 is not limited to PpiB. The (S)-
diene 12 was not evaluated, as incorporation was not observed (Section 5.4). 
 
CFPS of ubiquitin was conducted with each of the twenty proteinogenic amino acids, 
with (S)-leucine withheld, and withholding (S)-leucine but supplementing with either (S)-2-
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amino-4-(trifluoromethyl)pent-4-enoic acid (8), 2-amino-4-chloropent-4-enoic acid 9, 2-
amino-4-bromopent-4-enoic acid 10 or 2-amino-4-iodopent-4-enoic acid 11. Soluble ubiquitin 
was purified by immobilised metal ion affinity chromatography as the protein possessed an 
N- terminal polyhistidine-tag and was then analysed by 20% SDS-PAGE (Figure 5.15) and 
mass spectrometry (Figures 5.16-5.21). 
 
 
Figure 5.15 SDS-PAGE of ubiquitin synthesised with: A) all 20 proteinogenic amino acids, B) no (S)-
leucine, C) no (S)-leucine but with the (S)-trifluoride 8, D) no (S)-leucine but with the chloride 9, E) no 
(S)-leucine but with the bromide 10, and F) no (S)-leucine but with the iodide 11. 
 
A large amount of ubiquitin was synthesised when each of the twenty proteinogenic 
amino acids were supplied (Lane A of Figure 5.15). However, withholding (S)-leucine but 
supplementing with each of the other nineteen proteinogenic amino acids leads to a marked 
decrease in ubiquitin synthesis (Lane B of Figure 5.15) as observed previously with PpiB. 
With the supplementation of the chloride 9 or the bromide 10 in place of (S)-leucine and 
with each of the other nineteen proteinogenic amino acids, a similar amount of ubiquitin 
was synthesised as when each of the twenty proteinogenic amino acids were supplied (Lane 
D & E of Figure 5.15).  In contrast, when the (S)-trifluoride 8 or the iodide 11 were 
supplemented in place of (S)-leucine and each of the other nineteen proteinogenic amino 
acids, a similar amount of ubiquitin was synthesised as when (S)-leucine was withheld and 
only the other nineteen proteinogenic amino acids were supplied (Lane C & F of Figure 
5.15). The level of protein synthesis obtained with each of these amino acids is consistent 
with that observed for PpiB (Figure 5.3, Section 5.4). 
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Analysis of the mass spectrum of ubiquitin synthesised with each of the twenty 
proteinogenic amino acids revealed strong signals at 10756, 10597, 9456 and 6531 Da (Figure 
5.16). These signals correspond to full-length N-formylated His6-ubiquitin and the G2-G96, 
S12-G96 and P39-G96 fragments of ubiquitin respectively.   
 
 
Figure 5.16 Deconvoluted mass spectrum of ubiquitin formed in the presence of 1 mM all of twenty 
proteinogenic amino acids.  
 
Analysis of the mass spectrum of the diminutive amount of ubiquitin synthesised 
when (S)-leucine was withheld and each of the nineteen proteinogenic amino acids were 
supplied revealed signals at 10756, 10424, 9456 and 6434 Da (Figure 5.17). These signals 
correspond to full-length N-formylated His6-ubiquitin and the S3-R94, S12-G96 and S40-G96 
fragments of ubiquitin respectively. 
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Figure 5.17 Deconvoluted mass spectrum of ubiquitin formed without the addition of (S)-leucine but 
with 1 mM of each of the other nineteen proteinogenic amino acids. 
 
Analysis of the mass spectrum of the diminutive amount of ubiquitin synthesised 
when the (S)-trifluoride 8 was supplemented in place of (S)-leucine and each of the other 
nineteen proteinogenic amino acids were supplied revealed signals at 10424, 9456 and 8348 
Da (Figure 5.18). These signals correspond to the S3-R94, S12-G96 and P16-L89 fragments of 
ubiquitin respectively. No peaks corresponding to ubiquitin substituted with the (S)-
trifluoride 8 were observed. 
 
Analysis of the mass spectrum of ubiquitin synthesised when the chloride 9 was 
supplemented in place of (S)-leucine and the nineteen other proteinogenic amino acids were 
supplied revealed two different protein chain lengths were present (Figure 5.19). The signals 
at 10940, 10920 and 10911 Da correspond to replacement with ten, nine and eight of the 
chloride 9 respectively in place of (S)-leucine at the ten possible sites in N-formylated 
His6-ubiquitin. The other series of signals at 10782, 10763 and 10745 Da correspond to 
replacement with ten, nine and eight of the chloride 9 respectively in place of (S)-leucine at 
the ten possible sites in the G2-G96 fragment of ubiquitin. The average level of replacement 
with the chloride 9 in place of (S)-leucine was ca. 85%. 
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Figure 5.19 Deconvoluted mass spectrum of ubiquitin formed in the presence of 4 mM 2-amino-4-
chloropent-4-enoic acid 9 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
Analysis of the mass spectrum of ubiquitin synthesised when the bromide 10 was 
supplemented in place of (S)-leucine and each of the nineteen other proteinogenic amino 
acids were supplied revealed modified N-formylated His6-ubiquitin, His6-ubiquitin, and 
fragmented ubiquitin were present (Figure 5.20). The signals at 11385, 11322, 11260 and 
11197 Da correspond to replacement with ten, nine, eight and seven of the bromide 10 
respectively in place of (S)-leucine at the ten possible sites in N-formylated His6-ubiquitin. 
The signal at 11357 Da, corresponds to full replacement (ten out of ten) with the bromide 10 
in place of (S)-leucine in His6-ubiquitin. The signals at 11226, 11163 and 11100 Da correspond 
to replacement with ten, nine and eight of the bromide 10 respectively in place of (S)-leucine 
at the ten possible sites in the G2-G96 fragment of ubiquitin. The average level of 
replacement with the bromide 10 in place of (S)-leucine was ca. 75%. 
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Figure 5.20 Deconvoluted mass spectrum of ubiquitin formed in the presence of 4 mM 2-amino-4-
bromopent-4-enoic acid 10 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids. 
 
 
Figure 5.21 Deconvoluted mass spectrum of ubiquitin formed in the presence of 4 mM 2-amino-4-
iodopent-4-enoic acid 11 instead of 1 mM (S)-leucine, and with 1 mM of each of the other nineteen 
proteinogenic amino acids.  
  
Analysis of the mass spectrum of the diminutive amount of ubiquitin synthesised 
when the iodide 11 was supplemented in place of (S)-leucine and each of the other nineteen 
other proteinogenic amino acids were supplied revealed signals at 9477 Da and 6318 Da 
(Figure 5.21). These signals correspond to the H6-G89 and S40-R94 fragments of ubiquitin 
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respectively. No peaks corresponding to ubiquitin substituted with the iodide 11 were 
observed. 
 
A number of truncated ubiquitin proteins were present as indicated by analysis of 
the mass spectra of these purified samples (Figures 5.16-5.21). While it is possible this may 
be from the use of contaminated DNA it is more likely these truncated ubiquitin proteins are 
the result of protein degradation. Any degradation would apparently occur after 
purification (possibly auto-catalytic), since truncated ubiquitin proteins without an intact 
His6-tag were present in these purified samples. Proteins without his-tags are almost 
completely removed during purification by immobilised metal affinity chromatography.  
 
The relative amounts of ubiquitin synthesised when either the (S)-trifluoride 8, 
chloride 9, bromide 10 or iodide 11 were supplemented instead of (S)-leucine but with the 
other 19 proteinogenic amino acids was comparable to the identical experiment conducted 
with PpiB as the test protein (Section 5.4). PpiB synthesised in the presence of the (S)-
trifluoride 8 and the iodide 11 was poorly substituted, whereas no replacement with these 
amino acids was observed for ubiquitin synthesised under the same conditions as only weak 
signals corresponding to degraded unsubstituted ubiquitin were observed in these samples. 
It is possible that ubiquitin substituted with (S)-trifluoride 8 and the iodide 11 was formed, 
but not observed due to degradation leading to removal of the his-tag, which would prevent 
the purification of these proteins. The degree of substitution observed in ubiquitin and PpiB 
with the chloride 9 and the bromide 10 in place of (S)-leucine in ubiquitin was comparable. 
Nevertheless, ubiquitin substituted with the bromide 10 has been prepared to investigate if 
this protein bound vinyl bromide moiety can be utilised for palladium-catalysed cross-
coupling reactions. 
 
5.6.4 Evaluation of Ubiquitin with the Conditions Required for Suzuki 
Cross-Coupling 
The treatment of a protein sample with 3-mercaptopropionic acid is not mandatory for the 
detection of protein by LC-MS after exposure to the palladium pyrimidine catalyst[11] 
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however treatment with 3-mercaptopropionic acid drastically improves the signal 
strength.[37] To investgate whether treatment with 3-mercaptopropionic acid could be 
circumvented, ubiquitin synthesised with proteinogenic amino acids was treated with 36 
equivalents of the palladium pyrimidine catalyst[11] and was then incubated at 37 °C for 0.5 h 
before a sample of this solution was directly injected into the mass spectrometer. No signals 
corresponding to ubiquitin were observed in the deconvoluted mass spectrum (Figure 5.22). 
 
 
Figure 5.22 Deconvoluted mass spectrum of ubiquitin synthesised with proteinogenic amino acids 
treated with 36 equivalents of palladium catalyst.  
 
This lack of signal is believed to be due to the non-specific co-ordination of 
numerous palladium ions to the protein leading to the formation of many adduct isoforms 
at undetectable levels.[37] To attempt to overcome this, 3-mercaptopropionic acid was added 
to the palladium treated protein as this has previously been reported to scavenge palladium 
and thereby enhancing the detection of the protein by mass spectrometry.[37] Ubiquitin was 
treated with 21 equivalents the palladium pyrimidine catalyst[11]  and incubated at 37 °C for 
0.5 h before 230 equivalents of 3-mercaptopropionic acid was added. The yellow precipitate 
that quickly formed upon addition of the thiol reagent was removed by centrifugation and 
the supernatant was directly injected into the mass spectrometer (Figure 5.23). 
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Figure 5.23 Deconvoluted mass spectrum of ubiquitin treated with 21 eq. of palladium catalyst  
followed by 230 eq. of 3-mercaptopropionic acid. 
 
Treatment with 3-mercaptopropionic acid restored signals corresponding to 
ubiquitin. The signals observed at 9456, 9369, 9311 and 6531 Da correspond to the S4-G96, 
S12-G96, G13-G95 and P39-G96 fragments of ubiquitin. It appears that the ubiquitin 
synthesised from proteinogenic amino acids (Figure 5.16) has undergone degradation to 
shorter fragments (Figure 5.23). This degradation is possibly associated with the treatment 
of ubiquitin with the palladium catalyst, 3-mercaptopropionic acid or is perhaps the 
outcome of spontaneous self-catalytic degradation.  
 
Ubiquitin substituted with the vinyl bromide 10 was then treated with the palladium 
catalyst[11]  and 3-mercaptopropionic acid to assess whether it was also detectable by mass 
spectrometry. Ubiquitin modified with the vinyl bromide 10 was treated with 35 equivalents 
the palladium pyrimidine catalyst[11]  and incubated at 37 °C for 0.5 h before 240 equivalents 
of 3-mercaptopropionic acid were added. Only two weak signals were observed in the 
deconvoluted mass spectrum for this treated ubiquitin (Figure 5.24). Neither signal was 
identifiable as corresponding to the vinyl bromide 10 substituted ubiquitin or any derivative 
thereof. This experiment was repeated but with a larger excess of 3-mercaptopropionic acid 
to ensure no palladium ions were co-ordinated to the protein disrupting detection by mass 
spectrometry. The deconvoluted mass spectrum after the treatment with 475 equivalents of 
Mass reconstruction of  +TOF MS: 0.071 to 0.270 min from Sample 5 (A) of 310513 Sam.wiff Agilent Max. 6.8e5 cps.
7000.0 8000.0 9000.0 1.0e4 1.1e4 1.2e4 1.3e4 1.4e4 1.5e4
Mass, Da
5.0e4
1.0e5
1.5e5
2.0e5
2.5e5
3.0e5
3.5e5
4.0e5
4.5e5
5.0e5
5.5e5
6.0e5
6.5e5
6.8e5
In
te
n
s
ity
, C
o
u
n
ts
9369.0036
9456.0413
9311.9112
9542.9169
6531.6725
9477.8391 9695.2282
9255.12946434.0712 10423.93128489.5534 13692.718513282.0924 15009.739912482.644210213.4032
!147 
3-mercaptopropionic acid was (Figure 5.25) comparable to the spectrum when 240 
equivalents of 3-mercaptopropionic acid were used (Figure 5.24). Further investigation is 
required to establish cross-coupling conditions compatible with vinyl bromide 10 
substituted ubiquitin.  
 
 
Figure 5.24 Deconvoluted mass spectrum of ubiquitin treated with 35 eq. of palladium catalyst and 
then 240 eq. of 3-mercaptopropionic acid. 
 
 
Figure 5.25 Deconvoluted mass spectrum of ubiquitin treated with 35 eq. of palladium catalyst and 
then 475 eq. of 3-mercaptopropionic acid. 
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SDS-PAGE analysis of the vinyl bromide 10 substituted ubiquitin after treatment 
with the 3-mercaptopropionic acid may prove useful to indicate whether the ubiquitin is 
soluble and verify its molecular weight, akin to that performed for the vinyl bromide 
substituted PpiB treated with 3-mercaptopropionic acid (Figure 5.14). Separation of the 
treated protein samples by liquid-chromatography prior to analysis by mass spectrometry 
may aid detection of the vinyl bromide 10 modified ubiquitin and this is suggested for 
future attempts.  
 
 
5.7 Conclusions 
The amino acids 8-12 have been prepared and evaluated as translational surrogates for the 
aliphatic amino acid (S)-leucine during protein synthesis with native biosynthetic 
machinery. The (S)-diene 12 was not incorporated into protein as confirmed by SDS-PAGE 
and mass spectrometry. Neither the (S)-trifluoride 8 nor iodide 11 could support high levels 
of protein synthesis, but partial replacement of (S)-leucine with the (S)-trifluoride 8 and 
iodide 11 of 39% and 21% was observed in the synthesised PpiB respectively. By contrast, 
the chloride 9 and bromide 10 are effective surrogates of (S)-leucine and the degree of 
substitution with these amino acids was much higher at ca. 85% and 75% respectively.  
 
The degree of misincorporation with the amino acids 8-11 was compared with the 
calculated molecular volumes and surface areas for the trifluoromethyl, chloro, bromo and 
iodo substituents of amino acids 8-11 and their van der Waals radii, to evaluate the best 
measure of steric size. Of these, the calculated surface area appears to align best with the 
experimental data. This simple calculation may prove to be useful as an indicator of whether 
one functional group can substitute for another in residue-specific approaches to incorporate 
unnatural amino acids. 
 
Replacing the side chain of the aliphatic amino acid (S)-leucine with the halogenated 
amino acids 8-11 results in the introduction of functionality at a previously unactivated 
position, which is of significant interest in chemistry. The vinyl bromide side chain of the 
!149 
protected amino acid 13 was found to undergo a Suzuki cross-coupling reaction under 
conditions compatible with peptides and proteins. However, this could not be replicated 
with PpiB modified with the unnatural amino acid 10. Instead ubiquitin was investigated as 
the model protein and was detectable by mass spectrometry after treatment with palladium 
catalyst and 3-mercaptopropionic acid. When this experiment was repeated with vinyl 
bromide 10 modified ubiquitin, no signals corresponding to ubiquitin or any identifiable 
derivative thereof were observed. Further examination is required to adjust the 
methodology to enable the detection of modified protein after treatment with the 
components required for the Suzuki cross-coupling reaction.  
 
 
5.8 Experimental Details 
5.8.1 Calculations of Molecular Volumes and Surface Areas 
Molecular volumes and surface areas were determined using Spartan '14 (Wavefunction, 
Inc. Irvine, CA). Structures of the amino acids were minimised using Hartree-Fock 
calculations with a 6-31G* basis in vacuum, followed by determination of the volume and 
surface area. 
 
5.8.2 Syntheses of Unsaturated Amino Acids 
Synthesis of (S)-2-Amino-4-(trifluoromethyl)pent-4-enoic Acid (8) 
Diethyl (2-(trifluoromethyl)prop-2-enyl)acetomidomalonate 2-(Bromo-
methyl)-3,3,3-trifluoropropene (Oakwood Products, Inc.) (100 µL) was 
added to diethyl acetamidomalonate (0.23 g, 1.1 mmol) and Cs2CO3 (0.60 
g, 1.8 mmol) in dry MeCN (4 mL), and the mixture was heated at 100 °C in a microwave 
(closed vessel, 300 W, 250 psi) for 1 h, before it was cooled and filtered, and the filtrate was 
concentrated under reduced pressure to give a colourless solid. Flash chromatography of the 
solid on silica, eluting with EtOAc/PET, gave diethyl 
(2-(trifluoromethyl)prop-2-enyl)acetamidomalonate as colourless needles. Yield 0.28 g 
(82%); M.p. 75-77 °C; ¹H NMR (400 MHz, CDCl3): δ=6.80 (br s, 1H), 5.83 (q, 4J(19F,1H)=1.6 Hz, 
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1H), 5.37 (q, 4J(19F,1H)=1.2 Hz, 1H), 4.23 (m, 4H), 3.35 (d, 2H), 2.02 (s, 3H), 1.25 ppm (t, 3J=7.2 
Hz, 6H); 13C NMR (101 MHz, CDCl3): δ=169.3, 166.9, 132.8 (q, 2J(19F,13C)=30.6 Hz), 123.7 (q, 
3J(19F,13C)=5.8 Hz), 123.1 (q, 1J(19F,13C)=273.1 Hz), 65.4, 62.6, 31.5, 22.4, 13.6 ppm; 19F NMR 
(282 MHz, CDCl3): δ=-71.5 ppm (s, 3F); HRMS (ESI): m/z calcd for C13H19F3NO5: 326.1215 
[M+H]+; found: 326.1212; elemental analysis calcd (%) for C13H18F3NO4: C 48.00, H 5.58, F 
17.52, N 4.31; found: C 48.17, H 5.62, F 17.38, N 4.29. 
 
(S)-2-Amino-4-(trifluoromethyl)pent-4-enoic Acid (8) Na2CO3 solution (10%, 2 
mL) was added to diethyl (2-(trifluoromethyl)prop-2-enyl)acetomidomalonate 
(46 mg, 0.14 mmol) and heated at reflux for 3 h, before the solution was cooled 
to RT and was acidified with 2 M HCl to pH 1. The aqueous solution was extracted three 
times with EtOAc. The combined organic phases were concentrated under reduced pressure 
to give a colourless residue, before it was dissolved in a HEPES buffer (10 mL, 10 mM, pH 
7.2) containing CoCl2 (5 mM). Acylase I (10 mg, activity 720 µmol/mg) was added to the 
buffer and the solution was incubated at 30 °C for 18 h. The solution was acidified to pH 1 
with 6 M HCl and then filtered through a Millipore Amicon YM-3 filter. The filtrate was 
concentrated to dryness and the residue purified by HPLC (Alltech Prevail C18 250 x 10 mm, 
5 µm) using a mobile phase of 0.1% TFA in H2O/ 0.1% TFA in MeCN (70:30) at a flow rate of 
4.7 mL min-1, and gave the TFA salt of (S)-2-amino-4-(trifluoromethyl)pent-4-enoic acid (4.1) 
as an off-white solid. Yield 11 mg (54%); HPLC tR  =  2.7 min; ¹H NMR (400 MHz, D2O): 
δ=6.06 (s, 1H), 5.76 (s, 1H), 4.22 (dd, 3J=9.2, 3J=5.3 Hz, 1H), 3.06 (dd, 2J=15.6, 3J=5.3 Hz, 1H), 
2.83 ppm (dd, 2J=15.6, 3J=9.2 Hz, 1H); 13C NMR (125 MHz, D2O): δ=171.8, 131.6, 125.2, 52.5, 
30.9, 1.5 ppm; HRMS (ESI): m/z calcd for C6H7F3NO2: 182.0429 [M-H]-; found: 182.0427; An 
analytically pure sample was obtained by dissolution in EtOH/HCl followed by the 
addition of propylene oxide,[41] to give colourless crystals of (S)-2-amino-4-
(trifluoromethyl)pent-4-enoic acid (4.1). M.p. >270 °C (decomp.); 19F NMR (376 MHz, D2O): 
δ=-86.5 ppm (s, 3F); elemental analysis calcd (%) for C6H8F3NO2: C 39.35, H 4.40, F 31.12, N 
7.65; found: C 39.73, H 4.82, F 30.86, N 7.96. 
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Synthesis of 4-Amino-4-chloropent-4-enoic Acid 9 
Diethyl (2-chloroprop-2-enyl)acetamidomalonate 2,3-Dichloropropene 
(0.21 mL, 2.3 mmol) was added to a mixture of diethyl acetamidomalonate 
(0.23 g, 1.1 mmol) and Cs2CO3 (0.75 g, 2.3 mmol) in dry MeCN (3 mL), and 
the mixture was heated at 100 °C in a microwave (closed vessel, 300 W, 250 psi) for 70 min, 
before it was cooled and filtered, and the filtrate was concentrated under reduced pressure. 
Recrystallisation of the residue from MeCN gave diethyl (2-chloroprop-2-
enyl)acetamidomalonate as colourless crystals. Yield 0.26 g (84%); M.p. 71-73 °C; ¹H NMR 
(300 MHz, CDCl3): δ=6.88 (s, 1H), 5.22 (s, 1H), 5.11 (s, 1H), 4.19 (q, 3J=7.1 Hz, 4H), 3.34 (s, 
2H), 1.96 (s, 3H), 1.21 ppm (t, 3J=7.1 Hz, 6H); HRMS (ESI): m/z calcd for C12H1935ClNO5: 
292.0952 [M+H]+; found: 292.0951. These spectral data are consistent with reported values.[42]  
 
2-Amino-4-chloropent-4-enoic Acid 9 Diethyl (2-chloroprop-2-enyl) 
acetamidomalonate (0.10 g, 0.34 mmol) was added to 2 M HCl (20 mL) and the 
mixture was heated at reflux for 5 h, before it was concentrated under reduced 
pressure. The residual solid was purified by dissolution in EtOH/HCl followed by the 
addition of propylene oxide,[41] to give colourless crystals of 2-amino-4-chloropent-4-enoic 
acid 9. Yield 36 mg (70%); M.p. 195-196 °C (decomp.); ¹H NMR (300 MHz, D2O): δ=5.51 (s, 
1H), 5.50 (s, 1H), 4.32 (dd, 3J=9.3, 3J=4.5 Hz, 1H), 3.11 (dd, 2J=15.0, 3J=4.5 Hz, 1H), 2.99 ppm 
(dd, 2J=15.0, 3J=9.3 Hz, 1H); 13C NMR (125 MHz, D2O): δ=172.0, 135.3, 119.1, 51.5, 40.0 ppm; 
HRMS (ESI): m/z calcd for C5H735ClNO2: 148.0165 [M-H]-; found: 148.0165. An analytically 
pure sample was obtained by HPLC (Alltech Prevail, C18 250 x 10 mm, 5 µm) using a mobile 
phase of 0.1% TFA in H2O at a flow rate of 4 mL min-1. HPLC tR  =  11.6 min; elemental 
analysis calcd (%) for C7H9ClF3NO4: C 31.90, H 3.44, Cl 13.45, F 21.62, N 5.31; found: C 31.86, 
H 3.45, Cl 13.47, F 21.62, N 5.37. 
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Synthesis of 2-Amino-4-bromopent-4-enoic Acid 10 
Diethyl (2-bromoprop-2-enyl)acetamidomalonate Sodium metal (0.22 g, 
9.6 mmol) was added to a stirred solution of diethyl acetamidomalonate 
(2.0 g, 9.2 mmol) and dry EtOH (50 mL) under an atmosphere of N2. 
After the sodium had reacted, 2,3-dibromopropene (2.0 mL, 21 mmol) (technical grade 80%, 
Sigma-Aldrich, Inc.) was added slowly and the solution was stirred at 30 °C for 3 h before it 
was concentrated under reduced pressure. The residue was partitioned between EtOAc and 
H2O, and the organic phase was washed with a brine solution and dried (MgSO4), before it 
was concentrated under reduced pressure to give a colourless solid. Flash chromatography 
of the solid on silica, eluting with EtOAc/hexane, gave diethyl (2-bromoprop-2-
enyl)acetamidomalonate as a colourless solid. Yield 2.7 g (86%); M.p. 82-84 °C; 1H NMR (400 
MHz, CDCl3): δ=6.88 (br s, 1H), 5.60 (s, 1H), 5.55 (s, 1H), 4.26 (m, 4H), 3.56 (s, 2H), 2.04 (s, 
3H), 1.27 ppm (t, 3J=7.2 Hz, 6H); 13C NMR (101 MHz, CDCl3): δ=169.3, 167.3, 126.4, 122.6, 
65.5, 63.1, 43.3, 23.1, 14.1 ppm; HRMS (ESI): m/z calcd for C12H1979BrNO5: 336.0447 [M+H]+; 
found: 336.0446. These spectral data are consistent with reported values.[27] 
 
2-Amino-4-bromopent-4-enoic Acid 10 Hydrobromic acid (24%, 10 mL) was 
added to diethyl (2-bromoprop-2-enyl)acetamidomalonate (46 mg, 0.14 mmol) 
and the mixture was heated at reflux for 2 h, before it was concentrated under 
reduced pressure to give an off-white solid. Ion-exchange chromatography (Dowex 50W X8) 
of this material, followed by crystallisation from EtOH/H2O (7:3) gave 2-amino-4-
bromopent-4-enoic acid 10 as off-white crystals. Yield 19 mg (72%); M.p. >190 °C (decomp.); 
1H NMR (300 MHz, D2O): δ=5.94 (s, 1H), 5.75 (s, 1H), 4.26 (dd, 3J=9.0, 3J=4.8 Hz, 1H), 3.18 
(dd, 2J=15.0, 3J=4.8 Hz, 1H), 3.02 ppm (dd, 2J=15.0, 3J=9.0 Hz, 1H); 13C NMR (125 MHz, D2O): 
δ=172.4, 126.5, 123.7, 52.5, 42.4 ppm; HRMS (ESI): m/z calcd for C5H979BrNO2: 193.9817 
[M+H]+; found: 193.9819. An analytically pure sample was obtained by HPLC (Alltech 
Prevail C18 250 x 10 mm, 5 µm) using a mobile phase of 0.1% TFA in H2O at a flow rate of 4 
mL min-1. HPLC tR  =  12.2 min; elemental analysis calcd (%) for C7H9BrF3NO4: C 27.29, H 
2.94, Br 25.94, F 18.50, N 4.55; found: C 27.32, H 3.02, Br 25.95, F 18.54, N 4.69. 
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Synthesis of 2-Amino-4-iodopent-4-enoic Acid 11 
Diethyl (prop-2-ynyl)acetamidomalonate Sodium metal (0.62 g, 0.027 
mol) was added in portions to a stirred solution of diethyl 
acetamidomalonate (5.0 g, 0.023 mol) and dry EtOH (100 mL) under an 
atmosphere of N2. After the sodium had reacted, 3-bromoprop-1-yne (2.6 mL, 0.035 mol) 
was added slowly and the solution was stirred at 60 °C for 3 h before it was concentrated 
under reduced pressure. The residue was partitioned between EtOAc and H2O, and the 
organic phase was washed with a brine solution and dried (MgSO4), before it was 
concentrated under reduced pressure to give a colourless solid. Flash chromatography of the 
solid on silica, eluting with EtOAc/hexane, gave diethyl (prop-2-ynyl)acetamidomalonate as 
a colourless solid. Yield 5.3 g (91%); M.p. 90-91 °C; 1H NMR (400 MHz, CDCl3): δ=6.93 (br. s, 
1H), 4.26 (m, 4H), 3.27 (d, 4J=2.4 Hz, 2H), 2.06 (s, 3H), 1.97 (t, 4J=2.4 Hz, 1H), 1.26 ppm (t, 
3J=7.2 Hz, 6H). HRMS (ESI): m/z calcd for C12H17NO5Na: 278.1004 [M+Na]+; found: 278.1003. 
These spectral data are consistent with reported values.[43] 
 
Ethyl 2-Acetamidopent-4-ynoate LiBr (68 mg, 0.78 mmol) and H2O (28 µL, 
1.6 mmol) was added to a solution of diethyl (2-
propynyl)acetamidomalonate (0.20 g, 0.78 mmol) and DMF (20 mL) and the 
mixture was heated at reflux for 6 h, before it was concentrated under reduced pressure. The 
residue was partitioned between EtOAc and H2O, and the aqueous phase was removed and 
extracted with EtOAc three times. The organic phases were combined, washed with a brine 
solution, dried (MgSO4), and concentrated under reduced pressure to give a residue. Flash 
chromatography of the residue on silica, eluting with EtOAc/hexane, gave ethyl 2-
acetamidopent-4-ynoate as a colourless solid. Yield 0.12 g (84%); M.p. 52-54 °C; 1H NMR 
(400 MHz, CDCl3): δ=6.33 (br. s, 1H), 4.72 (m, 1H), 4.25 (m, 2H), 2.77 (m, 2H), 2.10 (s, 3H), 
2.02 (t, 4J=2.4 Hz, 1H), 1.29 ppm (t, 3J=7.2 Hz, 3H); HRMS (ESI): m/z calcd for C9H13NO3Na: 
206.0793 [M+Na]+; found: 206.0792. These spectral data are consistent with reported 
values.[44] 
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Ethyl 2-Acetamido-4-(tributylstannyl)pent-4-enoate Bu3SnH (80 µL, 0.30 
mmol) was added to a solution of ethyl 2-acetamidopent-4-ynoate (50 mg, 
0.27 mmol), Pd(PPh3)4 (15 mg, 0.014 mmol) and benzene (10 mL). The 
solution was let stand for 5 min at RT, before being concentrated under reduced pressure to 
give a yellow residue. Flash chromatography of the residue on silica, eluting with 
EtOAc/hexane, gave ethyl 2-acetamido-4-(tributylstannyl)pent-4-enoate as a colourless oil. 
Yield 86 mg (66%); 1H NMR (300 MHz, CDCl3): δ=5.73 (s, 3J(117/119Sn-1H)=64.0 Hz, 1H), 5.71 
(s, 1H), 5.25 (s, 3J(117/119Sn-1H)=29.7 Hz, 1H), 4.48 (m, 1H), 4.18 (q, 3J=7.2 Hz, 2H), 2.79 (dd, 
2J=14.1, 3J=5.1 Hz, 1H), 2.50 (dd, 2J=14.1, 3J=9.0 Hz, 1H), 1.99 (s, 3H), 1.60-1.40 (m, 6H), 1.40-
1.25 (m, 9H), 1.0-0.80 ppm (m, 15H); HRMS (ESI): m/z calcd for C21H41NO3120SnNa: 498.2006 
[M+Na]+; found: 498.2005. These spectral data are consistent with reported values.[28]  
 
Ethyl 2-Acetamido-4-iodopent-4-enoate A solution of I2 (17 mg, 0.13 mmol) 
in dry CHCl3 (5 mL) was slowly added to a solution of ethyl 
2-acetamido-4-(tributylstannyl)pent-4-enoate (57 mg, 0.12 mmol) in dry 
CHCl3 (5 mL) at RT. After 1 h the solution was passed through a mixture of KF and celite. 
The flow-through was concentrated under reduced pressure and the residue applied to a 
plug of silica. The silica was washed with hexane to remove any unreacted organostannane 
and then washed with EtOAc. The EtOAc wash was collected and concentrated under 
reduced pressure to give a colourless residue. HPLC (Alltech Prevail C18 250 x 10 mm, 5 µm) 
of this residue using a gradient mobile phase over 35 min from H2O (100:0) to MeCN (0:100) 
at a flow rate of 5 mL min-1, gave ethyl 2-acetamido-4-iodopent-4-enoate as a colourless oil. 
Yield 18 mg (48%); HPLC tR  = 19.8 min; 1H NMR (400 MHz, CDCl3): δ=6.19 (d, 3J=7.0 Hz, 
1H), 6.09 (s, 1H), 5.83 (s, 1H), 4.73 (m, 1H), 4.21 (q, 3J=7.2 Hz, 2H), 3.01 (dd, 2J=14.8, 3J=5.6 
Hz, 1H), 2.86 (dd, 2J=14.8, 3J=6.8 Hz, 1H), 2.02 (s, 3H), 1.29 ppm (t, 3J=7.2 Hz, 3H); 13C NMR 
(101 MHz, CDCl3): δ=171.1, 170.0, 129.8, 102.8, 62.0, 51.9, 46.7, 23.2, 14.2 ppm; HRMS (ESI): 
m/z calcd for C9H15127INO3: 312.0097 [M+H]+; found: 312.0098. These spectral data are 
consistent with reported values.[28] 
 
N
H
O
O
O
SnBu3
N
H
O
O
O
I
!155 
2-Amino-4-iodopent-4-enoic Acid 11 A solution of 6 M HCl (2 mL), AcOH (1 
mL) and H2O (2 mL) was added to ethyl 2-acetamido-4-iodopent-4-enoate (32 
mg, 0.10 mmol) and the mixture was heated at reflux for 3 h. The solution was 
concentrated under reduced pressure and colourless crystals of the HCl salt of 2-amino-4-
iodopent-4-enoic acid 21 formed. Yield 23 mg (81%); M.p. 188-189 °C (decomp.); 1H NMR 
(400 MHz, D2O): δ=6.37 (s, 1H), 6.05 (s, 1H), 4.25 (dd, 3J=9.2, 3J=4.8 Hz, 1H), 3.15 (dd, 
2J=15.2, 3J=4.8 Hz, 1H), 2.95 ppm (dd, 2J=15.2, 3J=9.2 Hz, 1H); 13C NMR (101 MHz, D2O): 
δ=171.6, 132.8, 102.1, 52.9, 45.9 ppm; HRMS (ESI): m/z calcd for C5H9127INO2: 241.9678 
[M+H]+; found: 241.9678; elemental analysis calcd (%) for C5H9ClINO2: C 21.64, H 3.27, Cl 
12.78, I 45.73, N 5.05; found: C 21.55, H 3.33, Cl 12.74, I 45.53, N 5.13. 
 
Synthesis of (S)-2-Amino-4-methylenehex-5-enoic Acid (12) 
Diethyl (2-methylene but-3-enyl)acetamidomalonate Tributyl(vinyl)tin 
(340 µL, 1.2 mmol) was added to a solution of diethyl (2-bromoprop-2-
enyl)acetamidomalonate (0.30 g, 0.89 mmol), Pd(PPh3)4 (51 mg, 0.05 
mmol) and benzene (300 µL) under an atmosphere of N2 in a sealed tube, before heating at 
80 °C for 3 h. The solution was left to cool to RT and was passed through a mixture of KF 
and celite. The flow-through was collected and applied to a plug of silica. The silica was 
washed with benzene to remove any unreacted organostannane and then washed with 
EtOAc/hexane. The EtOAc/hexane wash was collected and concentrated under reduced 
pressure to give a colourless residue. HPLC (Grace Altima C18 250 x 22 mm, 5 µm) of this 
residue using a mobile phase of MeOH/H2O (75:15) at a flow rate of 12 mL min-1, gave 
diethyl (2-methylene but-3-enyl)acetamidomalonate as a colourless solid. Yield 0.19 g (74%); 
HPLC tR  = 9.1 min; M.p. 47-48 °C; 1H NMR (400 MHz, CDCl3): δ=6.68 (br. s, 1H, NH), 6.29 
(ddd, 3J=17.6, 3J=10.9, 4J=0.8 Hz, 1H, olefinic), 5.24 (d, 3J=17.6 Hz, 1H), 5.16 (s, 1H), 5.01 (d, 
3J=10.9 Hz, 1H), 4.88 (s, 1H), 4.22 (m, 4H), 3.28 (d, 4J=0.8 Hz, 2H), 1.97 (s, 3H) 1.27 ppm (t, 
3J=7.1 Hz, 6H); 13C NMR (101 MHz, CDCl3): δ=169.1, 167.9, 141.1, 138.9, 119.9, 114.0, 66.4, 
62.7, 33.1, 23.2, 14.1 ppm; HRMS (ESI): m/z calcd for C14H22NO5: 284.1498 [M+H]+; found: 
O
O
O
O
HN
O
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O
O
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284.1499; elemental analysis calcd (%) for C14H21NO5: C 59.35, H 7.47, N 4.94; found: C 59.04, 
H 7.53, N 4.81.  
 
2-Acetamido-4-methylenehex-5-enoic Acid Na2CO3 solution (10%, 10 mL) was 
added to diethyl (2-methylene but-3-enyl)acetamidomalonate (120 mg, 0.42 
mmol) and the mixture was heated at reflux for 5 h, before it was allowed to 
cool to RT and acidified with 6 M HCl solution to pH 1. The aqueous solution was extracted 
three times with EtOAc. The combined organic phases were concentrated under reduced 
pressure to give a colourless residue. Ion-exchange chromatography (Dowex 1x8) of this 
material gave 2-acetamido-4-methylenehex-5-enoic acid as a colourless solid. Yield 33 mg 
(42%); M.p. 106-107 °C; 1H NMR (400 MHz, D2O): δ=6.44 (dd, 3J=17.8, 3J=11.0 Hz, 1H), 5.36 
(d, 3J=17.8 Hz, 1H), 5.22 (s, 1H), 5.19 (d, 3J=11.0 Hz, 1H), 5.12 (s, 1H), 4.57 (dd, 3J=9.7, 3J=4.8 
Hz, 1H), 2.89 (dd, 2J=14.8, 3J=4.8 Hz, 1H), 2.61 (dd, 2J=14.8, 3J=9.7, 1H), 2.00 ppm (s, 3H); 13C 
NMR (101 MHz, D2O): δ=176.0, 174.7, 141.9, 138.2, 119.7, 115.0, 52.4, 33.5, 22.2 ppm; HRMS 
(ESI): m/z calcd for C9H13NO3Na: 206.0793 [M+Na]+; found: 206.0794.  
 
(S)-2-Amino-4-methylenehex-5-enoic Acid (12) 2-Acetamido-4-methylenehex-
5-enoic acid (33 mg, 0.18 mmol) was dissolved in a sodium phosphate buffer 
(10 mM, 20 mL, pH 7.3) containing CoCl2 (5 mM). Acylase I (2 mg, activity 720 
µmol/mg) was added and the resulting solution was let stand for 18 h at RT. The solution 
was passed through a Millipore Amicon YM-10 filter, and the filtrate concentrated under 
reduced pressure to give a pale pink residue. HPLC (Alltech Prevail C18 250 x 10 mm, 5 µm) 
of this material using a gradient mobile phase over 20 min from 0.1% TFA in H2O (100:0) to 
MeOH (0:100) at a flow rate of 5 mL min-1, gave the TFA salt of (S)-2-amino-4-methylenehex-
5-enoic acid (22) as a colourless solid. Yield 9 mg (39%); HPLC tR  = 15.0 min; 1H NMR (400 
MHz, D2O): δ=6.48 (dd, 3J=17.9, 3J=10.9 Hz, 1H), 5.40 (d, 3J=17.9 Hz, 1H), 5.34 (s, 1H), 5.27 
(d, 3J=10.9 Hz, 1H), 5.24 (s, 1H), 4.14 (dd, 3J=9.8, 3J=4.8 Hz, 1H), 3.10 (dd, 2J=14.8, 3J=4.8 Hz, 
1H), 2.71 ppm (dd, 2J=14.8, 3J=9.8, 1H); 13C NMR (101 MHz, D2O): δ=172.8, 140.1, 137.3, 
121.5, 116.0, 52.4, 33.0 ppm; HRMS (ESI): m/z calcd for C7H12NO3: 142.0868 [M+H]+; found: 
142.0867. 
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Synthesis of 2-Acetamido-4-(4-fluorophenyl)pent-4-enoic Acid (14) 
2-Acetamido-4-bromopent-4-enoic Acid (13) Aqueous Na2CO3 solution (10%, 
10 mL) was added to diethyl (2-bromopro-2-enyl)acetamidomalonate (50 mg, 
0.15 mmol) and the mixture was heated at reflux for 5 h, before it was 
allowed to cool to RT and acidified with 6 M HCl solution to pH 1. The aqueous solution 
was extracted three times with EtOAc. The combined organic phases were concentrated 
under reduced pressure to give crude 2-acetamido-4-bromopent-4-enoic acid (13). 1H NMR 
(300 MHz, CDCl3): δ=7.08 (s, 1H), 5.70 (s, 1H), 5.57 (s, 1H), 4.78 (m, 1H), 3.10 (dd, 2J=14.6, 
3J=5.0 Hz, 1H), 2.96 (dd, 2J=14.6, 3J=7.6 Hz, 1H), 2.06 ppm (s, 3H). 
 
2-Acetamido-4-(4-fluorophenyl)pent-4-enoic Acid (14) Na2HPO4 (90 mg, 0.63 
mmol), palladium catalyst solution (20 µL, 0.01 M), 4-fluorophenylboronic 
acid (26 mg, 0.19 mmol) and water (1 mL) were added to crude 2-acetamido-
4-bromopent-4-enoic acid (13) (30 mg) and the solution was stirred at RT 
under an atmosphere of N2 overnight. The palladium catalyst used in this 
investigation was prepared as a 0.01 M solution as described previously.[11] The aqueous 
solution was then acidified with 6 M HCl solution to pH 1 and was extracted twice with 
EtOAc. The combined organic phases were concentrated under reduced pressure to give ca. 
90% conversion to 2-acetamido-4-(4-fluorophenyl)pent-4-enoic acid. 1H NMR (300 MHz, 
CDCl3): δ=7.82-7.72 (m, 2H), 7.39-7.31 (m, 2H), 5.90 (d, 3J=7.0 Hz, 1H), 5.33 (s, 1H), 5.15 (s, 
1H), 4.59 (m, 1H), 3.18 (dd, 2J=14.1, 3J=4.7 Hz, 1H), 2.90 (dd, 2J=14.1, 3J=7.6 Hz, 1H), 1.90 
ppm (s, 3H). 
 
5.8.3 NMR Spectra of Selected Compounds 
Spectra of samples recorded in D2O have been recorded with and without reference 
material. Both spectra have been provided for clarity. 
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13C NMR, 101 MHz, CDCl3 
1H NMR, 400 MHz, CDCl3 Ethyl 2-Acetamido-4-iodopent-4-enoate 
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1H NMR, 400 MHz, D2O 
13C NMR, 101 MHz, D2O 
2-Amino-4-iodopent-4-enoic Acid 11  
2-Amino-4-iodopent-4-enoic Acid 11  
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5.8.4 Cell-Free Protein Synthesis 
Plasmid DNA (pKL1450) encoding for N-terminal His6-ubiquitin was obtained from Dr. K. 
Loscha. Plasmid DNA encoding for N-terminal His6-ubiquitin with expression under control 
of the phage T7 promoter was prepared using a plasmid purification kit from Qiagen.  
 
 CFPS was conducted as described in Chapter 3. For misincorporation experiments 
(S)-leucine was replaced with either 4 mM of the racemic chloride 9, bromide 10 and iodide 
11 or 2 mM of the (S)-trifluoride 8 or (S)-diene 12, whilst 1 mM of the other nineteen 
proteinogenic amino acids were supplied. Ubiquitin was purified in the same way as PpiB, 
utilising the polyhistidine-tag to purify by metal affinity chromatography. Soluble ubiquitin 
was concentrated using Amicon Ultra 0.5 mL (YM-3) centrifugal devices from EMD 
Millipore, Merck KGaA. 
 
The sequence of the His6-ubiquitin construct in the standard single letter amino acid code is:  
MGSSHHHHHHSSGLVPRGSHMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQ 
QRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 
 
Mass = 10728 Da, N-formyl His6-ubiquitin = 10756 Da 
 
5.8.5 Evaluation of Ubiquitin with the Conditions Required for Suzuki 
Cross-Coupling 
Palladium catalyst solution[11] (0.01 M, 10 µL, 0.1 mmol) and water (10 µL) were added to 
ubiquitin (94 µM, 30 µL, 2.8 nmol) in a NaH2PO4 buffer (20 mM, pH 8) and the solution was 
incubated at 37 °C for 0.5 h, before it was directly injected into the mass spectrometer. No 
signals corresponding to ubiquitin were observed (Figure 4.22). Palladium catalyst solution 
(0.01 M, 10 µL, 0.1 µmol) was added to unmodified ubiquitin (94 µM, 50 µL, 4.7 nmol) in a 
NaH2PO4 buffer (20 mM, pH 8) and then incubated at 37 °C for 0.5 h, before a solution of 3-
mercaptopropionic acid (0.5%, 20 µL, 1.14 µmol) was added. A yellow precipitate formed 
within 20 min and was removed by centrifugation. Direct injection of the supernatant into 
the spectrometer revealed signals corresponding to ubiquitin (Figure 4.23).  
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5.8.6 Evaluation of Vinyl Bromide Modified Ubiquitin with the Conditions 
Required for Suzuki Cross-Coupling 
The palladium catalyst (0.01 M, 8.4 µL, 84 nmol) was added to a solution of the vinyl 
bromide 10 substituted ubiquitin (80 µM, 30µL, 2.4 nmol) in a NaH2PO4 buffer (20 mM, pH 8) 
and then incubated at 37 °C for 0.5 h, before a solution of 3-mercaptopropionic acid (0.5%, 10 
µL, 0.57 µmol) was added. A yellow precipitate formed within 20 min and was removed by 
centrifugation. Direct injection of the supernatant into the mass spectrometer revealed no 
signals corresponding to ubiquitin or any identifiable derivative thereof (Figure 5.24). The 
palladium treated vinyl bromide was also treated with 475 eq. of 3-mercaptopropionic acid 
(0.5%, 20 µL, 1.14 µmol). A yellow precipitate formed within 20 min and was removed by 
centrifugation. Direct injection of the supernatant into the mass spectrometer revealed no 
signals corresponding to ubiquitin or any discernible derivative thereof (Figure 5.25). 
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6 
 
Concluding Remarks 
 
 
Incorporation of non-proteinogenic amino acids into proteins enables the production of 
proteins with enhanced properties and functional moieties. Such modified proteins have a 
variety of applications, which are not limited to protein engineering and protein labelling. 
Incorporation via a residue-specific approach with wild-type translational machinery 
provides a simple method for the preparation of modified proteins without the need for 
extensive genetic manipulation. The limitation of this is the restriction on the diversity of 
unnatural amino acids able to be accepted as surrogates for protein synthesis since the 
wild-type machinery selects amino acids with high fidelity. Here a number of known and 
novel unnatural amino acids were prepared and found to be acceptable substitutes for 
proteinogenic amino acids with native machinery.  
 
In chapter 2, the S30 cellular extract employed for the cell-free production of proteins 
in this thesis was found to remove many common protecting groups from α – amino acids. 
This cellular extract was used to remove protecting groups from three unnatural amino 
acids including 4,5-dehydroleucine hydrazide to produce the corresponding free amino acid 
in situ, which was subsequently incorporated into His6-PpiB. The majority of the protein 
formed was fully substituted with the dehydro amino acid. This method is particularly 
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useful for amino acids that are unstable after deprotection. This work forms part of the 
experimental work comprising an article published in Chemistry - A European Journal. 
 
In chapter 3, a range of dehydro amino acids were evaluated as residue-specific 
replacements for the aliphatic amino acids, (S)-valine, (S)-leucine and (2S,3S)-isoleucine. The 
degree of substitution of the proteins modified with the dehydro amino acids was 
determined indirectly by amino acid analysis. Competition efficiencies were determined for 
the dehydro amino acids utilising per-deuterated amino acids and analysing the resulting 
proteins. Per-deuterated amino acids were required as they enlarge the otherwise small 
mass differences between the dehydro and proteinogenic amino acids enabling analysis of 
the formed proteins by mass spectrometry. Apart from PpiB substituted with 3,4-
dehydrovaline, the other dehydro modified proteins showed no change in secondary 
structure or enzyme activity to the unmodified protein.  
 
In chapter 4, the dehydro amino acids 4,5-dehydroleucine and 4,5-dehydroisoleucine 
were found to undergo rapid site-specific cleavage of the protein backbone upon treatment 
with iodine. This was exploited to produce the human peptide hormones gastrin-releasing 
peptide and prolactin-releasing peptide via a fusion protein approach, demonstrating the 
utility of these dehydro amino acids. Optimisation of the iodine-induced cleavage of 4,5-
dehydroleucine to produce the peptide hormone PRPG enabled a cleavage efficiency of ca. 
38% to be achieved.  
  
In chapter 5, a trifluoromethylalkene, three vinyl halides and a diene were evaluated 
as translational substitutes of (S)-leucine. The level of incorporation of the modified amino 
acids were determined directly by mass spectrometry, enabled by the larger difference in 
molecular weight for these amino acids. 2-Amino-4-chloropent-4-enoic acid and 2-amino-4-
bromopent-4-enoic acid were found to be excellent replacements of (S)-leucine with 
incorporation levels of over 75% observed in each case. The structure of PpiB substituted 
with these amino acids was near-identical to unmodified PpiB, but these proteins were 
significantly less thermostable.  
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The combined work herein, demonstrates that functional moieties can be 
incorporated into proteins with unmodified translational machinery and can be exploited in 
downstream applications. It is hoped that the research conducted during this candidature 
opens up many more avenues of fruitful research.  
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7 
 
General Experimental 
 
 
7.1 Instrumentation  
1H NMR spectra were recorded using either a Varian Mercury 300 MHz spectrometer, a 
Varian MR 400 MHz spectrometer or a Bruker 400 MHz Ascend spectrometer at 298 K. 13C 
NMR spectra, HSQC, and HMBC spectra were recorded on either a Varian MR 400 MHz, a 
Varian INOVA 500 MHz spectrometer or a Bruker 400 MHz Ascend spectrometer at 298 K. 
19F NMR were recorded on either a Varian Mercury 300 MHz spectrometer or a Varian NMR 
400 MHz spectrometer at 298 K. 1H resonances are reported to the nearest 0.01 ppm whereas 
13C and 19F resonances are reported to the nearest 0.1 ppm. δ are reported in parts per million 
(ppm), while J values are given in Hz and are reported to the nearest 0.1 Hz for 1H-1H, 19F-
1H, 19F-13C and 117/119Sn-1H couplings. Multiplicities are abbreviated to: s, singlet; d, doublet; 
dd, doublet of doublets; ddd, doublet of doublet of doublets; t, triplet; q, quartet; m, 
multiplet; br, broad. CDCl3 was referenced at its non-deuterated solvent peak δH 7.26 for 1H 
NMR spectroscopy and δC 77.16 for 13C NMR spectroscopy. D2O was referenced in 1H NMR 
spectroscopy by either addition of acetonitrile as an internal standard referenced at δH 2.06 
and δC 1.47 or 119.68 for 13C NMR spectroscopy, or referenced from sodium [D4]3-
(trimethylsilyl)-2,2',3,3'-tetradeuteropropionate introduced by using a coaxial insert with a 
standard 5 mm NMR tube referenced at δH 0.00. Monofluoroacetonitrile was added as an 
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internal reference for 19F NMR spectroscopy and referenced to δF -251.0 when D2O was used 
as the solvent. Hexafluorobenzene was added as an internal reference for 19F NMR 
spectroscopy and referenced to δF -164.9 when CDCl3 was used as the solvent. CDCl3 with an 
isotopic purity of 99.8%, D2O with an isotopic purity of 99.75% was purchased from 
Cambridge Isotope Laboratories, Inc. Sodium [D4]3-(trimethylsilyl)-2,2',3,3'-
tetradeuteropropionate was purchased from Merck Sharpe & Dohme, Inc. 
 
Melting points were determined using a Stanford Research Systems MP100 Optimelt 
Automated Melting Point System in open capillaries in air and are uncorrected. Elemental 
analyses were performed on a Carlo Erla 1106 automatic analyser by the Research School of 
Chemistry Microanalytical Service at the Australian National University. High resolution 
ESI mass spectra were recorded using a Waters LCT premier TM XE oa-TOF mass 
spectrometer by the Research School of Chemistry Mass Spectrometry unit at the Australian 
National University. Mass spectral data are reported as mass-to-charge ratios (m/z). Semi-
preparative and preparative HPLC were performed on either a HP Agilent 1100 series 
HPLC with a quaternary pump, analytical automatic liquid sampler, column compartment 
and diode array detector running with Agilent Chemstation software, or a HP Agilent 1100 
series HPLC with a preparative binary pump system, preparative automatic liquid sampler 
and a diode array detector with a preparative flow cell running with Agilent Chemstation 
software, or a Waters 600 Controller with a Waters 717 plus Autosampler and a Waters 2996 
Photodiode Array Detector running with Empower Pro Empower 2 software. Eluting 
fractions with the latter system were collected using a Waters Fraction Collector III. Flash 
column chromatography was run on Merck KGaA Silica 60 (240-400 mesh) using the eluent 
system as described. Thin layer chromatography was performed on Merck KGaA Kieselgel 
60 F254 coated plates (0.2 mm), visualised with a 254 nm UV lamp where applicable, or 
dipping the plates into a solution of 1.5 g of KMnO4, 10 g K2CO3 and 0.125 g NaOH in 200 
mL of water, followed by heating with a heat gun. Reactions were stirred with the 
appropriate size teflon coated stir bars. Microwave reactions were performed using a CEM 
24 position Discovery Explorer system. Reaction conditions at -78 °C refer to a dry 
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ice/acetone cooling bath and -20 °C refers cooling bath with a slurry of a 3:1 ratio of ice and 
NaCl by weight.!!!
 
7.2 Materials  
Commercially available chemicals were purchased from Sigma-Aldrich, Inc., Alfa Aesar or 
Merck KGaA unless otherwise stated. Most reagents were used without further purification, 
where further purification was required, drying and purification of these reagents was 
performed using standard laboratory procedures.[1] Dry solvent was obtained by storage 
over of activated 3 Å or 4 Å molecular sieves where appropriate, for at least 24 h. Organic 
solutions were dried by the addition of anhydrous MgSO4. All reactions requiring the use of 
organometallic compounds made use of Schlenk technique and all procedures were carried 
out under an atmosphere of dry nitrogen.  
 
 
7.3 General Details of Cell-Free Protein Synthesis 
The amino acids (S)-valine, (S)-leucine, and (2S,3S)-isoleucine used for CFPS were Bio-Ultra 
grade from Sigma-Aldrich, Inc. Spectra/Por dialysis membrane (#2, MWCO: 12-14,000) was 
purchased from Spectrum Laboratories, Inc. Deionised water was treated with a Milli-QTM 
reagent system before use, ensuring a resistivity of >15 MΩ cm-1. E. coli DH5α/pND1098 cells 
were generously gifted by Prof. N. Dixon (University of Wollongong, NSW, Australia).[2] 
Plasmid DNA was prepared using a plasmid purification kit from Qiagen. E. coli DH5α or 
AN1459 containing the plasmid were grown in 20 mL of LB medium supplemented with 
ampicillin (50 mg L-1) at 37 °C for 10 h. This culture was then used to inoculate 2 L of 
minimal medium supplemented with ampicillin (50 mg L-1) and was incubated overnight. 
The cells were harvested and the desired plasmid DNA was extracted and then purified by 
anion exchange chromatography. DNA concentration was measured on a Nanodrop ND-
1000 UV/Vis spectrophotometer at A260. Purity was assessed by 1% DNA agarose gel 
electrophoresis (0.5 mg mL-1 ethidium bromide) in sodium borate buffer, with visualisation 
by UV irradiation at 285 nm. DNA molecular weight standards 1 kb DNA ladder was 
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obtained from New England BioLabs, Inc. 20% SDS-PAGE gels were run on a Mini-
PROTEIN Tetra system and stained with Bio-Safe Coomassie Blue stain from Bio-Rad 
Laboratories, Inc. Acrylamide, bisacrylamide and SDS-PAGE molecular weight standard 
(broad range) solutions were purchased from New England BioLabs, Inc. Protein sample 
buffer is 100 mM Tris, 2% SDS, 10% glycerol, 5% β-mercaptoethanol and 0.1% bromophenol 
blue. Gels were heated in a microwave for 3 x 1 min in Milli-Q water. The gel was then 
stained with Coomassie blue for 1 h followed by destaining with water. 
 
A280 of protein samples was measured on a Nanodrop ND-1000 UV/Vis 
spectrophotometer with protein concentrations calculated from the extinction coefficient 
estimated by the PROTPARAM program on the EXPASy Proteomic Server.[3] 
 
The amino acid sequence of the His6-PpiB construct (with an additional C-terminal 
asparagine residue[2]) is:  
MHHHHHHMVTFHTNHGDIVIKTFDDKAPETVKNFLDYCREGFYNNTIFHRVINGFMIQ
GGGFEPGMKQKATKEPIKNEANNGLKNTRGTLAMARTQAPHSATAQFFINVVDNDFLN
FSGESLQGWGYCVFAEVVDGMDVVDKIKGVATGRSGMHQDVPKE DVIIESVTVS EN 
  
Mass = 19221 Da, N-formyl-His6-PpiB = 19250 Da 
 
 
7.4 Mass Spectrometry of Synthesised Proteins 
Protein solutions (1 µL) were directly injection into an Agilent 1100 series LC/MSD TOF 
instrument operating in the positive ESI ionization, eluting with 0.1% aqueous formic acid. 
Mass reconstructions are reported in Daltons. 
 
 
7.5 Circular Dichroism Spectroscopy 
Circular dichroism spectra were recorded on a Chirascan CD spectrometer calibrated with 
(S)-(+)-10-camphorsulphonic acid. Protein concentration was determined by dilution of a 
known stock solution to a final concentration of 0.6 µM, with a 0.22 µm filtered solution of 10 
!187 
mM sodium phosphate and 100 mM ammonium sulphate at pH 7.4. Spectral data was 
obtained in a square Hellma Analytics Quartz Supracil cell, path length 10 mm, 200 µL 
volume. The wavelength scan range was 190 to 260 nm, with a reading every at every 0.5 
nm. The bandwidth was set at 2.0 nm with 3.0 s per point for data collection. Experiments 
were conducted at 10 °C with use of a Quantum Northwest Temperature Controller TC125 
and a Fisons Haake F3 thermostatic circulator bath. The same setup was used for the 
thermal stability studies where the wavelength was set 222 nm with a bandwidth of 2.0 nm 
and the data collection increased to 5.0 s per point. The temperature was increased at a rate 
of 2.0 °C min-1 with a reading every minute. The melting temperature was determined by 
taking the first derivative. Scans were run in triplicate and were expressed as an average. 
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